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Summary
Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk 
assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising 
evidence on risks and risk–outcome associations. With each annual GBD study, we update the GBD CRA to 
incorporate improved methods, new risks and risk–outcome pairs, and new data on risk exposure levels and risk–
outcome associations.
Methods We used the CRA framework developed for previous iterations of GBD to estimate levels and trends in 
exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, sex, year, and 
location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 
2017. This study included 476 risk–outcome pairs that met the GBD study criteria for convincing or probable evidence 
of causation. We extracted relative risk and exposure estimates from 46 749 randomised controlled trials, cohort 
studies, household surveys, census data, satellite data, and other sources. We used statistical models to pool data, 
adjust for bias, and incorporate covariates. Using the counterfactual scenario of theoretical minimum risk exposure 
level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. We explored the 
relationship between development and risk exposure by modelling the relationship between the Socio-demographic 
Index (SDI) and risk-weighted exposure prevalence and estimated expected levels of exposure and risk-attributable 
burden by SDI. Finally, we explored temporal changes in risk-attributable DALYs by decomposing those changes into 
six main component drivers of change as follows: (1) population growth; (2) changes in population age structures; 
(3) changes in exposure to environmental and occupational risks; (4) changes in exposure to behavioural risks; 
(5) changes in exposure to metabolic risks; and (6) changes due to all other factors, approximated as the risk-deleted 
death and DALY rates, where the risk-deleted rate is the rate that would be observed had we reduced the exposure 
levels to the TMREL for all risk factors included in GBD 2017.
Findings In 2017, 34·1 million (95% uncertainty interval [UI] 33·3–35·0) deaths and 1·21 billion (1·14–1·28) DALYs 
were attributable to GBD risk factors. Globally, 61·0% (59·6–62·4) of deaths and 48·3% (46·3–50·2) of DALYs were 
attributed to the GBD 2017 risk factors. When ranked by risk-attributable DALYs, high systolic blood pressure (SBP) 
was the leading risk factor, accounting for 10·4 million (9·39–11·5) deaths and 218 million (198–237) DALYs, 
followed by smoking (7·10 million [6·83–7·37] deaths and 182 million [173–193] DALYs), high fasting plasma 
glucose (6·53 million [5·23–8·23] deaths and 171 million [144–201] DALYs), high body-mass index (BMI; 4·72 million 
[2·99–6·70] deaths and 148 million [98·6–202] DALYs), and short gestation for birthweight (1·43 million [1·36–1·51] 
deaths and 139 million [131–147] DALYs). In total, risk-attributable DALYs declined by 4·9% (3·3–6·5) between 2007 
and 2017. In the absence of demographic changes (ie, population growth and ageing), changes in risk exposure and 
risk-deleted DALYs would have led to a 23·5% decline in DALYs during that period. Conversely, in the absence of 
changes in risk exposure and risk-deleted DALYs, demographic changes would have led to an 18·6% increase in 
DALYs during that period. The ratios of observed risk exposure levels to exposure levels expected based on SDI 
(O/E ratios) increased globally for unsafe drinking water and household air pollution between 1990 and 2017. This 
result suggests that development is occurring more rapidly than are changes in the underlying risk structure in a 
population. Conversely, nearly universal declines in O/E ratios for smoking and alcohol use indicate that, for a given 
SDI, exposure to these risks is declining. In 2017, the leading Level 4 risk factor for age-standardised DALY rates was 
high SBP in four super-regions: central Europe, eastern Europe, and central Asia; north Africa and Middle East; 
south Asia; and southeast Asia, east Asia, and Oceania. The leading risk factor in the high-income super-region was 
smoking, in Latin America and Caribbean was high BMI, and in sub-Saharan Africa was unsafe sex. O/E ratios for 
unsafe sex in sub-Saharan Africa were notably high, and those for alcohol use in north Africa and the Middle East 
were notably low.
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Interpretation By quantifying levels and trends in exposures to risk factors and the resulting disease burden, this 
assessment offers insight into where past policy and programme efforts might have been successful and highlights 
current priorities for public health action. Decreases in behavioural, environmental, and occupational risks have 
largely offset the effects of population growth and ageing, in relation to trends in absolute burden. Conversely, the 
combination of increasing metabolic risks and population ageing will probably continue to drive the increasing 
trends in non-communicable diseases at the global level, which presents both a public health challenge and 
opportunity. We see considerable spatiotemporal heterogeneity in levels of risk exposure and risk-attributable burden. 
Although levels of development underlie some of this heterogeneity, O/E ratios show risks for which countries are 
overperforming or underperforming relative to their level of development. As such, these ratios provide a 
benchmarking tool to help to focus local decision making. Our findings reinforce the importance of both risk exposure 
monitoring and epidemiological research to assess causal connections between risks and health outcomes, and they 
highlight the usefulness of the GBD study in synthesising data to draw comprehensive and robust conclusions that 
help to inform good policy and strategic health planning.
Funding Bill & Melinda Gates Foundation and Bloomberg Philanthropies.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Research in context
Evidence before the study
Population-level estimates of individual risks have been 
produced periodically by both WHO and UNICEF, whereas 
independent scientific publications provide risk estimates that 
are limited in the number of risks assessed and population size 
evaluated. Since 2010, the Global Burden of Diseases, Injuries, 
and Risk Factors Study (GBD) has produced comprehensive 
assessments of risk factor burden by age, sex, cause, and location. 
The previous iteration of this study, GBD 2016, assessed 
84 behavioural, environmental and occupational, and metabolic 
risks between 1990 and 2016, with major updates in the 
assessment of second-hand smoke, alcohol use, and diet. 
The GBD study remains the only peer-reviewed, comprehensive, 
and annual assessment of risk factor burden by age, sex, cause, 
location, and year that complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting.
Added value of this study
GBD 2017 expands the scope of GBD 2016 with the estimation 
of one new risk factor—bullying victimisation—and 80 new 
risk–outcome pairs, with a total of 476 risk–outcome pairs. 
GBD 2017 incorporates 46 749 sources. We have expanded our 
estimation locations with the addition of subnational locations 
for Ethiopia, Iran, Norway, and Russia, and estimates for Māori 
and non-Māori populations in New Zealand. We implemented 
broad improvements to methods to better estimate risk factor 
exposures and relative risks. Notably, we have moved from 
total cholesterol to low-density lipoprotein cholesterol, 
implemented continuous measures of exposure for smoking, 
and updated the ambient particulate matter pollution model 
with new ground measurement data from almost 4000 sites. 
We expanded upon our decomposition analyses to investigate 
the drivers of risk-attributable burden and the changes in 
burden by country, and to decompose risk-attributable changes 
between broad categories of risks, thus providing deeper 
insight into changing patterns of risk-attributable burden and 
their underlying causes. We broadened our analyses of 
geographical and temporal trends in risk exposure and burden 
by estimating expected risk-weighted prevalence of exposures 
based on Socio-demographic Index. We explored the observed 
relationship between development status and risk exposure 
across all locations and years, and for the first time we described 
spatiotemporal patterns in the ratio of observed-to-expected 
levels of risk exposure.
Implications of all the available evidence
Decomposing trends by their underlying drivers reveals 
improvements in risk-deleted burden (ie, burden not 
attributed to risks in the GBD analysis), and broadly, 
improvements in exposure to environmental and behavioural 
risks. Conversely, increasing exposure to metabolic risks is 
driving increases in burden, indicating a crucial need for risk 
mitigation policies in this area. By quantifying the relationship 
between development and risk exposure, we highlight which 
risks appear sensitive to development and, of those, which are 
likely to improve or worsen with development. This analysis 
highlights areas where countries are either overperforming or 
underperforming relative to their economic peers and provides 
insight into areas where risk-modification strategies might be 
the best targets to improve health.
Introduction
The environmental, behavioural, and metabolic risks 
that drive injury and disease are the mechanisms by 
which public health efforts can most efficiently and 
effectively prevent health loss. Effecting population 
health improvements, therefore, requires understanding 
of not only the injuries and diseases that drive 
health burdens, but also the risks that drive injury and 
disease. Through a constantly evolving collection of 
cohort studies, randomised trials, and case-control 
studies, decades of epidemiological research have worked 
to quantify the nature and magnitude of associations 
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between risk exposures and outcomes in studied pop-
ulations. Moving beyond individual studies of individual 
populations, this raw evidence can be synthesised to 
draw the comprehensive and robust conclusions that are 
necessary to inform good public health policy. The Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) comparative risk assessment (CRA) is a com-
prehensive and comparable approach to risk factor 
quantifi cation that offers a useful tool for synthesising 
evidence on risks and risk–outcome associations. With 
each annual GBD, we update the GBD CRA to incor-
porate new data on risk–outcome pairs, risk exposure 
levels, and risk–outcome associations.
Previous GBD studies have assessed the relationship 
between development, as measured by the Socio-demo-
graphic Index (SDI), and both the magnitude and 
composition of disease burden.1–4 The results of those 
analyses highlighted the dramatic declines in com-
municable, maternal, neonatal, and nutritional diseases 
(CMNNDs) that have generally occurred with increases 
in socioeconomic development as well as the subsequent 
increases in life expectancy and absolute burden of non-
communicable diseases (NCDs)—a pattern referred to as 
the epidemio logical transition. Previous GBD analyses 
also estimated the expected burden for each cause in 
every location and year, based on that location’s SDI. The 
comparison of observed burden to the burden expected 
based on SDI offered insight into the relative performance 
of countries at similar levels of development. Here, we 
extend those methods to analyse epidemiological 
transition with regards to risk exposure and risk-
attributable burden. This analysis allows the identification 
of risks that are positively associated with development, 
negatively associated with development, or independent 
of development status. By estimating the levels of risk 
exposure and risk-attributable burden on the basis of 
SDI, and comparing these expectations to observed 
levels, it is possible to identify locations that either 
underperform or overperform compared with similarly 
developed countries.
The GBD 2017 CRA includes 84 risk factors and 
476 associated risk–outcome pairs. We expanded the 
scope of GBD 2016 with the inclusion of 80 new outcomes 
for existing risks and one new risk factor: bullying 
victimisation. The study provides estimates of exposure 
and attributable deaths and disability-adjusted life-years 
(DALYs) for 195 countries and territories for 1990 through 
2017, including new subnational estimates for Ethiopia, 
Iran, New Zealand, Norway, and Russia. We explored 
changes in risk-attributable DALYs by decomposing 
those changes into six main component drivers of 
change, explored the relationship between risk exposure 
and SDI, and estimated the ratio of observed-to-expected 
levels of exposure and risk-attributable burden by SDI. 
As with previous iterations of GBD, the GBD 2017 CRA 
results presented here supersede all previously published 
GBD CRA estimates.
Methods
Overview
The CRA conceptual framework was developed by 
Murray and Lopez,5 who established a causal web of 
hierarchically organised risks that contribute to health 
outcomes and facilitate the quantification of risks at any 
level in the framework. In GBD 2017, as in previous 
GBDs, we assessed a set of behavioural, environmental 
or occupational, and metabolic risks that were organised 
into five hierarchical levels (appendix 1 section 5). At 
Level 0, GBD 2017 reports estimates for all risk factors 
combined. Nested within Level 0, Level 1 includes three 
risk categories: environmental and occupational, meta-
bolic, and behavioural risk factors. This hierarchical 
structure continues, with each subsequent level 
including more detailed risks factors that are nested 
within the broader category above it. There are 19 risks at 
Level 2, 39 risks at Level 3, and 22 risks at Level 4, for a 
total of 84 risks or risk groups, where all risks (Level 0) is 
included as a risk group. Although we have added 
bullying as a new risk factor, the total number of risk 
factors remains un changed from GBD 2016 because of 
the merging of two risk factors: we previously estimated 
second-hand smoke and occupational exposure to 
second-hand smoke as two separate risks but have 
incorporated the two exposures into one second-hand 
smoke Level 3 risk for GBD 2017. Each risk factor is 
associated with an outcome or outcomes, and each 
combination of risk and outcome included in the GBD is 
Key messages
• The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 expands on 
GBD 2016 with the estimation of one new risk factor—bullying victimisation—and 
80 new risk–outcome pairs, making a total of 476 risk–outcome pairs. The study further 
investigates the drivers of changes in risk-attributable burden and explores the 
relationship between development and risk exposure.
• In 2017, 34·1 million (95% uncertainty interval [UI] 33·3–35·0) deaths and 1·21 billion 
(1·14–1·28) disability-adjusted life-years (DALYs) were attributable to risk factors 
included in GBD 2017. All included risks combined contributed to 61·0% (59·6–62·4) 
of deaths and 48·3% (46·3–50·2) of DALYs worldwide.
• The five leading risks in 2017 were high systolic blood pressure, smoking, high fasting 
plasma glucose, high body-mass index, and short gestation for birthweight.
• DALY-based ranks for all metabolic risks increased between 1990 and 2017 for both 
males and females. Consequently, four of the five leading risks were behavioural risks 
in 1990, whereas three of the five leading risks were metabolic risks in 2017.
• Between 2007 and 2017, the absolute number of risk-attributable DALYs declined by 
3·44% (95% UI 2·47–4·40). During that period, exposures to behavioural, 
environmental, and occupational risks declined (improved), but these gains were 
somewhat offset by increases in exposure to metabolic risks, population growth, 
and population ageing.
• Socioeconomic development was strongly associated with exposure levels for many 
risks. Among the leading risks, unsafe water, household air pollution, and child 
wasting show pronounced decreasing trends with development. Conversely, smoking, 
alcohol use, drug use, and high low-density lipoprotein cholesterol all show a 
pronounced increasing trend with development.
See Online for appendix 1
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referred to as a risk–outcome pair. Risk–outcome pairs 
were included on the basis of evidence rules (appendix 1 
section 5). To date, we have not quantified the con-
tribution of distal social, cultural, and economic risk 
factors; however, our analysis of the relationship between 
risk exposures and socio demographic development, 
measured with SDI, offers insights into the relationship 
between economic context and risk factors.
This analysis largely follows the CRA methods used in 
GBD 2016.2 Given the scope of the analysis, we offer a 
high-level overview of the study methods and analytical 
logic, detailing areas of notable change and innovation 
since GBD 2016 and include risk-specific details in 
appendix 1 (section 4). This study complies with the 
Guidelines for Accurate and Transparent Health 
Estimates Reporting statement6 (appendix 1 section 5).
Geographical units of analysis and years for estimation
For GBD 2017, we have estimated risk factor exposure 
and attributable burden by age, sex, cause, and location 
from 1990 to 2017. GBD locations are arranged in a nested 
hierarchy: 195 countries and territories are within 
21 regions and these 21 regions are within seven super-
regions. Each year, GBD includes sub national analyses for 
a few new countries and continues to provide subnational 
estimates for countries that were added in previous cycles. 
Subnational estimation in GBD 2017 includes five new 
countries (Ethiopia, Iran, New Zealand, Norway, Russia) 
and countries previously estimated at subnational levels 
(GBD 2013: China, Mexico, and the UK [regional level]; 
GBD 2015: Brazil, India, Japan, Kenya, South Africa, 
Sweden, and the USA; GBD 2016: Indonesia and the UK 
[local government authority level]). All analyses are at the 
first level of administrative organisation within each 
country except for New Zealand (by Māori ethnicity), 
Sweden (by Stockholm and non-Stockholm), and the UK 
(by local government authorities). All subnational 
estimates for these countries were incorporated into 
model development and evaluation as part of GBD 2017. 
To meet data use requirements, in this publication we 
present all subnational estimates excluding those pending 
publication (Brazil, India, Japan, Kenya, Mexico, Sweden, 
the UK, and the USA; appendix 2). Subnational estimates 
for countries with populations larger than 200 million 
(measured using the most recent year of pub lished 
estimates) that have not yet been published else where 
are presented wherever estimates are illustrated with 
maps but are not included in data tables.
Attributable burden estimation
Four components were used for the calculations to 
estimate the attributable burden for a given risk–
outcome pair: (1) the estimate of the burden metric 
being assessed for the cause (ie, number of deaths, 
years of life lost [YLLs], years lived with disability 
[YLDs], or DALYs); (2) the exposure levels for the risk 
factor; (3) the counter factual level of risk factor exposure 
or theoretical minimum risk exposure level (TMREL); 
and (4) the relative risk of the outcome relative to the 
TMREL. For a given risk–outcome pair, we estimated 
attributable DALYs as total DALYs for the outcome 
multiplied by the population attributable fraction (PAF) 
for the risk–out come pair for each age, sex, location, 
and year. The same logic applies to estimating 
attributable deaths, YLLs, and YLDs. The PAF is the 
proportion by which the outcome would be reduced in 
a given population and in a given year if the exposure to 
a risk factor in the past were reduced to the 
counterfactual level of the TMREL. The PAF for each 
individual risk–outcome pair is estimated independently 
and incorporates all burden for the outcome that is 
attributable to the risk, whether directly or indirectly. 
For example, the burden of ischaemic heart disease 
attributable to high body-mass index (BMI) includes 
the burden resulting from the direct effect of BMI on 
ischaemic heart disease risk, as well as the burden 
through the effects of BMI on ischaemic heart disease 
that are mediated through other risks (eg, high systolic 
blood pressure [SBP] and high low-density lipoprotein 
[LDL] cholesterol). When aggregating PAFs across 
multiple risks we used a mediation adjustment 
to compute the excess attenuated risk for each of 
205 mediation-risk-cause sets (appendix 1 section 5).
Estimation process
Information about the data sources, estimation methods, 
computational tools, and statistical analyses used to 
derive our estimates are provided in appendix 1 
(sections 1–4). The analytical steps for estimating the 
burden attributable to single or clusters of risk–out come 
pairs are summarised in the appendix 1 (section 2). 
Table 1 provides definitions of exposure for each risk 
factor and the TMREL used. Although the approach taken 
is largely similar to GBD 2016, we have implemented 
improve ments to methods and incorpor ated new data 
sources. Appendix 1 (section 4) details each analytical step 
by risk. Citation information for the data sources used for 
relative risks is provided in an online source tool.
We report all point estimates with 95% uncertainty 
intervals (UIs). To ensure that UIs capture uncertainty 
from all relevant sources (uncertainty in exposures, 
relative risks, TMRELs, and burden estimates) we 
propagate uncertainty through the estimation chain 
using posterior simulation using 1000 draws, from which 
we derive the lower and upper bounds of the UI based on 
the 2·5th and 97·5th percentiles. Where reported, esti-
mates of percentage change were computed on the basis 
of the point estimates for the timepoints being compared.
Summary exposure values
For each risk, we produced a summary measure of 
exposure, called the summary exposure value (SEV). The 
metric is a risk-weighted prevalence of an exposure, and 
it offers an easily comparable single-number summary 
For the online results tool see 
http://ghdx.healthdata.org/gbd-
results-tool
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Risk factors Exposure definition Theoretical minimum risk exposure 
level
Data representativeness index
Before 2007 2007–17 Total
0 All ·· ·· 100·0% 100·0% 100·0%
1 Environmental and occupational risks ·· ·· 100·0% 100·0% 100·0%
2 Unsafe water, sanitation, and 
handwashing
·· ·· 80·3% 63·7% 82·4%
3 Unsafe water source Proportion of individuals with access to different 
water sources (unimproved, improved except piped, 
or piped water supply) and reported use of 
household water treatment methods (boiling or 
filtering, chlorinating or solar filtering, or no 
treatment)
All individuals have access to water 
from a piped water supply that is also 
boiled or filtered before drinking
78·2% 61·1% 79·8%
3 Unsafe sanitation Proportion of individuals with access to different 
sanitation facilities (unimproved, improved except 
sewer, or sewer connection)
All individuals have access to toilets 
with sewer connection
75·7% 54·9% 78·8%
3 No access to handwashing facility Proportion of individuals with access to 
handwashing facility with soap, water, and wash 
station
All individuals have access to 
handwashing facility with soap, water, 
and wash station
13·5% 34·7% 39·4%
2 Air pollution ·· ·· 100·0% 100·0% 100·0%
3 Particulate matter pollution ·· ·· 82·9% 88·6% 96·4%
4 Ambient particulate matter pollution Annual average daily exposure to outdoor air 
concentrations of particulate matter with an 
aerodynamic diameter of ≤2·5 µm (PM2·5), 
measured in μg/m³
Joint theoretical minimum risk 
exposure level for both household and 
ambient particulate matter pollution is 
a uniform distribution between 2·4 and 
5·9 μg/m³, with burden attributed 
proportionally between household and 
particulate matter pollution on the 
basis of source of PM2·5 exposure in 
excess of theoretical minimum risk 
exposure level
17·1% 57·0% 58·0%
4 Household air pollution from solid 
fuels
Individual exposure to PM2·5 due to use of solid 
cooking fuel
See ambient particulate matter 
pollution
82·9% 63·4% 85·5%
3 Ambient ozone pollution Seasonal (6-month period with highest ozone) 
8-h daily maximum ozone concentrations, 
measured in ppb
Uniform distribution between 29·1 and 
35·7 ppb
100·0% 100·0% 100·0%
2 Other environmental risks ·· ·· 47·2% 30·1% 48·7%
3 Residential radon Average daily exposure to indoor air radon levels 
measured in becquerels (radon disintegrations 
per second) per cubic metre (Bq/m³)
10 Bq/m³, corresponding to the 
outdoor concentration of radon
36·8% 8·8% 36·8%
3 Lead exposure Blood lead levels in µg/dL of blood, bone lead levels 
in µg/g of bone
2 μg/dL, corresponding to lead levels in 
pre-industrial humans as natural 
sources of lead prevent the feasibility of 
zero exposure
35·8% 26·9% 40·9%
2 Occupational risks ·· ·· 100·0% 100·0% 100·0%
3 Occupational carcinogens ·· ·· 100·0% 100·0% 100·0%
4 Occupational exposure to asbestos Proportion of the population with cumulative 
lifetime exposure to occupational asbestos
No occupational exposure to asbestos 100·0% 100·0% 100·0%
4 Occupational exposure to arsenic Proportion of the population ever exposed to 
arsenic at work or through their occupation
No occupational exposure to arsenic 100·0% 100·0% 100·0%
4 Occupational exposure to benzene Proportion of the population ever exposed to 
benzene at work or through their occupation
No occupational exposure to benzene 100·0% 100·0% 100·0%
4 Occupational exposure to beryllium Proportion of the population ever exposed to 
beryllium at work or through their occupation
No occupational exposure to beryllium 100·0% 100·0% 100·0%
4 Occupational exposure to cadmium Proportion of the population ever exposed to 
cadmium at work or through their occupation
No occupational exposure to cadmium 100·0% 100·0% 100·0%
4 Occupational exposure to chromium Proportion of the population ever exposed to 
chromium at work or through their occupation
No occupational exposure to chromium 100·0% 100·0% 100·0%
4 Occupational exposure to diesel engine 
exhaust
Proportion of the population ever exposed to diesel 
engine exhaust at work or through their occupation
No occupational exposure to diesel 
engine exhaust
100·0% 100·0% 100·0%
4 Occupational exposure to 
formaldehyde
Proportion of the population ever exposed to 
formaldehyde at work or through their occupation
No occupational exposure to 
formaldehyde
100·0% 100·0% 100·0%
(Table 1 continues on next page)
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Risk factors Exposure definition Theoretical minimum risk exposure 
level
Data representativeness index
Before 2007 2007–17 Total
(Continued from previous page)
4 Occupational exposure to nickel Proportion of the population ever exposed to nickel 
at work or through their occupation
No occupational exposure to nickel 100·0% 100·0% 100·0%
4 Occupational exposure to polycyclic 
aromatic hydrocarbons
Proportion of the population ever exposed to 
polycyclic aromatic hydrocarbons at work or 
through their occupation
No occupational exposure to polycyclic 
aromatic hydrocarbons
100·0% 100·0% 100·0%
4 Occupational exposure to silica Proportion of the population ever exposed to silica 
at work or through their occupation
No occupational exposure to silica 100·0% 100·0% 100·0%
4 Occupational exposure to sulphuric 
acid
Proportion of the population ever exposed to 
sulphuric acid at work or through their occupation
No occupational exposure to sulphuric 
acid
100·0% 100·0% 100·0%
4 Occupational exposure to 
trichloroethylene
Proportion of the population ever exposed to 
trichloroethylene at work or through their 
occupation
No occupational exposure to 
trichloroethylene
100·0% 100·0% 100·0%
3 Occupational asthmagens Proportion of the population currently exposed to 
asthmagens at work or through their occupation
Background asthmagen exposures 88·1% 82·9% 91·2%
3 Occupational particulate matter, gases, 
and fumes
Proportion of the population ever exposed to 
particulates, gases, or fumes at work or through 
their occupation
No occupational exposure to 
particulates, gases, or fumes
86·5% 81·9% 89·6%
3 Occupational noise Proportion of the population ever exposed to noise 
greater than 85 decibels at work or through their 
occupation
Background noise exposure 86·5% 81·0% 89·6%
3 Occupational injuries Proportion of the population at risk to injuries 
related to work or through their occupation
The rate of injury deaths per 100 000 
person-years is zero
88·1% 82·9% 92·2%
3 Occupational ergonomic factors Proportion of the population who are exposed to 
ergonomic risk factors for low back pain at work or 
through their occupation
All individuals have the ergonomic 
factors of clerical and related workers
84·5% 81·9% 89·6%
1 Behavioural risks ·· ·· 100·0% 100·0% 100·0%
2 Child and maternal malnutrition ·· ·· 98·5% 97·4% 98·5%
3 Suboptimal breastfeeding ·· ·· 75·1% 60·6% 83·4%
4 Non-exclusive breastfeeding Proportion of children younger than 6 months who 
receive predominant, partial, or no breastfeeding
All children are exclusively breastfed for 
first 6 months of life
75·1% 60·6% 83·4%
4 Discontinued breastfeeding Proportion of children aged 6–23 months who do 
not receive any breast milk
All children continue to receive breast 
milk until 2 years of age
75·1% 60·6% 83·4%
3 Child growth failure ·· ·· 76·2% 65·3% 77·2%
4 Child underweight Proportion of children ≥3 SDs, 2–3 SDs, and 1–2 SDs 
lower than the WHO 2006 standard weight-for-age 
curve
All children are <1 SD below the WHO 
2006 standard weight-for-age curve
75·1% 63·7% 76·7%
4 Child wasting Proportion of children ≥3 SDs, 2–3 SDs, and 1–2 SDs 
lower than the WHO 2006 standard 
weight-for-length curve
All children are <1 SD below the WHO 
2006 standard weight-for-height curve
75·1% 65·3% 77·2%
4 Child stunting Proportion of children ≥3 SDs, 2–3 SDs, and 1–2 SDs 
lower than the WHO 2006 standard height-for-age 
curve
All children are <1 SD below the WHO 
2006 standard height-for-age curve
75·1% 64·8% 77·2%
3 Low birthweight and short gestation ·· ·· 75·7% 78·2% 86·0%
4 Low birthweight for gestation Proportion of births occurring in 2-week gestational 
age categories from [0–24) weeks to [40–42) weeks, 
for each 500-g birthweight category starting from 
[0–500) g to [4000–4500) g*
500-g birthweight category with lowest 
risk within each gestational age 
category
75·7% 78·2% 86·0%
4 Short gestation for birthweight Proportion of births occurring in 500-g birthweight 
categories from [0–500) g to [4000–4500) g, 
for each 2-week gestational age category starting 
from [0–24) weeks to [40–42) weeks*
2-week gestational age category with 
lowest risk within each birthweight 
category
75·7% 78·2% 86·0%
3 Iron deficiency Peripheral blood haemoglobin concentration in g/L 
for all iron-responsive causes
Counterfactual haemoglobin 
concentration in the absence of iron 
deficiency in g/L for all iron-responsive 
causes
75·1% 78·2% 86·0%
3 Vitamin A deficiency Proportion of children aged 0–5 years with serum 
retinol concentration <0·7 µmol/L
No childhood vitamin A deficiency 63·7% 43·5% 64·8%
(Table 1 continues on next page)
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Risk factors Exposure definition Theoretical minimum risk exposure 
level
Data representativeness index
Before 2007 2007–17 Total
(Continued from previous page)
3 Zinc deficiency Proportion of the population with inadequate zinc 
intake versus loss
No inadequate zinc intake 92·2% 92·2% 92·2%
2 Tobacco ·· ·· 99·0% 99·0% 100·0%
3 Smoking Prevalence of current use of any smoked tobacco 
product and prevalence of former use of any smoked 
tobacco product; among current smokers, cigarette 
equivalents smoked per smoker per day and 
cumulative pack-years of exposure; among former 
smokers, number of years since quitting
All individuals are lifelong non-smokers 98·5% 98·5% 99·5%
3 Chewing tobacco Current use of any chewing tobacco product All individuals are lifelong non-users of 
chewing tobacco products
33·2% 70·5% 73·6%
3 Second-hand smoke Average daily exposure to air particulate matter 
from second-hand smoke with an aerodynamic 
diameter smaller than 2·5 µg, measured in µg/m³, 
among non-smokers
No second-hand smoke exposure 80·3% 73·1% 88·1%
2 Alcohol use Average daily alcohol consumption of pure 
alcohol (measured in g per day) in current 
drinkers who had consumed alcohol during the 
past 12 months
Estimated distribution 0–10 g per day 52·3% 33·2% 59·6%
2 Drug use Proportion of the population dependent upon 
opioids, cannabis, cocaine, or amphetamines; 
proportion of the population who have ever 
injected drugs
No drug use 17·6% 30·1% 39·4%
2 Dietary risks ·· ·· 100·0% 100·0% 100·0%
3 Diet low in fruits Average daily consumption of fruits (fresh, frozen, 
cooked, canned, or dried, excluding fruit juices and 
salted or pickled fruits)
Consumption of fruit 200–300 g 
per day
68·9% 38·3% 78·8%
3 Diet low in vegetables Average daily consumption of vegetables (fresh, 
frozen, cooked, canned, or dried, excluding legumes 
and salted or pickled vegetables, juices, nuts and 
seeds, and starchy vegetables such as potatoes or 
corn)
Consumption of vegetables 
290–430 g per day
100·0% 100·0% 100·0%
3 Diet low in legumes Average daily consumption of legumes (fresh, 
frozen, cooked, canned, or dried legumes)
Consumption of legumes 50–70 g 
per day
100·0% 100·0% 100·0%
3 Diet low in whole grains Average daily consumption of whole grains (bran, 
germ, and endosperm in their natural proportion) 
from breakfast cereals, bread, rice, pasta, biscuits, 
muffins, tortillas, pancakes, and other sources
Consumption of whole grains 
100–150 g per day
58·6% 28·0% 68·9%
3 Diet low in nuts and seeds Average daily consumption of nut and seed foods Consumption of nuts and seeds 
16–25 g per day
100·0% 100·0% 100·0%
3 Diet low in milk Average daily consumption of milk, including 
non-fat, low-fat, and full-fat milk, excluding soy 
milk and other plant derivatives
Consumption of milk 350–520 g 
per day
100·0% 100·0% 100·0%
3 Diet high in red meat Average daily consumption of red meat (beef, pork, 
lamb, and goat but excluding poultry, fish, eggs, and 
all processed meats)
Consumption of red meat 18–27 g 
per day
100·0% 100·0% 100·0%
3 Diet high in processed meat Average daily consumption of meat preserved by 
smoking, curing, salting, or addition of chemical 
preservatives
Consumption of processed meat 0–4 g 
per day
100·0% 100·0% 100·0%
3 Diet high in sugar-sweetened beverages Average daily consumption of beverages with 
≥50 kcal per 226·8 g serving, including carbonated 
beverages, sodas, energy drinks, fruit drinks, 
but excluding 100% fruit and vegetable juices
Consumption of sugar-sweetened 
beverages 0–5 g per day
13·0% 16·1% 26·9%
3 Diet low in fibre Average daily intake of fibre from all sources 
including fruits, vegetables, grains, legumes, and 
pulses
Consumption of fibre 19–28 g per day 100·0% 100·0% 100·0%
3 Diet low in calcium Average daily intake of calcium from all sources, 
including milk, yogurt, and cheese
Consumption of calcium 1·0–1·5 g 
per day
100·0% 100·0% 100·0%
(Table 1 continues on next page)
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of exposure to each risk. SEVs range from 0% to 100%, 
where 0% reflects no risk exposure in a population and 
100% indicates that an entire population is exposed to the 
maximum possible level for that risk. We show estimates 
of SEVs for each risk factor (table 2; appendix 2) and 
provide details on how SEVs are computed for categorical 
and continuous risks in the appendix 1 (section 2).
Updates to spatiotemporal Gaussian process regression
Spatiotemporal Gaussian process regression has been 
used in previous versions of GBD to estimate exposure 
for many risks, typically those with rich age-sex-specific 
data. It synthesises noisy data by borrowing strength 
across space, time, and age to best estimate the underlying 
trends for a given risk. With sufficient data, spatiotemporal 
Gaussian process regression is a fast and flexible 
modelling strategy for fitting non-linear temporal trends. 
Although methods were detailed for previous iterations of 
GBD,2 we have implemented several improve ments for 
GBD 2017. First, we have added a space-time interaction 
weight, which flexibly adjusts the spatial weight of 
datapoints as an inverse function of data density over 
Risk factors Exposure definition Theoretical minimum risk exposure 
level
Data representativeness index
Before 2007 2007–17 Total
(Continued from previous page)
3 Diet low in seafood omega 3 fatty acids Average daily intake of eicosapentaenoic acid and 
docosahexaenoic acid
Consumption of seafood omega 3 fatty 
acids 200–300 mg per day
100·0% 100·0% 100·0%
3 Diet low in polyunsaturated fatty acids Average daily intake of omega 6 fatty acids from all 
sources, mainly liquid vegetable oils, including 
soybean oil, corn oil, and safflower oil
Consumption of polyunsaturated fatty 
acids as 9–13% of total daily energy
61·1% 31·1% 67·9%
3 Diet high in trans fatty acids Average daily intake of trans fat from all sources, 
mainly partially hydrogenated vegetable oils and 
ruminant products
Consumption of trans fatty acids as 
0–1% of total daily energy
35·8% 36·8% 36·8%
3 Diet high in sodium 24-h urinary sodium measured in g per day 24-h urinary sodium 1–5 g per day 13·5% 17·6% 21·8%
2 Intimate partner violence Proportion of the population who have ever 
experienced one or more acts of physical or sexual 
violence by a present or former intimate partner 
since age 15 years
No intimate partner violence 65·8% 70·5% 84·5%
2 Childhood maltreatment ·· ·· 44·6% 62·2% 70·5%
3 Childhood sexual abuse Proportion of the population ever having had the 
experience of intercourse or other contact abuse 
(ie, fondling and other sexual touching) when aged 
15 years or younger, and the perpetrator or partner 
was more than 5 years older than the victim
No childhood sexual abuse 31·1% 20·7% 38·9%
3 Bullying victimisation Proportion of population attending school who 
have been exposed to bullying victimisation within 
the past year
No bullying victimisation 26·4% 52·3% 58·6%
2 Unsafe sex Proportion of the population with exposure to 
sexual encounters that convey the risk of disease
No exposure to disease-causing 
pathogen through sex
18·7% 49·2% 50·3%
2 Low physical activity Average weekly physical activity at work, home, 
transport-related and recreational measured by 
MET min per week
All adults experience 
3000–4500 MET min per week
51·3% 32·1% 67·4%
1 Metabolic risks ·· ·· 100·0% 100·0% 100·0%
2 High fasting plasma glucose Serum fasting plasma glucose measured in 
mmol/L
4·8–5·4 mmol/L 50·3% 50·3% 67·9%
2 High low-density lipoprotein 
cholesterol
Serum low-density lipoprotein, measured in 
mmol/L
0·7–1·3 mmol/L 49·7% 48·2% 71·5%
2 High systolic blood pressure Systolic blood pressure, measured in mm Hg 110–115 mm Hg 61·1% 64·8% 81·4%
2 High body-mass index Body-mass index, measured in kg/m² 20–25 kg/m² 100·0% 100·0% 100·0%
2 Low bone mineral density Standardised mean bone mineral density values 
measured by dual x-ray absorptiometry at the 
femoral neck in g/cm²
99th percentile of NHANES 
1988–2014 by age and sex
23·8% 10·4% 25·9%
2 Impaired kidney function Proportion of the population with ACR >30 mg/g 
or GFR <60 mL/min/1·73 m², excluding end-stage 
renal disease
GFR >60 mL/min/1·73 m² and ACR 
<30 mg/g
16·1% 28·5% 31·1%
The data representativeness index is calculated as the percentage of locations for which we have data in a given time period. ACR=albumin-to-creatine ratio. GBD=Global Burden of Diseases, Injuries, and Risk 
Factors Study. GFR=glomerular filtration rate. MET=metabolic equivalent. NHANES=National Health and Nutrition Examination Survey. PM2·5=particulate matter with an aerodynamic diameter smaller than 
2·5 µm, measured in µm/m³. ppb=parts per billion. *In numbered intervals, square brackets indicate included endpoints and round brackets indicate excluded endpoints. 
Table 1: GBD 2017 risk factor hierarchy and accompanying exposure definitions, theoretical minimum risk exposure level, and data representativeness index for each risk factor, 
pre-2007, 2007–17, and total (across all years)
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time. Second, we refined our method for calculating 
model uncertainty to ensure that modelling CIs aligned 
better with observed data variance and were more resilient 
to parameter changes. Finally, we improved raking, a 
post-processing step that ensures internal consistency 
between nested locations (sub nationals) and their parents. 
Specifically, we implemented an option to rake in logit 
space, ensuring that raked estimates of prevalence data 
are naturally constrained between 0 and 1. More details 
are given in appendix 1 (section 2).
Drivers of trends in DALYs
We decomposed temporal changes in DALYs into six main 
component drivers of change: (1) population growth; 
(2) changes in population age structures; (3) changes in 
exposure to environmental and occu pational risks; 
(4) changes in exposure to behavioural risks, (5) changes 
in exposure to metabolic risks; and (6) changes due to all 
other factors, approximated as the risk-deleted death and 
DALY rates. The risk-deleted rate is the death or DALY 
rate that would be observed had we removed all risk 
factors included in GBD 2017. In other words, the risk-
deleted rate is the rate that would be observed had we 
reduced exposure levels to the TMREL for all risk factors 
included in GBD 2017. Changes in risk-deleted rates might 
reflect changes in risks or risk–outcome pairs that are not 
included in our analysis, or changes in other factors like 
improved treatments. We used methods developed by 
Das Gupta7 and adapted in GBD 2016 to ensure that 
decomposition results are linear aggregates over time or 
risk. We did a decomposition analysis for the 10-year 
period of 2007–17, for individual risks and the all-risk 
aggregate, accounting for risk mediation at the Level 4 risk 
and cause level. The contribution of changes in exposure 
to the individual risks was scaled to the all-risk effect. The 
contribution of risk exposures at higher cause and risk 
aggregates (eg, all-cause attributable to Level 1 GBD risks), 
or for all ages and both sexes combined, were calculated as 
the linear aggregate of the effect of individual risks for 
each cause, age, and sex.
Epidemiological transition
SDI is a composite indicator of development status that 
was originally constructed for GBD 2015, and is derived 
from components that correlate strongly with health 
outcomes. It is the geometric mean for indices of the 
total fertility rate among women younger than 25 years, 
mean education for those aged 15 years or older, and lag-
distributed income per capita. The resulting metric 
ranges from 0 to 1, with higher values corresponding to 
higher levels of development. SDI estimation methods 
and estimates are detailed in appendix 1 (section 2). We 
examined the relationship between SDI and SEV to 
understand the relationship between development status 
and risk factor exposure levels. For each risk factor, we fit a 
separate generalised additive model with a Loess smoother 
on SDI for each combination of age group and sex. Inputs 
to this model were age-sex-specific SEVs for all Level 4 
risks in the GBD risk hierarchy, for all national GBD 
locations and years between 1990 and 2017. Using an 
analogous modelling framework, we estimated the 
expected age and sex structure by SDI and used these 
expected age and sex proportions to calculate age and sex 
aggregates of expected exposure. For each risk–outcome 
pair, we used the expected SEVs to calculate expected 
PAFs. Because the SEVs for a given risk are not cause 
specific, the expected PAF estimates were then corrected 
using cause-specific correction factors that were derived by 
calibrating expected PAFs against empirical PAFs. To 
estimate expected risk-attributable burden, we drew from 
the CRA methods, first calculating the joint adjusted 
expected PAF for all risks for a cause using mediation 
factors (appendix 1 section 2). We then drew from the 
methods for observed risk-attributable burden calculation, 
using expected YLLs, deaths, and YLDs (appendix 1 
section 2) to generate expected burden for a given SDI.
New risks and risks with substantial changes in the 
estimation methods compared with GBD 2016
Bullying victimisation is a new risk factor for GBD 2017. 
We estimate two outcomes for bullying in the GBD 
analysis: anxiety disorders and major depressive 
disorder. Bullying is commonly conceptualised as the 
intentional and repeated harm of a less powerful 
individual by peers and defined in the GBD as bullying 
victimisation of children and adolescents attending 
school by peers. This does not mean that bullying 
occurs exclusively at school and includes bullying that 
might occur to and from school as well as cyberbullying. 
We developed inclusion criteria that were robust 
while adaptable to the hetero geneity in largely non-
health literature. Prevalence data were sourced from 
multicountry survey series including the Global School-
based Student Health Survey and the Health Behavior in 
School-aged Children survey, as well as peer-reviewed 
studies, and were available for 153 GBD locations, 
covering all seven GBD super-regions. To reflect the 
exposure data and the definition of bullying victimisation 
in GBD, we adjusted prevalence estimates for the 
proportion of young people attending school using 
data published by the UN Educational, Scientific, and 
Culture Organization. Because the effect of bullying on 
depressive and anxiety disorders has been reported to 
wane over time and because prevalence estimates were 
from surveys of young people reporting current bullying 
victimisation rather than estimates of past exposure at 
the time the outcomes occur (ie, retrospective estimates), 
we developed a cohort method in which the prevalence 
of bullying victimisation exposure was tracked for the 
cohort of interest and relative risks varied with time 
between exposure to bullying and the point of estimation.
In GBD 2017, the modelling process for air pollution, 
including ambient, household, and ozone exposure 
sources, was substantially improved. We adjusted the 
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Risk Both sexes Males Females
Percentage 
change, 
1990–2017
1990 2007 2017 Percentage 
change, 
1990–2007
Percentage 
change, 
2007–17
Percentage 
change, 
1990–2017
1990 2007 2017 Percentage 
change, 
1990–2007
Percentage 
change, 
2007–17
Percentage 
change, 
1990–2017
1 Environmental and occupational risks
2 Unsafe water, sanitation, and handwashing
3 Unsafe water 
source
–21·24% 
(–25·26 to 
–17·26)*
43·22 
(41·16 to 
44·81)
36·07 
(33·72 to 
37·87)
33·57 
(30·81 to 
35·60)
–16·53% 
(–19·34 to 
–13·99)*
–6·93% 
(–9·73 to 
–3·91)*
–22·32% 
(–26·29 to 
–18·32)*
42·46 
(40·42 to 
44·03)
35·94 
(33·62 to 
37·70)
33·87 
(31·09 
to 
35·88)
–15·35% 
(–18·19 to 
–12·85)*
–5·76% 
(–8·53 to 
–2·77)*
–20·23% 
(–24·28 to 
–16·19)*
3 Unsafe 
sanitation
–47·80% 
(–52·10 to 
–43·25)*
58·10 
(53·42 to 
64·54)
40·88 
(36·53 to 
46·98)
29·88 
(25·66 
to 35·37)
–29·64% 
(–33·19 to 
–26·07)*
–26·92% 
(–31·82 to 
–21·86)*
–48·58% 
(–52·90 to 
–44·00)*
57·19 
(52·49 to 
63·65)
40·82 
(36·45 to 
46·95)
30·28 
(26·02 
to 
35·86)
–28·62% 
(–32·16 to 
–25·19)*
–25·81% 
(–30·56 to 
–20·97)*
–47·04% 
(–51·30 to 
–42·56)*
3 No access to 
handwashing 
facility
–12·72% 
(–16·05 to 
–9·07)*
37·81 
(36·77 to 
38·82)
34·52 
(33·41 to 
35·60)
32·51 
(31·36 to 
33·63)
–8·72% 
(–11·64 to 
–5·64)*
–5·82% 
(–8·35 to 
–3·11)*
–14·04% 
(–17·38 to 
–10·35)*
37·33 
(36·35 to 
38·30)
34·58 
(33·52 to 
35·62)
33·05 
(31·93 to 
34·14)
–7·37% 
(–10·17 to 
–4·35)*
–4·43% 
(–6·89 to 
–1·78)*
–11·47% 
(–14·82 to 
–7·86)*
2 Air pollution
3 Particulate matter pollution
4 Ambient 
particulate 
matter 
pollution
41·21% 
(32·15 to 
51·99)*
30·08 
(23·45 to 
38·60)
39·91 
(31·90 to 
50·67)
41·90 
(33·87 
to 
52·75)
32·71% 
(25·60 to 
40·41)*
4·97% 
(–0·59 to 
10·91)
39·30% 
(29·87 to 
50·14)*
26·83 
(21·00 to 
34·70)
36·13 
(28·60 
to 46·32)
38·48 
(30·87 
to 
49·05)
34·66% 
(27·56 to 
42·79)*
6·50% 
(0·68 to 
13·17)*
43·41% 
(33·87 to 
55·06)*
4 Household air 
pollution from 
solid fuels
–45·83% 
(–49·75 to 
–41·46)*
45·57 
(39·19 to 
54·22)
31·57 
(26·36 to 
39·05)
23·90 
(19·50 
to 30·22)
–30·73% 
(–34·45 to 
–26·65)*
–24·30% 
(–28·40 to 
–19·95)*
–47·56% 
(–51·58 to 
–42·78)*
46·00 
(39·75 to 
54·60)
33·13 
(27·85 to 
40·66)
25·67 
(21·04 
to 
32·02)
–27·98% 
(–31·53 to 
–24·27)*
–22·50% 
(–26·61 to 
–18·30)*
–44·19% 
(–48·30 to 
–39·43)*
3 Ambient ozone 
pollution
3·02% 
(2·30 to 
4·82)*
41·72 
(18·06 
to 51·11)
41·88 
(18·13 to 
51·37)
42·89 
(18·89 
to 52·32)
0·38% 
(0·16 to 
0·61)*
2·42% 
(1·77 to 
4·14)*
2·81% 
(2·22 to 
4·43)*
41·25 
(17·72 to 
50·99)
41·50 
(17·88 to 
51·27)
42·58 
(18·65 
to 
52·26)
0·62% 
(0·41 to 
0·91)*
2·60% 
(1·88 to 
4·36)*
3·24% 
(2·40 to 
5·22)*
2 Other environmental risks
3 Residential 
radon
–0·23% 
(–5·56 to 
5·43)
23·73 
(14·82 to 
33·91)
23·64 
(14·79 to 
33·99)
23·68 
(14·72 to 
34·19)
–0·40% 
(–3·44 to 
2·75)
0·18% 
(–1·97 to 
2·32)
–0·22% 
(–5·27 to 
5·15)
23·72 
(14·85 to 
33·65)
23·64 
(14·80 
to 33·92)
23·66 
(14·75 to 
34·15)
–0·33% 
(–3·57 to 
3·21)
0·10% 
(–2·29 to 
2·38)
–0·23 
(–5·72 to 
5·66)
3 Lead exposure –27·66% 
(–33·58 to 
–22·08)*
15·65 
(11·46 to 
19·44)
13·94 
(9·97 to 
17·65)
11·14 
(7·54 to 
14·68)
–10·93% 
(–13·35 to 
–8·81)*
–20·12% 
(–24·35 to 
–16·16)*
–28·85% 
(–34·39 to 
–23·60)*
9·56 
(5·94 to 
13·25)
8·79 
(5·34 to 
12·41)
7·15 
(4·10 to 
10·63)
–8·11% 
(–10·42 to 
–6·13)*
–18·67% 
(–23·43 to 
–14·24)*
–25·26 
(–31·19 to 
–19·60)*
2 Occupational risks
3 Occupational carcinogens
4 Occupational 
exposure to 
asbestos
–13·76% 
(–26·71 to 
2·19)
2·67 
(2·33 to 
3·05)
2·47 
(2·38 to 
2·60)
2·36 
(2·28 to 
2·45)
–7·69% 
(–15·84 to 
3·65)
–4·24% 
(–8·89 to 
–0·25)*
–11·61% 
(–22·98 to 
2·54)
0·98 
(0·76 to 
1·25)
0·79 
(0·73 to 
0·88)
0·74 
(0·70 to 
0·79)
–18·62% 
(–30·99 to 
–2·32)*
–6·58% 
(–13·55 to 
–0·85)*
–23·97% 
(–40·00 to 
–3·78)*
4 Occupational 
exposure to 
arsenic
5·12% 
(–0·36 to 
25·19)
0·32 
(0·09 to 
0·61)
0·33 
(0·10 to 
0·60)
0·34 
(0·10 to 
0·61)
2·14% 
(–1·61 to 
13·84)
2·96% 
(0·27 to 
8·66)*
5·16% 
(–0·22 to 
22·82)
0·29 
(0·08 to 
0·57)
0·30 
(0·09 to 
0·57)
0·31 
(0·10 to 
0·57)
3·10% 
(–1·78 to 
18·37)
2·08% 
(–1·89 to 
9·22)
5·25% 
(–1·93 to 
27·75)
4 Occupational 
exposure to 
benzene
26·04% 
(18·96 to 
41·92)*
0·54 
(0·26 to 
1·11)
0·60 
(0·31 to 
1·20)
0·65 
(0·35 to 
1·27)
11·09% 
(7·19 to 
19·40)*
7·85% 
(5·67 to 
11·95)*
19·81% 
(13·79 to 
33·14)*
0·51 
(0·22 to 
1·10)
0·60 
(0·28 to 
1·26)
0·68 
(0·34 to 
1·37)
18·18% 
(13·55 to 
28·19)*
12·38% 
(8·91 to 
18·81)*
32·80% 
(24·14 to 
51·85)*
4 Occupational 
exposure to 
beryllium
16·89% 
(14·86 to 
18·95)*
0·06 
(0·06 to 
0·06)
0·07 
(0·07 to 
0·07)
0·07 
(0·07 to 
0·07)
8·52% 
(6·79 to 
10·34)*
4·84% 
(3·52 to 
6·14)*
13·77% 
(11·32 to 
16·13)*
0·05 
(0·05 to 
0·06)
0·06 
(0·06 to 
0·06)
0·07 
(0·06 to 
0·07)
13·36% 
(10·83 to 
16·02)*
6·40% 
(4·63 to 
8·17)*
20·61% 
(17·00 to 
23·99)*
4 Occupational 
exposure to 
cadmium
19·99% 
(16·30 to 
23·69)*
0·13 
(0·12 to 
0·13)
0·14 
(0·14 to 
0·14)
0·15 
(0·14 to 
0·15)
10·87% 
(7·77 to 
14·21)*
6·98% 
(4·25 to 
9·51)*
18·60% 
(14·62 to 
23·00)*
0·11 
(0·11 to 
0·11)
0·13 
(0·12 to 
0·13)
0·14 
(0·13 to 
0·14)
13·74% 
(8·91 to 
18·80)*
6·97% 
(2·93 to 
11·70)*
21·67% 
(15·26 to 
28·32)*
4 Occupational 
exposure to 
chromium
27·30% 
(23·48 to 
31·27)*
0·27 
(0·26 to 
0·27)
0·31 
(0·30 to 
0·32)
0·34 
(0·33 to 
0·35)
14·76% 
(11·61 to 
18·16)*
9·57% 
(6·88 to 
12·06)*
25·75% 
(21·56 to 
30·31)*
0·23 
(0·23 to 
0·24)
0·28 
(0·26 to 
0·29)
0·30 
(0·29 to 
0·32)
17·53% 
(12·32 to 
22·84)*
9·97% 
(5·72 to 
14·97)*
29·25% 
(22·17 to 
36·37)*
4 Occupational 
exposure to 
diesel engine 
exhaust
35·56% 
(32·42 to 
38·55)*
1·51 
(1·48 to 
1·54)
1·83 
(1·80 to 
1·87)
2·07 
(2·03 to 
2·11)
21·61% 
(18·81 to 
24·46)*
13·01% 
(10·71 to 
15·21)*
37·44% 
(33·50 to 
41·49)*
0·94 
(0·92 to 
0·97)
1·12 
(1·09 to 
1·15)
1·25 
(1·22 to 
1·29)
19·06% 
(15·56 to 
22·55)*
11·94% 
(8·84 to 
15·03)*
33·27% 
(28·17 to 
38·41)*
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4 Occupational 
exposure to 
formaldehyde
21·55% 
(17·49 to 
25·59)*
0·59 
(0·57 to 
0·60)
0·66 
(0·63 to 
0·68)
0·71 
(0·68 to 
0·74)
12·38% 
(8·98 to 
16·13)*
8·08% 
(5·06 to 
10·93)*
21·45% 
(16·98 to 
26·18)*
0·49 
(0·47 to 
0·51)
0·55 
(0·53 to 
0·58)
0·60 
(0·57 to 
0·63)
12·83% 
(7·23 to 
18·52)*
7·96% 
(3·51 to 
12·96)*
21·81% 
(14·97 to 
28·83)*
4 Occupational 
exposure to 
nickel
1·54% 
(–5·26 to 
19·70)
0·35 
(0·08 to 
1·10)
0·35 
(0·09 to 
1·08)
0·36 
(0·10 to 
1·08)
0·75% 
(–3·92 to 
11·90)
2·38% 
(–0·40 to 
8·20)
3·15% 
(–3·54 to 
20·18)
0·28 
(0·06 to 
0·90)
0·28 
(0·07 to 
0·85)
0·28 
(0·07 to 
0·84)
–0·34% 
(–5·50 to 
14·23)
0·17% 
(–3·46 to 
8·49)
–0·17% 
(–7·70 to 
20·71)
4 Occupational 
exposure to 
polycyclic 
aromatic 
hydrocarbons
27·66% 
(23·85 to 
31·43)*
0·55 
(0·54 to 
0·56)
0·64 
(0·62 to 
0·65)
0·70 
(0·68 to 
0·72)
14·82% 
(11·95 to 
18·02)*
9·71% 
(7·23 to 
12·04)*
25·97% 
(21·96 to 
30·35)*
0·48 
(0·47 to 
0·49)
0·56 
(0·54 to 
0·59)
0·62 
(0·59 to 
0·65)
17·49% 
(12·50 to 
22·50)*
10·47% 
(6·20 to 
15·11)*
29·79% 
(23·18 to 
36·31)*
4 Occupational 
exposure to 
silica
2·21% 
(–2·51 to 
12·86)
3·71 
(1·52 to 
9·28)
3·86 
(1·70 to 
9·29)
4·05 
(1·85 to 
9·56)
4·01% 
(0·32 to 
11·54)*
4·82% 
(2·21 to 
8·77)*
9·02% 
(3·50 to 
21·16)*
2·50 
(1·00 to 
6·31)
2·36 
(1·01 to 
5·64)
2·32 
(1·01 to 
5·48)
–5·37% 
(–9·14 to 
2·24)
–2·09% 
(–5·24 to 
2·77)
–7·35% 
(–12·39 to 
2·21)
4 Occupational 
exposure to 
sulphuric acid
6·40% 
(0·16 to 
15·05)*
0·65 
(0·39 to 
1·34)
0·68 
(0·42 to 
1·36)
0·69 
(0·44 to 
1·35)
4·15% 
(0·11 to 
10·25)*
2·25% 
(–0·37 to 
5·61)
6·50% 
(0·25 to 
15·14)*
0·58 
(0·34 to 
1·20)
0·61 
(0·38 to 
1·23)
0·61 
(0·39 to 
1·22)
5·26% 
(0·24 to 
12·06)*
1·15% 
(–2·49 to 
6·06)
6·47% 
(–0·62 to 
16·38)
4 Occupational 
exposure to 
trichloro-
ethylene
30·29% 
(27·26 to 
33·55)*
0·16 
(0·15 to 
0·16)
0·18 
(0·18 to 
0·19)
0·20 
(0·20 to 
0·21)
16·76% 
(14·28 to 
19·65)*
10·21% 
(8·22 to 
12·23)*
28·67% 
(25·25 to 
32·40)*
0·13 
(0·13 to 
0·13)
0·16 
(0·15 to 
0·16)
0·17 
(0·17 to 
0·18)
19·59% 
(15·55 to 
23·76)*
10·72% 
(7·41 to 
14·55)*
32·42% 
(26·78 to 
38·05)*
3 Occupational 
asthmagens
–4·99% 
(–9·49 to 
–0·40)*
16·13 
(13·44 to 
19·43)
15·59 
(13·03 to 
18·78)
15·39 
(12·87 to 
18·38)
–3·33% 
(–7·27 to 
0·67)
–1·27% 
(–4·61 to 
1·74)
–4·55% 
(–9·66 to 
0·49)
8·50 
(6·78 to 
10·63)
8·26 
(6·70 to 
10·20)
8·04 
(6·59 to 
9·74)
–2·78% 
(–9·20 to 
3·95)
–2·68% 
(–7·59 to 
2·70)
–5·38% 
(–12·99 to 
2·95)
3 Occupational 
particulate 
matter, gases, 
and fumes
1·85% 
(–0·08 to 
3·94)
8·45 
(6·44 to 
11·42)
8·50 
(6·55 to 
11·39)
8·48 
(6·57 to 
11·31)
0·55% 
(–0·73 to 
2·07)
–0·24% 
(–1·20 to 
0·80)
0·31% 
(–1·86 to 
2·66)
5·00 
(3·80 to 
6·73)
5·22 
(4·01 to 
6·96)
5·20 
(4·02 to 
6·95)
4·35% 
(2·46 to 
6·58)*
–0·28% 
(–1·60 to 
1·19)
4·06% 
(1·28 to 
7·34)*
3 Occupational 
noise
6·30% 
(5·01 to 
7·56)*
8·60 
(8·24 to 
9·12)
8·80 
(8·44 to 
9·31)
8·91 
(8·55 to 
9·42)
2·27% 
(1·35 to 
3·32)*
1·28% 
(0·69 to 
1·87)*
3·58% 
(2·16 to 
5·19)*
5·21 
(4·96 to 
5·53)
5·58 
(5·34 to 
5·92)
5·74 
(5·50 to 
6·10)
7·15% 
(5·65 to 
8·90)*
2·91% 
(1·94 to 
3·84)*
10·28% 
(7·99 to 
12·79)*
3 Occupational 
injuries†
·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
3 Occupational 
ergonomic 
factors
–14·08% 
(–18·25 to 
–9·86)*
17·09 
(15·92 to 
18·44)
15·91 
(14·73 to 
17·38)
14·71 
(13·50 to 
16·15)
–6·90% 
(–11·17 to 
–2·80)*
–7·54% 
(–10·64 to 
–4·41)*
–13·92% 
(–18·71 to 
–9·08)*
11·25 
(10·41 to 
12·22)
10·54 
(9·70 to 
11·50)
9·65 
(8·75 to 
10·74)
–6·28% 
(–12·78 to 
0·55)
–8·42% 
(–13·25 to 
–3·44)*
–14·17% 
(–21·15 to 
–6·81)*
1 Behavioural risks
2 Child and maternal malnutrition
3 Suboptimal breastfeeding
4 Non-exclusive 
breastfeeding
–10·89% 
(–13·64 to 
–7·53)*
0·44 
(0·30 to 
0·62)
0·40 
(0·28 to 
0·57)
0·39 
(0·27 to 
0·53)
–7·10% 
(–8·99 to 
–5·22)*
–4·20% 
(–6·88 to 
–1·09)*
–11·01% 
(–13·78 to 
–7·61)*
0·43 
(0·30 to 
0·62)
0·41 
(0·28 to 
0·57)
0·39 
(0·27 to 
0·54)
–6·81% 
(–8·62 to 
–4·99)*
–4·25% 
(–6·87 to 
–1·20)*
–10·77% 
(–13·48 to 
–7·43)*
4 Discontinued 
breastfeeding
–1·40% 
(–3·55 to 
0·89)
1·16 
(1·13 to 
1·18)
1·08 
(1·07 to 
1·09)
1·14 
(1·13 to 
1·16)
–6·72% 
(–8·55 to 
–4·80)*
5·92% 
(4·43 to 
7·42)*
–1·20% 
(–3·41 to 
1·12)
1·16 
(1·14 to 
1·18)
1·07 
(1·06 to 
1·09)
1·14 
(1·12 to 
1·15)
–7·27% 
(–9·03 to 
–5·45)*
6·11% 
(4·67 to 
7·53)*
–1·61% 
(–3·71 to 
0·62)
3 Child growth 
failure
4 Child 
underweight
–44·35% 
(–48·14 to 
–41·23)*
1·65 
(1·48 to 
1·79)
1·22 
(1·06 to 
1·36)
0·94 
(0·80 to 
1·06)
–26·04% 
(–29·95 to 
–22·70)*
–23·14% 
(–25·36 to 
–21·61)*
–43·15% 
(–47·32 to 
–39·79)*
1·60 
(1·42 to 
1·76)
1·14 
(0·99 to 
1·29)
0·87 
(0·73 to 
0·99)
–28·37% 
(–32·92 to 
–24·87)*
–24·16% 
(–26·33 to 
–22·44)*
–45·67% 
(–50·14 to 
–42·24)*
4 Child wasting –22·51% 
(–25·73 to 
–19·67)*
0·57 
(0·48 to 
0·65)
0·50 
(0·42 to 
0·58)
0·45 
(0·37 to 
0·52)
–11·87% 
(–16·36 to 
–8·34)*
–11·30% 
(–13·24 to 
–9·44)*
–21·82% 
(–26·23 to 
–18·21)*
0·52 
(0·44 to 
0·59)
0·46 
(0·37 to 
0·53)
0·40 
(0·33 to 
0·46)
–11·72% 
(–16·12 to 
–8·29)*
–13·18% 
(–15·04 to 
–11·42)*
–23·36% 
(–27·37 to 
–19·99)*
4 Child stunting –36·16% 
(–41·11 to 
–32·42)*
2·75 
(1·89 to 
3·06)
2·35 
(1·64 to 
2·60)
1·81 
(1·27 to 
2·05)
–14·29% 
(–18·93 to 
–9·98)*
–22·97% 
(–26·72 to 
–20·02)*
–33·97% 
(–39·71 to 
–29·38)*
2·70 
(1·89 to 
3·01)
2·24 
(1·55 to 
2·50)
1·66 
(1·17 to 
1·91)
–16·94% 
(–22·01 to 
–12·76)*
–26·01% 
(–30·13 to 
–22·76)*
–38·54% 
(–44·24 to 
–33·98)*
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3 Low birthweight and short gestation
4 Short 
gestation for 
birthweight
25·26% 
(21·38 to 
29·51)*
0·00 
(0·00 to 
0·01)
0·01 
(0·00 to 
0·01)
0·01 
(0·00 to 
0·01)
18·60% 
(14·85 to 
22·55)*
7·38% 
(3·85 to 
10·34)*
27·35% 
(21·83 to 
32·59)*
0·00 
(0·00 to 
0·00)
0·00 
(0·00 to 
0·01)
0·00 
(0·00 to 
0·01)
16·51% 
(13·09 to 
19·73)*
5·10% 
(2·43 to 
7·72)*
22·45% 
(17·29 to 
27·17)*
4 Low 
birthweight 
for gestation
5·92% 
(1·12 to 
11·21)*
0·01 
(0·00 to 
0·01)
0·01 
(0·00 to 
0·01)
0·01 
(0·00 to 
0·01)
2·67% 
(–2·39 to 
8·23)
3·46% 
(0·62 to 
7·00)*
6·22% 
(–0·73 to 
14·61)
0·01 
(0·00 to 
0·01)
0·01 
(0·00 to 
0·01)
0·01 
(0·00 to 
0·01)
2·28% 
(–1·86 to 
7·30)
3·25% 
(0·71 to 
5·60)*
5·60% 
(–0·11 to 
11·72)
3 Iron deficiency† –23·44% 
(–27·96 to 
–19·44)*
·· ·· ·· ·· ·· ·· 12·69 
(10·50 to 
15·30)
10·78 
(8·67 to 
13·27)
9·70 
(7·68 to 
12·17)
–15·03% 
(–18·63 to 
–11·98)*
–10·04% 
(–12·97 to 
–7·26)*
–23·56% 
(–28·07 to 
–19·59)*
3 Vitamin A 
deficiency
–14·93% 
(–17·56 to 
–12·48)*
2·56 
(2·21 to 
2·95)
2·41 
(2·08 to 
2·79)
2·17 
(1·85 to 
2·54)
–5·88% 
(–7·27 to 
–4·57)*
–10·08% 
(–12·43 to 
–7·74)*
–15·37% 
(–18·17 to 
–12·89)*
2·49 
(2·15 to 
2·88)
2·36 
(2·03 to 
2·73)
2·13 
(1·82 to 
2·50)
–5·35% 
(–6·77 to 
–4·01)*
–9·63% 
(–12·19 to 
–7·27)*
–14·46% 
(–17·36 to 
–11·81)*
3 Zinc deficiency –30·29% 
(–35·62 to 
–24·00)*
0·92 
(0·28 to 
1·77)
0·76 
(0·24 to 
1·45)
0·64 
(0·19 to 
1·26)
–17·99% 
(–23·55 to 
–8·44)*
–14·85% 
(–22·51 to 
–8·70)*
–30·17% 
(–36·78 to 
–21·56)*
0·93 
(0·27 to 
1·76)
0·76 
(0·24 to 
1·45)
0·64 
(0·20 to 
1·29)
–18·32% 
(–23·86 to 
–9·54)*
–14·81% 
(–22·91 to 
–8·51)*
–30·42% 
(–37·34 to 
–22·61)*
2 Tobacco
3 Smoking –27·01% 
(–29·04 to 
–25·04)*
11·28 
(9·97 to 
12·66)
9·86 
(8·74 to 
11·12)
8·70 
(7·72 to 
9·79)
–12·55% 
(–15·17 to 
–9·96)*
–11·77% 
(–13·43 to 
–10·01)*
–22·84% 
(–25·22 to 
–20·48)*
3·03 
(2·69 to 
3·42)
2·14 
(1·87 to 
2·45)
1·76 
(1·52 to 
2·02)
–29·41% 
(–32·09 to 
–26·70)*
–17·69% 
(–19·36 to 
–16·15)*
–41·90% 
(–44·51 to 
–39·26)*
3 Chewing tobacco 2·29% 
(–7·00 to 
12·86)
3·87 
(3·50 to 
4·28)
3·84 
(3·62 to 
4·07)
3·75 
(3·49 to 
3·99)
–0·70% 
(–10·25 to 
10·88)
–2·38% 
(–8·94 to 
5·11)
–3·07% 
(–13·75 to 
9·32)
2·26 
(1·99 to 
2·56)
2·51 
(2·29 to 
2·76)
2·51 
(2·26 to 
2·78)
10·97% 
(–3·08 to 
26·36)
0·01% 
(–9·14 to 
10·78)
10·99% 
(–5·66 to 
29·80)
3 Second-hand 
smoke
–21·43% 
(–23·56 to 
–19·30)*
37·72 
(36·74 to 
38·70)
31·63 
(30·95 to 
32·28)
30·28 
(29·49 
to 31·03)
–16·14% 
(–18·81 to 
–13·41)*
–4·29% 
(–6·12 to 
–2·50)*
–19·73% 
(–22·82 to 
–16·64)*
55·74 
(54·84 to 
56·65)
46·24 
(45·64 to 
46·83)
43·06 
(42·34 
to 43·73)
–17·04% 
(–18·84 to 
–15·22)*
–6·87% 
(–7·86 to 
–5·78)*
–22·74% 
(–24·68 to 
–20·68)*
2 Alcohol use 5·06% 
(–3·78 to 
16·70)
14·70 
(10·85 
to 
19·08)
15·60 
(11·66 to 
19·90)
16·23 
(12·08 
to 
20·62)
6·16% 
(1·44 to 
12·04)*
4·04% 
(–3·29 to 
12·12)
10·45% 
(0·63 to 
22·45)*
5·20 
(3·28 to 
8·08)
4·77 
(3·02 to 
7·43)
4·65 
(2·96 to 
7·16)
–8·27% 
(–11·62 to 
–4·80)*
–2·55% 
(–7·82 to 
3·98)
–10·62% 
(–17·02 to 
–2·18)*
2 Drug use 6·12% 
(–1·31 to 
12·81)
0·80 
(0·66 to 
0·98)
0·81 
(0·68 to 
0·97)
0·86 
(0·72 to 
1·04)
1·62% 
(–2·63 to 
5·43)
6·46% 
(2·56 to 
10·64)*
8·19% 
(0·33 to 
15·62)*
0·41 
(0·34 to 
0·52)
0·40 
(0·34 to 
0·50)
0·42 
(0·35 to 
0·52)
–2·11% 
(–6·24 to 
1·44)
4·62% 
(1·89 to 
7·45)*
2·42% 
(–3·92 to 
8·46)
2 Dietary risks
3 Diet low in fruits –16·58% 
(–20·93 to 
–13·20)*
41·15 
(35·95 to 
43·87)
37·76 
(32·37 to 
40·96)
34·72 
(29·05 to 
38·30)
–8·23% 
(–10·79 to 
–6·35)*
–8·07% 
(–10·70 to 
–6·07)*
–15·64% 
(–19·96 to 
–12·32)*
38·99 
(33·82 to 
42·00)
35·35 
(29·94 to 
38·89)
32·14 
(26·64 
to 
36·06)
–9·33% 
(–12·16 to 
–7·13)*
–9·08% 
(–12·00 to 
–6·77)*
–17·57% 
(–22·33 to 
–13·68)*
3 Diet low in 
vegetables
–25·60% 
(–31·95 to 
–20·57)*
35·04 
(31·55 to 
38·18)
29·42 
(25·21 to 
33·30)
25·63 
(21·20 to 
29·72)
–16·03% 
(–21·02 to 
–12·12)*
–12·88% 
(–17·07 to 
–9·52)*
–26·84% 
(–33·90 to 
–21·22)*
36·41 
(33·12 to 
39·35)
31·17 
(26·96 
to 34·90)
27·51 
(23·05 to 
31·60)
–14·40% 
(–18·99 to 
–10·80)*
–11·75% 
(–15·63 to 
–8·63)*
–24·46% 
(–30·99 to 
–19·15)*
3 Diet low in 
legumes
–6·18% 
(–9·08 to 
–2·69)*
21·06 
(17·40 to 
24·33)
21·13 
(18·06 to 
23·93)
19·88 
(16·89 
to 22·61)
0·34% 
(–3·84 to 
5·80)
–5·93% 
(–8·59 to 
–3·70)*
–5·61% 
(–10·07 to 
0·10)
24·79 
(21·35 to 
27·99)
24·52 
(21·44 to 
27·34)
23·17 
(20·20 
to 
25·82)
–1·09% 
(–4·01 to 
2·82)
–5·51% 
(–7·37 to 
–3·55)*
–6·54% 
(–9·76 to 
–2·67)*
3 Diet low in 
whole grains
–1·99% 
(–2·77 to 
–1·31)*
39·23 
(36·80 
to 41·29)
39·21 
(36·79 to 
41·28)
38·46 
(35·92 to 
40·64)
–0·04% 
(–0·73 to 
0·65)
–1·93% 
(–2·80 to 
–1·24)*
–1·97% 
(–2·99 to 
–1·09)*
40·16 
(37·90 to 
42·09)
40·10 
(37·80 to 
42·05)
39·36 
(36·95 
to 
41·44)
–0·14% 
(–0·76 to 
0·52)
–1·84% 
(–2·63 to 
–1·16)*
–1·99% 
(–2·91 to 
–1·16)*
3 Diet low in nuts 
and seeds
–8·05% 
(–9·80 to 
–6·60)*
50·92 
(50·10 to 
51·59)
48·71 
(47·51 to 
49·73)
46·66 
(45·03 to 
48·05)
–4·34% 
(–5·29 to 
–3·53)*
–4·19% 
(–5·31 to 
–3·27)*
–8·35% 
(–10·24 to 
–6·76)*
51·05 
(50·27 to 
51·71)
49·00 
(47·85 to 
49·97)
47·09 
(45·46 
to 
48·40)
–4·02% 
(–4·92 to 
–3·27)*
–3·91% 
(–5·02 to 
–3·08)*
–7·77% 
(–9·62 to 
–6·30)*
3 Diet low in milk –0·17% 
(–0·45 to 
0·10)
45·53 
(43·68 to 
47·09)
45·56 
(43·72 to 
47·13)
45·35 
(43·45 to 
46·95)
0·07% 
(–0·23 to 
0·32)
–0·47% 
(–0·77 to 
–0·21)*
–0·41% 
(–0·81 to 
–0·05)*
45·57 
(43·74 to 
47·13)
45·69 
(43·88 
to 47·21)
45·57 
(43·77 
to 47·11)
0·26% 
(0·01 to 
0·53)*
–0·24% 
(–0·52 to 
–0·00)*
0·01% 
(–0·36 to 
0·35)
(Table 2 continues on next page)
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Risk Both sexes Males Females
Percentage 
change, 
1990–2017
1990 2007 2017 Percentage 
change, 
1990–2007
Percentage 
change, 
2007–17
Percentage 
change, 
1990–2017
1990 2007 2017 Percentage 
change, 
1990–2007
Percentage 
change, 
2007–17
Percentage 
change, 
1990–2017
(Continued from previous page)
3 Diet high in red 
meat
24·36% 
(12·39 to 
37·31)*
11·92 
(10·57 to 
13·60)
13·20 
(10·85 to 
15·28)
15·11 
(12·67 
to 17·16)
10·73% 
(–1·26 to 
23·05)
14·51% 
(4·18 to 
25·74)*
26·80% 
(13·02 to 
42·06)*
5·69 
(4·55 to 
6·96)
5·50 
(3·77 to 
7·28)
6·81 
(4·68 to 
8·84)
–3·36% 
(–18·75 to 
13·13)
23·71% 
(7·41 to 
42·85)*
19·55% 
(–0·62 to 
43·50)
3 Diet high in 
processed meat
–9·26% 
(–17·94 to 
–1·01)*
5·14 
(4·22 to 
6·43)
5·04 
(4·16 to 
6·49)
4·70 
(3·59 to 
6·30)
–1·86% 
(–7·74 to 
3·41)
–6·86% 
(–14·14 to 
–1·12)*
–8·60% 
(–18·72 to 
0·86)
3·67 
(2·72 to 
4·89)
3·56 
(2·72 to 
4·88)
3·31 
(2·37 to 
4·78)
–3·07% 
(–9·76 to 
3·22)
–7·01% 
(–15·25 to 
–0·53)*
–9·87% 
(–20·20 to 
–0·10)*
3 Diet high in 
sugar-sweetened 
beverages
17·14% 
(8·34 to 
28·02)*
5·40 
(2·78 to 
6·11)
5·78 
(2·98 to 
6·46)
6·58 
(3·37 to 
7·53)
7·07% 
(–0·77 to 
16·86)
13·84% 
(7·17 to 
22·04)*
21·88% 
(10·56 to 
36·93)*
4·26 
(2·19 to 
4·93)
4·32 
(2·24 to 
4·90)
4·74 
(2·43 to 
5·52)
1·48% 
(–8·10 to 
12·66)
9·71% 
(2·50 to 
18·05)*
11·34% 
(–1·05 to 
27·07)
3 Diet low in fibre –8·91% 
(–11·91 to 
–6·62)*
33·29 
(29·03 to 
36·82)
31·63 
(27·12 to 
35·34)
29·89 
(25·25 to 
33·84)
–4·98% 
(–7·48 to 
–3·12)*
–5·49% 
(–8·09 to 
–3·59)*
–10·20% 
(–14·35 to 
–7·24)*
37·43 
(33·84 to 
40·34)
36·00 
(32·26 to 
39·08)
34·51 
(30·41 
to 37·81)
–3·80% 
(–5·65 to 
–2·43)*
–4·15% 
(–6·08 to 
–2·76)*
–7·79% 
(–10·94 to 
–5·47)*
3 Diet low in 
calcium
–8·74% 
(–11·17 to 
–6·88)*
40·27 
(37·48 to 
42·55)
38·34 
(35·16 to 
40·93)
36·24 
(32·61 to 
39·15)
–4·81% 
(–6·29 to 
–3·71)*
–5·47% 
(–7·29 to 
–4·14)*
–10·01% 
(–13·01 to 
–7·83)*
41·68 
(39·09 to 
43·76)
40·22 
(37·39 to 
42·57)
38·52 
(35·36 
to 
41·16)
–3·52% 
(–4·57 to 
–2·67)*
–4·21% 
(–5·56 to 
–3·23)*
–7·58% 
(–9·83 to 
–5·91)*
3 Diet low in 
seafood omega 3 
fatty acids
–6·77% 
(–8·52 to 
–5·29)*
44·02 
(42·36 to 
45·64)
42·10 
(40·09 to 
44·08)
40·58 
(38·22 to 
42·83)
–4·37% 
(–5·47 to 
–3·41)*
–3·62% 
(–4·82 to 
–2·64)*
–7·83% 
(–9·93 to 
–6·06)*
44·84 
(43·28 to 
46·33)
43·42 
(41·57 to 
45·17)
42·25 
(40·08 
to 
44·25)
–3·17% 
(–4·03 to 
–2·44)*
–2·70% 
(–3·66 to 
–1·93)*
–5·78% 
(–7·42 to 
–4·39)*
3 Diet low in 
polyunsaturated 
fatty acids
–12·92% 
(–16·36 to 
–10·15)*
39·12 
(36·71 to 
41·43)
35·30 
(32·30 to 
38·06)
33·81 
(30·64 
to 36·77)
–9·75% 
(–12·76 to 
–7·20)*
–4·23% 
(–5·79 to 
–2·96)*
–13·57% 
(–17·22 to 
–10·52)*
39·10 
(36·62 to 
41·39)
35·61 
(32·53 to 
38·35)
34·29 
(31·08 to 
37·22)
–8·93% 
(–11·82 to 
–6·58)*
–3·72% 
(–5·16 to 
–2·57)*
–12·31% 
(–15·97 to 
–9·43)*
3 Diet high in trans 
fatty acids
–46·57% 
(–66·28 to 
–32·85)*
4·26 
(2·41 to 
6·95)
2·85 
(1·23 to 
5·40)
2·26 
(0·77 to 
4·67)
–33·08% 
(–49·65 to 
–22·64)*
–20·61% 
(–37·67 to 
–12·32)*
–46·87% 
(–68·26 to 
–32·36)*
5·73 
(3·62 to 
8·61)
3·91 
(1·96 to 
6·68)
3·08 
(1·28 to 
5·71)
–31·76% 
(–45·68 to 
–22·25)*
–21·33% 
(–35·58 to 
–13·42)*
–46·32% 
(–64·75 to 
–33·34)*
3 Diet high in 
sodium
–8·75% 
(–16·90 to 
–3·84)*
17·26 
(12·52 to 
22·33)
16·84 
(11·76 to 
21·97)
16·56 
(11·68 
to 21·75)
–2·42% 
(–10·60 to 
3·97)
–1·66% 
(–6·07 to 
2·60)
–4·04% 
(–13·12 to 
3·03)
16·88 
(12·31 to 
21·94)
15·62 
(10·79 to 
20·87)
14·62 
(9·86 to 
19·92)
–7·47% 
(–16·41 to 
–2·36)*
–6·43% 
(–11·89 to 
–2·61)*
–13·42% 
(–23·48 to 
–6·76)*
2 Intimate 
partner violence
–4·50% 
(–6·66 to 
–2·42)*
·· ·· ·· ·· ·· ·· 6·80 
(5·72 to 
7·88)
6·47 
(5·60 to 
7·37)
6·46 
(5·49 to 
7·42)
–4·82% 
(–8·10 to 
–1·03)*
–0·19% 
(–2·16 to 
1·54)
–4·99% 
(–7·15 to 
–2·88)*
2 Childhood 
maltreatment
3 Childhood sexual 
abuse
5·52% 
(4·00 to 
7·07)*
6·19 
(5·08 to 
7·61)
6·42 
(5·33 to 
7·78)
6·81 
(5·63 to 
8·33)
3·60% 
(1·22 to 
6·01)*
6·16% 
(4·19 to 
8·06)*
9·98% 
(8·09 to 
11·92)*
6·79 
(5·53 to 
8·23)
6·53 
(5·38 to 
7·84)
6·87 
(5·59 to 
8·33)
–3·86% 
(–5·76 to 
–1·92)*
5·25% 
(2·75 to 
7·94)*
1·18% 
(–1·11 to 
3·42)
3 Bullying 
victimisation
32·17% 
(25·93 to 
41·72)*
5·92 
(2·59 to 
11·93)
7·11 
(3·19 to 
14·32)
7·56 
(3·40 to 
15·32)
20·06% 
(14·26 to 
27·46)*
6·40% 
(4·67 to 
8·45)*
27·74% 
(21·09 to 
37·84)*
4·35 
(1·87 to 
8·68)
5·48 
(2·42 to 
10·72)
6·01 
(2·66 to 
11·89)
25·93% 
(19·70 to 
34·55)*
9·74% 
(7·97 to 
11·82)*
38·20% 
(30·75 to 
48·42)*
2 Unsafe sex† ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2 Low physical 
activity
0·12% 
(–0·20 to 
0·38)
0·40 
(0·18 to 
0·75)
0·40 
(0·18 to 
0·75)
0·40 
(0·18 to 
0·76)
0·28% 
(–0·00 to 
0·55)
0·67% 
(0·35 to 
1·01)*
0·96% 
(0·56 to 
1·36)*
0·37 
(0·16 to 
0·70)
0·36 
(0·16 to 
0·69)
0·36 
(0·16 to 
0·69)
–1·29% 
(–2·01 to 
–0·52)*
0·43% 
(0·20 to 
0·69)*
–0·87% 
(–1·54 to 
–0·18)*
1 Metabolic risks
2 High fasting 
plasma glucose
37·71% 
(29·15 to 
48·42)*
1·93 
(1·46 to 
2·50)
2·44 
(1·83 to 
3·19)
2·72 
(2·08 to 
3·50)
26·67% 
(20·02 to 
33·69)*
11·44% 
(4·82 to 
19·39)*
41·16% 
(31·63 to 
52·98)*
1·76 
(1·34 to 
2·29)
2·19 
(1·63 to 
2·89)
2·35 
(1·79 to 
3·07)
24·51% 
(17·30 to 
31·74)*
7·26% 
(–0·08 to 
15·53)
33·55% 
(23·51 to 
45·92)*
2 High 
low-density 
lipoprotein 
cholesterol
–6·82% 
(–7·88 to 
–5·82)*
11·22 
(9·83 to 
12·77)
10·32 
(8·93 to 
11·89)
10·23 
(8·86 to 
11·81)
–7·98% 
(–9·26 to 
–6·78)*
–0·86% 
(–1·28 to 
–0·46)*
–8·77% 
(–10·10 to 
–7·52)*
11·72 
(10·40 
to 13·25)
11·05 
(9·71 to 
12·58)
11·18 
(9·83 to 
12·72)
–5·73% 
(–6·78 to 
–4·78)*
1·15% 
(0·78 to 
1·55)*
–4·65% 
(–5·64 to 
–3·71)*
2 High systolic 
blood pressure
–1·37% 
(–3·03 to 
0·26)
7·12 
(6·46 to 
7·78)
7·21 
(6·53 to 
7·89)
7·39 
(6·67 to 
8·12)
1·26% 
(–0·66 to 
3·14)
2·54% 
(0·95 to 
4·22)*
3·83% 
(1·65 to 
6·05)*
7·18 
(6·64 to 
7·75)
6·81 
(6·25 to 
7·39)
6·77 
(6·19 to 
7·33)
–5·16% 
(–7·15 to 
–3·11)*
–0·56% 
(–2·45 to 
1·33)
–5·68% 
(–8·11 to 
–3·31)*
2 High body-mass 
index
70·39% 
(57·13 to 
84·52)*
5·70 
(4·04 to 
8·07)
8·15 
(6·18 to 
11·15)
9·95 
(7·76 to 
13·28)
43·04% 
(34·24 to 
53·89)*
22·09% 
(18·44 to 
26·34)*
74·63% 
(59·63 to 
92·99)*
6·50 
(4·75 to 
8·85)
9·11 
(7·01 to 
11·99)
10·88 
(8·54 to 
14·17)
40·22% 
(32·65 to 
49·58)*
19·41% 
(15·97 to 
23·19)*
67·43% 
(54·96 to 
82·04)*
(Table 2 continues on next page)
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risk hierarchy, retaining air pollution as a Level 2 risk, 
adding particulate matter pollution at Level 3, and 
moving both household air pollution due to exposure to 
smoke from solid cooking fuels and ambient particulate 
matter pollution to Level 4 of the hierarchy. Developed 
for risk attribution for particulate matter pollution, the 
integrated exposure response curves combine epidemio-
logical data from ambient, household, second-hand, and 
active smoking sources to construct a risk curve for the 
full exposure range. We updated the integrated exposure 
responses to include studies on ambient air pollution 
cohorts that were published after we completed our 
literature review for GBD 2016, systematic reviews of all 
active smoking cohorts, and a systematic review of 
second-hand smoke and chronic obstructive pulmonary 
disease (COPD). We also developed a strategy to map 
cohort studies of household air pollution to exposure 
levels of particulate matter less than 2·5 µm in diameter 
(PM₂.₅) to incorporate them into the curves.
We did a systematic search of the scientific literature of 
health outcomes resulting from long-term exposure to 
ambient particulate matter pollution and, consequently, 
included type 2 diabetes as a new outcome for both 
ambient and household air pollution. Evidence suggests 
that exposure to PM₂·₅ might be mechanistically linked 
to type 2 diabetes through altered lung function, vascular 
inflammation, and insulin sensitivity.8
We estimated ambient PM₂·₅ exposure by combining 
satellite data with a chemical transport model and land 
use infor mation. We calibrated satellite measurements 
to ground measurements using the Data Integration 
Model for Air Quality (DIMAQ).9 We made three 
not able improvements as follows: (1) we expanded our 
database of ground measure ments from approximately 
6000 to 9700 sites; (2) we made updates so the calibration 
model varies smo othly over space and time in data-dense 
regions; and (3) we improved uncertainty estimation by 
sampling from the DIMAQ’s poster distribution in each 
grid cell (appendix 1 section 4).
For previous GBDs, we have calculated relative risks 
from the integrated exposure response curves to produce 
PAFs and attributable burden for ambient particulate 
matter and household air pollution using the same 
TMREL for both risk factors. However, were a population 
to reduce one of the component exposures (ie, either 
household or ambient pollution), the other would 
remain. To capture this, we used a proportional PAF 
approach in which the integrated exposure response is 
used to calculate a relative risk and PAF for exposure to 
particulate matter from both ambient and household 
sources, and these are then weighted by the proportion of 
individuals exposed to each source (appendix 1 section 4).
In GBD 2016, we estimated the burden attributable to 
low intake of polyunsaturated fatty acids, where low 
intake was the result of polyunsaturated fatty acids being 
replaced by saturated fats. Considering that it is equally 
harmful to replace polyunsaturated fatty acids with either 
saturated fat or carbohydrates,10 we have redefined the 
risk factor as low polyunsaturated fatty acids intake 
where these were replaced by either saturated fatty acids 
or carbohydrates. In this approach, the TMREL for poly-
unsaturated fatty acids does not account for saturated fat 
intake.
For estimating consumption of whole grains, we 
developed an approach to use UN Food and Agriculture 
Organization (FAO) data, notably increasing our data 
coverage across countries and through time. First, we 
separately estimated total grain and refined grain avail-
ability, where availability includes domestic production, 
adjusted for imports, exports, waste, and animal feed. 
With whole grains and refined grains representing the 
entirety of all grain available, we calculated the availability 
of whole grains as the difference between total and 
refined grains. Finally, we adjusted these estimates using 
24-h dietary recall data to represent consumption.
In past cycles of GBD, given the strength of the causal 
relationship between sugar-sweetened beverage intake 
and BMI compared with the association between sugar-
sweetened beverages and disease endpoints, we 
estimated the disease burden of high intake of sugar-
sweetened beverages through its effect on BMI. This 
decision was based on the observation that evidence 
supporting a causal relationship between sugar-
sweetened beverages and BMI was stronger than 
Risk Both sexes Males Females
Percentage 
change, 
1990–2017
1990 2007 2017 Percentage 
change, 
1990–2007
Percentage 
change, 
2007–17
Percentage 
change, 
1990–2017
1990 2007 2017 Percentage 
change, 
1990–2007
Percentage 
change, 
2007–17
Percentage 
change, 
1990–2017
(Continued from previous page)
2 Low bone 
mineral density
–2·17% 
(–3·46 to 
–0·97)*
5·31 
(4·53 to 
6·08)
5·15 
(4·42 to 
5·90)
5·10 
(4·34 to 
5·87)
–2·94% 
(–4·06 to 
–1·79)*
–1·02% 
(–2·37 to 
0·25)
–3·93% 
(–5·37 to 
–2·55)*
6·90 
(6·05 to 
7·85)
6·86 
(6·04 to 
7·79)
6·86 
(5·94 to 
7·87)
–0·63% 
(–1·75 to 
0·58)
0·02% 
(–1·65 to 
1·75)
–0·61% 
(–2·19 to 
0·93)
2 Impaired kidney 
function
1·48% 
(–1·94 to 
4·14)
2·46 
(1·13 to 
6·12)
2·49 
(1·14 to 
6·17)
2·49 
(1·14 to 
6·16)
0·95% 
(–1·26 to 
3·10)
0·31% 
(–1·42 to 
2·46)
1·25% 
(–1·90 to 
3·81)
2·93 
(1·40 to 
6·81)
2·94 
(1·39 to 
6·86)
2·99 
(1·42 to 
6·96)
0·25% 
(–2·44 to 
2·56)
1·75% 
(–0·01 to 
4·02)
2·00% 
(–1·47 to 
4·69)
Data in parentheses are 95% uncertainty intervals. *Statistically significant increase or decrease (p<0·05). †Estimation methods for these risks precludes the estimation of summary exposure values.
Table 2: Global age-standardised summary exposure values for all risk factors, 1990, 2007, and 2017, with mean percentage change for 1990–2007, 2007–17, and 1990–2017
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evidence for a direct causal relationship between sugar-
sweetened beverages and disease endpoints. In GBD 
2017, we reassessed all existing evidence on causal 
relationships between sugar-sweetened beverages and 
disease endpoints, and found sufficient evidence for a 
causal relationship between sugar-sweetened beverages 
and ischaemic heart disease and type 2 diabetes. There-
fore, we have updated our approach and quantified the 
burden of disease attributable to the direct effect of 
sugar-sweetened beverages on disease endpoints.
We added four new outcomes for high BMI as follows: 
type 2 diabetes, liver cancer due to non-alcoholic fatty 
liver disease, subarachnoid haemorrhage, and intra-
cerebral haemorrhage. We applied the relative risk of 
diabetes only to type 2 diabetes. Relative risks for the 
association between high BMI and all liver cancers were 
used for both liver cancer due to non-alcoholic fatty liver 
and liver cancer due to other causes. Similarly, relative 
risks for the association between high BMI and haemor-
rhagic stroke were used for both subarachnoid haemor-
rhage and intracerebral haemorrhage.
We added five additional outcomes for high fasting 
plasma glucose (FPG) as follows: type 1 diabetes, type 2 
diabetes, liver cancer due to non-alcoholic fatty liver 
disease,11 subarachnoid haemorrhage, and intracerebral 
haemorrhage.12 Because an increased FPG concentration 
is the hallmark of diabetes, we assumed the PAFs were 
1·0 for FPG and both type 1 diabetes and type 2 diabetes. 
Relative risks for the association between high FPG and 
all liver cancers were used for liver cancer due to non-
alcoholic fatty liver and liver cancer due to other causes. 
Similarly, relative risks for the association between high 
FPG and haemorrhagic stroke were used for both 
subarachnoid haemorrhage and intracerebral haemor-
rhage.
We made four important changes related to the 
estimation of burden attributable to iron deficiency. 
First, the definitions of the GBD cause “dietary iron 
deficiency” and the risk factor “iron deficiency” are no 
longer iden tical. The GBD cause name was changed 
from “iron-deficiency anaemia” to “dietary iron 
deficiency” to clarify the focus on inadequate intake and 
exclusion of other causes that can manifest as absolute 
or functional iron deficiency. Second, although the 
GBD risk factor name remained “iron deficiency”, the 
exposure estimates were expanded to include all iron 
deficiency, irrespective of whether or not inadequate 
dietary intake is the underlying cause (appendix 1 
section 4). This change was based on review of the 
Child Health Epidemiology Research Group (CHERG) 
Iron Report,13 whose com ponent studies revealed no 
distinction as to the aetiology of iron deficiency. Third, 
on the basis of the studies included in the CHERG Iron 
Report,13 which only assessed overall maternal mortality 
as an outcome, we added all subcauses of maternal 
disorders as outcomes of iron deficiency (the risk), 
leading to higher estimates of the burden attributable to 
iron deficiency among women of reproductive age. 
Fourth, on the basis of the absence of evidence 
supporting dietary iron deficiency as a primary cause of 
death, dietary iron deficiency was removed from the 
GBD 2017 cause of death analysis, resulting in zero 
mortality burden and lower overall estimates of burden 
for dietary iron deficiency (the cause). Dietary iron 
deficiency (the cause) is expressed in terms of prevalence 
and YLDs, but the exposure to iron deficiency (the risk) 
remains expressed as the counterfactual haemoglobin 
concentration that would be present in a given popu-
lation group in the absence of all causes of anaemia that 
manifest as iron deficiency.
We made three major improvements to our analysis of 
low birthweight for gestation and short gestation for 
birthweight. First, we added individual-level linked birth 
and death cohort data from nearly 25 million births in 
Japan and Singapore to strengthen our analysis of the 
joint mortality risk surface. Second, we drew on the 
strong correlation between birthweight and gestational 
age that we identified in our microdata analysis and used 
birthweight data to inform exposure estimates of short 
gestation. We also strengthened the link between non-
fatal and risk analyses to ensure estimates of preterm 
birth were fully consistent throughout GBD 2017. The 
addition of individual-level linked birth and death cohort 
data resulted in higher estimates for low birthweight 
prevalence, mostly in data-sparse locations, whereas 
the consistency changes resulted in higher exposure 
estimates for both low birthweight and for short 
gestation, particularly in the late neonatal period. Third, 
we corrected an error where the risk attributable to low 
birthweight was mistakenly attributed to short gestation 
and vice versa in GBD 2016. This correction has no effect 
on the aggregate risk of low birthweight and short 
gestation but is the chief driver of differences in each 
individually.
We have moved from estimating total cholesterol 
in GBD 2016 to estimating LDL cholesterol for GBD 
2017. During the past two decades, substantially more 
data have been collected on LDL cholesterol than total 
cholesterol concentrations. The strong statistical rela-
tion ship between total and LDL cholesterol also allows 
us to model LDL cholesterol when other cholesterol 
sub fractions, such as high-density lipo protein, are 
reported, but LDL cholesterol concentrations are not.14 
The use of LDL cholesterol improves the policy rele-
vance of our estimates, because LDL cholesterol is the 
key target of cholesterol-lowering medications and is 
the most com monly used laboratory biomarker for 
clinical decision making. We applied this change to the 
full dataset, including data that were newly extracted for 
GBD 2017 and data that had been extracted in previous 
iter ations of GBD.
To estimate smoking-attributable burden for GBD 
2017, we transitioned from using 5-year lagged daily 
smoking prevalence (ie, the prevalence of smoking 
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5 years before the date for which estimates are being 
produced) and the smoking impact ratio to using 
continuous measures of exposure that incorporate 
cumulative effects among daily, occasional, and former 
smokers for 47 smoking-attributable health outcomes. 
We continue to use 5-year lagged daily smoking 
prevalence as the measure of exposure for ten outcomes. 
We estimated exposure among current smokers for two 
continuous indicators: cigarettes per smoker per day, 
and pack-years. We estimated exposure among former 
smokers using years since cessation. We estimated 
non-linear dose-response curves using a Bayesian 
meta-regression model for each of these continuous 
exposures. For nine out comes with significant differ-
ences in effect size by sex or age, we produced sex-
specific or age-specific risk curves (appendix 1 section 5). 
We included all forms of smoked tobacco in our exposure 
estimates and, given data limitations, assume that the 
risk of non-cigarette smoked tobacco products is the 
same as the risk of cigarettes; given the scarcity of data, 
we do not include electronic cigarette or vaporiser use in 
our exposure estimates.
We added two new outcomes for high SBP: sub arachnoid 
haemorrhage and calcific aortic valve disease. For both 
outcomes, we estimated relative risks on the basis of data 
from a pooled cohort study of 1·2 million participants.15 
We know of no large cohort that has reported age-sex-
specific relative risks of either sub arachnoid haemorrhage 
or calcific aortic valve disease due to increased SBP, and 
used proxy causes for each as follows: we estimated the 
relative risks for subarachnoid haemorrhage on the basis 
of all stroke and those for calcific aortic valve disease on the 
basis of other cardiovascular disease. For each cause, we 
estimated age-sex-specific relative risks associated with a 
10 mm Hg increase in SBP using the DisMod meta-
regression tool (appendix 1 section 2).
We have improved the exposure-modelling framework 
for unsafe water and sanitation. We estimate exposure 
Figure 1: Relationship between age-standardised summary exposure values and SDI for three of the top environmental and occupational, behavioural, and 
metabolic risk factors by number of attributable DALYs globally
The three leading risks for each Level 1 risk group are shown, except alcohol (fourth leading behavioural risk), which was included for variety instead of short 
gestation for birthweight. Each point corresponds to the age-standardised SEV in a country for males (blue), females (red), or both sexes (purple) for SEVs that are 
not sex specific. Points depict all country-years, 1990–2017. Lines show the expected SEV by SDI for each sex. Note that the y-axis scales differ by risk to correspond to 
the range of observed SEVs. DALYs=disability-adjusted life-years. SDI=Socio-demographic Index. SEV=summary exposure value.
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levels for unsafe water and sanitation using ordinal 
categories. For example, we estimate the prevalence of 
exposure to three levels of unsafe water: piped, improved, 
and unimproved drinking water. Previously, the preva-
lences of piped and improved water were modelled 
independently, and we derived the prevalence of unim-
proved water as one minus the sum of piped and 
improved water. For GBD 2017, we modelled the preva-
lence of piped water as before, but now explicitly model 
the prevalence of improved and unimproved water 
separately as proportions of the unpiped envelope. This 
approach enables us to use the exposure category for 
which we have the most data (ie, piped water access) 
while also ensuring that the three exposure categories 
sum to one. The modelling process for unsafe sanitation 
was revised in an analogous way.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
Global exposure to risks
We observed diverse temporal trends for levels of exposure 
to different risk factors between 1990 and 2017 (table 2). 
During that time, SEVs for two risks increased by more 
than 40%: SEVs for high BMI increased by 70·4% (95% UI 
57·1–84·5) and SEVs for ambient parti culate matter 
pollution increased by 41·2% (32·1–52·0). Conversely, 
SEVs for four risks decreased by more than 40%: SEVs for 
child underweight decreased by 44·4% (41·2–48·1), 
household air pollution by 45·8% (41·5–49·8), diet high 
in trans fatty acids by 46·6% (32·8–66·3), and unsafe 
sanitation by 47·8% (43·2–52·1).
SDI and SEVs were strongly associated for many risks 
(figure 1; for all risks, see appendix 2). Unsafe water source, 
unsafe sanitation, household air pollution, lead exposure, 
child underweight, child wasting, child stunting, iron 
deficiency, vitamin A deficiency, low calcium, and intimate 
partner violence all show a pronounced decreasing trend 
with increasing SDI. Conversely, discontinued breast-
feeding, smoking, alcohol use, drug use, high red meat 
consumption, high processed meat consumption, high 
sugar-sweetened bever age consumption, and high LDL 
cholesterol all show a pronounced increasing trend 
with increased SDI. Other risks show no clear association 
with SDI, including ozone, radon, low whole grains, 
and low fibre.
Global attributable burden for all risk factors combined
Globally, 61·0% (95% UI 59·6–62·4) of deaths and 
48·3% (46·3–50·2) of DALYs were attributed to the risk 
factors addressed in GBD 2017 (appendix 2). The largest 
percentage of deaths attributable to risk factors were 
among NCDs at 64·8% (63·1–66·6), followed by 
CMNNDs at 61·6% (59·0–64·4), and injuries at 24·4% 
(22·2–26·5). For DALYs, the largest risk-attributable 
proportion was among CMNNDs (64·0%, 61·8–66·0), 
followed by NCDs (45·6%, 42·8–48·4), and injuries 
(22·1%, 20·2–24·0). Risk-attributable DALYs declined 
4·9% (3·3–6·5) and deaths declined 8·3% (6·9–9·5) 
between 2007 and 2017. The numbers of risk-attributable 
deaths and DALYs in 2007 and 2017 are provided for each 
cause in table 3. 
In 2017, NCDs had the largest risk-attributable burden, 
with 26·6 million (95% UI 25·8–27·5) deaths and 
706 million (659–756) DALYs attributable to all risk 
factors combined (appendix 2). The five leading 
NCD causes of absolute risk-attributable DALYs were 
ischaemic heart disease, intracerebral haemorrhage, 
type 2 diabetes, COPD, and ischaemic stroke. In 2017, 
95·0% (95% UI 93·4–96·3), and 93·8% (91·3–95·9) 
of ischaemic heart disease DALYs and deaths were 
risk attri butable, resulting in 162 million (158–166) 
risk-attributable ischaemic heart disease DALYs, and 
8·38 million (8·10–8·65) risk-attributable ischaemic 
heart disease deaths. After ischaemic heart disease, intra-
cerebral haemorrhage had 57·9 million (55·2–60·6) risk-
attributable DALYs (89·8% [87·0–92·3] of all intracerebral 
haemorrhage DALYs), type 2 diabetes had 57·4 million 
(45·0–71·9), COPD had 54·9 million (48·1–60·4; 67·3% 
[60·8–72·8] of all COPD DALYs), and ischaemic stroke 
had 47·8 million (43·4–52·3; 86·7% [82·7–90·8] of 
ischaemic stroke DALYs). Because we estimated a PAF of 
1·0 for high FPG and type 2 diabetes, 100% of type 2 
diabetes DALYs and deaths were attributed to risk factors 
addressed in GBD 2017.
Among CMNNDs, 6·40 million (6·00–7·00) deaths 
and 446 million (419–475) DALYs were attributable to 
risks. The five leading causes of absolute risk-attributable 
DALYs among CMNNDs were lower respiratory infec-
tions, diarrhoeal diseases, neonatal preterm birth com-
plications, neonatal encephalopathy due to birth asphyxia 
and trauma, and HIV/AIDS resulting in other diseases. 
In 2017, 80·5% (95% UI 77·4–83·4) and 64·0% 
(59·9–68·1) of lower respiratory infection DALYs and 
deaths were risk attributable, resulting in 76·9 million 
(66·1–92·8) risk-attributable lower respiratory infection 
DALYs and 1·64 million (1·51–1·77) risk-attributable 
lower respiratory infection deaths. Diarrhoeal diseases 
had 76·9 million (66·1–92·8) risk-attributable DALYs 
(94·9% [89·8–97·7] of all diarrhoeal diseases DALYs), 
neonatal preterm birth had 70·2 million (64·4–77·2; 
100% of all neonatal preterm birth DALYs, since we 
estimate a PAF of 1·0 for this risk factor), neonatal 
encephalopathy due to birth asphyxia and trauma had 
41·2 million (36·7–45·0; 72·9% [66·6–78·3] of neonatal 
encephalopathy due to birth asphyxia and trauma 
DALYs), and HIV/AIDS resulting in other diseases 
had 32·6 million (29·1–36·3; 77·5% [75·6–79·2] of 
HIV/AIDS resulting in other diseases DALYs).
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Risk factors and outcomes 2007 deaths 
(thousands)
2017 deaths 
(thousands)
Percentage 
change in 
deaths, 
2007–17
Percentage 
change in age-
standardised 
death rate, 
2007–17
2007 DALYs 
(thousands)
2017 DALYs 
(thousands)
Percentage 
change in 
DALYs, 
2007–17
Percentage 
change in age-
standardised 
DALY rate, 
2007–17
0 All risk factors: all causes 31 500 
(30 900 to 
32 200)
34 100 
(33 300 to 
35 000)
8·3% 
(6·9 to 9·5)*
–15·7% 
(–16·6 to 
–14·8)*
1 270 000 
(1 210 000 to 
1 340 000)
1 210 000 
(1 140 000 to 
1280 000)
–4·9% 
(–6·5 to –3·3)*
–19·9% 
(–21·3 to 
–18·5)*
1 Environmental and 
occupational risks: all causes
8150 
(7590 to 8810)
8320 
(7690 to 
9020)
2·2% 
(–0·3 to 4·7)
–20·1% 
(–21·8 to 
–18·2)*
345 000 
(319 000 to 
370 000)
308 000 
(283 000 to 
333 000)
–10·7% 
(–13·7 to –7·5)*
–24·9% 
(–27·4 to 
–22·3)*
2 Unsafe water, sanitation, 
and handwashing: all causes
1990 
(1610 to 2570)
1610 
(1230 to 
2230)
–18·8% 
(–26·2 to 
–10·1)*
–31·6% 
(–36·9 to 
–25·0)*
120 000 
(103 000 to 
138 000)
84 400 
(71 800 to 
102 000)
–29·6% 
(–35·3 to 
–23·0)*
–36·0% 
(–41·2 to 
–30·3)*
3 Unsafe water source: all 
causes
1500 
(938 to 2110)
1230 
(736 to 1830)
–18·0% 
(–26·9 to –8·0)*
–31·2% 
(–37·2 to –23·3)*
90 100 
(58 500 to 
113 000)
63 900 
(40 800 to 83 100)
–29·1% 
(–35·4 to –21·5)*
–35·7% 
(–41·3 to –29·0)*
·· Diarrhoeal diseases 1500 
(938 to 2110)
1230 
(736 to 1830)
–18·0% 
(–26·9 to –8·0)*
–31·2% 
(–37·2 to –23·3)*
90 100 
(58 500 to 
113 000)
63 900 
(40 800 to 83 100)
–29·1% 
(–35·4 to –21·5)*
–35·7% 
(–41·3 to –29·0)*
3 Unsafe sanitation: all causes 1110 
(856 to 1450)
774 
(566 to 1060)
–30·2% 
(–37·4 to –21·6)*
–41·2% 
(–46·4 to –34·2)*
66 500 
(55 600 to 
78 100)
41 500 
(34 100 to 49 700)
–37·6% 
(–43·3 to –30·6)*
–43·2% 
(–48·4 to –37·1)*
·· Diarrhoeal diseases 1110 
(856 to 1450)
774 
(566 to 1060)
–30·2% 
(–37·4 to –21·6)*
–41·2% 
(–46·4 to –34·2)*
66 500 
(55 600 to 
78 100)
41 500 
(34 100 to 49 700)
–37·6% 
(–43·3 to –30·6)*
–43·2% 
(–48·4 to –37·1)*
3 No access to handwashing 
facility: all causes
892 
(528 to 1250)
707 
(416 to 1020)
–20·7% 
(–26·4 to –13·1)*
–32·5% 
(–36·9 to –26·9)*
55 300 
(33 200 to 
75 300)
38 400 
(22 800 to 52 100)
–30·5% 
(–35·6 to –24·7)*
–36·4% 
(–41·0 to –31·1)*
·· Lower respiratory 
infections
229 
(148 to 306)
188 
(122 to 249)
–17·9% 
(–21·9 to –13·6)*
–29·0% 
(–32·4 to –25·3)*
14 700 
(9630 to 19 700)
10 300 
(6780 to 13 800)
–29·8% 
(–34·1 to –25·0)*
–35·0% 
(–39·0 to –30·4)*
·· Diarrhoeal diseases 663 
(312 to 1010)
520 
(240 to 839)
–21·7% 
(–29·6 to –12·0)*
–33·7% 
(–39·6 to –26·4)*
40 500 
(19 500 to 
59 500)
28 100 
(13 500 to 41 500)
–30·7% 
(–37·1 to –22·9)*
–36·9% 
(–42·8 to –29·5)*
2 Air pollution: all causes 4630 
(4210 to 5040)
4900 
(4420 to 
5390)
5·8% 
(3·0 to 8·8)*
–18·7% 
(–20·7 to 
–16·7)*
158 000 
(142 000 to 
172 000)
147 000 
(132 000 to 
162 000)
–6·6% 
(–9·8 to –2·8)*
–23·5% 
(–26·0 to 
–20·8)*
3 Particulate matter pollution: 
all causes
4380 
(3960 to 4780)
4580 
(4130 to 5030)
4·6% 
(1·7 to 7·5)*
–19·5% 
(–21·5 to –17·4)*
154 000 
(138 000 to 
168 000)
143 000 
(129 000 to 
156 000)
–7·3% 
(–10·8 to –3·4)*
–23·9% 
(–26·6 to 
–21·1)*
4 Ambient particulate matter 
pollution: all causes
2420 
(2080 to 2760)
2940 
(2500 to 3360)
21·6% 
(16·2 to 26·8)*
–7·8% 
(–11·7 to –3·8)*
73 600 
(63 300 to 
83 400)
83 000 
(71 400 to 94 300)
12·8% 
(5·6 to 20·2)*
–9·3% 
(–15·1 to –3·0)*
·· Lower respiratory 
infections
420 
(337 to 500)
433 
(343 to 527)
2·9% 
(–8·8 to 15·4)
–15·3% 
(–24·3 to –5·1)*
22 300 
(17 700 to 
27 200)
18 500 
(14 400 to 23 400)
–16·9% 
(–29·4 to –0·9)*
–24·3% 
(–35·8 to –9·2)*
·· Tracheal, bronchus, and 
lung cancer
205 
(143 to 270)
265 
(183 to 351)
29·3% 
(22·0 to 36·3)*
–2·0% 
(–7·6 to 3·4)
4680 
(3280 to 6150)
5860 
(4050 to 7730)
25·1% 
(17·8 to 31·7)*
–3·9% 
(–9·5 to 1·3)
·· Ischaemic heart disease 780 
(671 to 901)
977 
(839 to 1120)
25·3% 
(20·6 to 30·2)*
–5·8% 
(–9·2 to –2·4)*
17 800 
(15 300 to 
20 600)
21 900 
(18 900 to 25 400)
23·1% 
(18·4 to 28·3)*
–4·2% 
(–7·8 to –0·5)*
·· Ischaemic stroke 147 
(113 to 183)
184 
(140 to 228)
24·6% 
(18·8 to 30·9)*
–7·8% 
(–11·4 to –3·8)*
3060 
(2360 to 3780)
3950 
(3040 to 4870)
28·9% 
(22·7 to 35·4)*
–2·0% 
(–6·2 to 2·4)
·· Intracerebral 
haemorrhage
194 
(152 to 238)
226 
(176 to 280)
17·0% 
(11·1 to 23·2)*
–11·3% 
(–15·2 to –6·9)*
4770 
(3800 to 5850)
5520 
(4340 to 6840)
15·8% 
(9·5 to 22·2)*
–9·8% 
(–14·0 to –5·2)*
·· Subarachnoid 
haemorrhage
29 
(22 to 36)
35 
(27 to 44)
22·1% 
(14·8 to 29·8)*
–5·4% 
(–10·9 to 0·1)
877 
(686 to 1100)
1040 
(809 to 1310)
18·8% 
(12·2 to 25·9)*
–5·0% 
(–10·3 to 0·2)
·· Chronic obstructive 
pulmonary disease
519 
(347 to 679)
633 
(416 to 838)
22·1% 
(13·7 to 29·8)*
–10·5% 
(–16·5 to –4·8)*
12 800 
(8460 to 16 700)
15 700 
(10 300 to 20 800)
23·5% 
(16·1 to 30·7)*
–6·0% 
(–11·6 to –0·5)*
·· Type 2 diabetes mellitus 122 
(82 to 149)
184 
(123 to 227)
50·7% 
(44·8 to 56·0)*
11·1% 
(6·8 to 15·1)*
7380 
(4720 to 9790)
10 500 
(6700 to 13 900)
41·9% 
(35·0 to 48·7)*
10·5% 
(5·3 to 15·6)*
(Table 3 continues on next page)
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1941
Risk factors and outcomes 2007 deaths 
(thousands)
2017 deaths 
(thousands)
Percentage 
change in 
deaths, 
2007–17
Percentage 
change in age-
standardised 
death rate, 
2007–17
2007 DALYs 
(thousands)
2017 DALYs 
(thousands)
Percentage 
change in 
DALYs, 
2007–17
Percentage 
change in age-
standardised 
DALY rate, 
2007–17
(Continued from previous page)
4 Household air pollution 
from solid fuels: all causes
1960 
(1700 to 2270)
1640 
(1400 to 1930)
–16·3% 
(–20·2 to –11·9)*
–34·2% 
(–37·3 to –31·0)*
80 100 
(68 300 to 
92 400)
59 500 
(50 800 to 68 900)
–25·8% 
(–30·2 to –20·9)*
–37·4% 
(–41·1 to –33·6)*
·· Lower respiratory 
infections
669 
(536 to 797)
459 
(367 to 552)
–31·4% 
(–36·6 to 
–25·9)*
–40·4% 
(–44·9 to 
–35·8)*
43 600 
(34 500 to 
52 000)
25 900 
(20 300 to 31 300)
–40·7% 
(–46·2 to –35·0)*
–44·9% 
(–50·1 to –39·6)*
·· Tracheal, bronchus, and 
lung cancer
94 
(69 to 120)
85 
(60 to 113)
–10·0% 
(–16·4 to –3·7)*
–31·5% 
(–36·4 to –26·7)*
2280 
(1660 to 2890)
1990 
(1410 to 2640)
–12·7% 
(–18·7 to –6·9)*
–32·6% 
(–37·2 to –28·0)*
·· Ischaemic heart disease 435 
(371 to 512)
410 
(344 to 490)
–5·8% 
(–10·1 to –1·5)*
–28·2% 
(–31·4 to –25·0)*
11 100 
(9400 to 13 000)
10 200 
(8450 to 12 100)
–8·2% 
(–12·7 to –3·9)*
–27·9% 
(–31·4 to –24·5)*
·· Ischaemic stroke 88 
(69 to 112)
81 
(62 to 104)
–8·2% 
(–13·0 to –3·3)*
–31·3% 
(–35·0 to –27·8)*
1980 
(1540 to 2470)
1830 
(1390 to 2330)
–7·2% 
(–12·4 to –2·6)*
–29·0% 
(–32·8 to –25·5)*
·· Intracerebral haemorrhage 156 
(123 to 191)
132 
(102 to 165)
–15·2% 
(–19·5 to –10·9)*
–35·3% 
(–38·5 to –32·1)*
4080 
(3210 to 5010)
3440 
(2660 to 4310)
–15·5% 
(–19·9 to –11·2)*
–34·0% 
(–37·2 to –30·9)*
·· Subarachnoid haemorrhage 20 
(16 to 27)
18 
(14 to 24)
–9·2% 
(–15·0 to –2·8)*
–29·0% 
(–33·6 to –24·2)*
664 
(506 to 870)
591 
(443 to 777)
–11·0% 
(–16·5 to –5·1)*
–28·4% 
(–32·7 to –23·9)*
·· Chronic obstructive 
pulmonary disease
421 
(296 to 548)
362 
(248 to 482)
–13·9% 
(–20·5 to –7·4)*
–36·3% 
(–41·1 to –31·6)*
10 800 
(7740 to 13 900)
9370 
(6480 to 12 400)
–13·0% 
(–19·0 to –7·4)*
–33·5% 
(–38·1 to 
–29·3)*
·· Type 2 diabetes mellitus 77 
(54 to 92)
92 
(63 to 113)
19·6% 
(12·6 to 27·1)*
–10·6% 
(–15·8 to –5·1)*
4360 
(2900 to 5780)
4750 
(3110 to 6190)
9·0% 
(2·6 to 15·5)*
–14·6% 
(–19·6 to –9·5)*
·· Cataract ·· ·· ·· ·· 1320 
(696 to 2010)
1440 
(732 to 2250)
9·2% 
(4·6 to 12·7)*
–17·3% 
(–20·9 to –14·7)*
3 Ambient ozone pollution: all 
causes
392 
(146 to 638)
472 
(177 to 768)
20·4% 
(15·9 to 24·5)*
–11·6% 
(–14·8 to –8·6)*
6330 
(2370 to 10 300)
7370 
(2740 to 12 000)
16·4% 
(12·0 to 20·6)*
–12·2% 
(–15·6 to –9·1)*
·· Chronic obstructive 
pulmonary disease
392 
(146 to 638)
472 
(177 to 768)
20·4% 
(15·9 to 24·5)*
–11·6% 
(–14·8 to –8·6)*
6330 
(2370 to 10 300)
7370 
(2740 to 12 000)
16·4% 
(12·0 to 20·6)*
–12·2% 
(–15·6 to –9·1)*
2 Other environmental risks: 
all causes
929 
(646 to 1240)
1140 
(794 to 1530)
23·0% 
(19·2 to 26·6)*
–7·9% 
(–10·4 to –5·3)*
23 500 
(16 500 to 
30 600)
26 400 
(18 400 to 34 800)
12·3% 
(8·9 to 15·6)*
–12·0% 
(–14·4 to 
–10·1)*
3 Residential radon: all causes 68 
(38 to 107)
88 
(50 to 139)
28·1% 
(21·4 to 34·9)*
–2·9% 
(–6·9 to 1·0)
1570 
(859 to 2420)
1930 
(1080 to 3020)
23·3% 
(16·1 to 30·2)*
–5·2% 
(–9·3 to –1·0)*
·· Tracheal, bronchus, and 
lung cancer
68 
(38 to 107)
88 
(50 to 139)
28·1% 
(21·4 to 34·9)*
–2·9% 
(–6·9 to 1·0)
1570 
(859 to 2420)
1930 
(1080 to 3020)
23·3% 
(16·1 to 30·2)*
–5·2% 
(–9·3 to –1·0)*
3 Lead exposure: all causes 860 
(586 to 1160)
1050 
(709 to 1430)
22·6% 
(18·7 to 26·4)*
–8·3% 
(–10·8 to –5·7)*
21 900 
(15 200 to 
28 900)
24 400 
(16 700 to 32 800)
11·5% 
(7·8 to 14·8)*
–12·5% 
(–15·0 to –10·5)*
·· Rheumatic heart disease 8 
(5 to 15)
8 
(4 to 14)
–2·9% 
(–12·8 to 6·5)
–25·0% 
(–31·6 to –18·8)*
255 
(145 to 430)
219 
(120 to 368)
–14·2% 
(–23·1 to –5·5)*
–31·1% 
(–38·1 to –25·4)*
·· Ischaemic heart disease 391 
(256 to 547)
488 
(317 to 685)
24·6% 
(20·7 to 28·4)*
–6·9% 
(–9·1 to –4·6)*
8350 
(5480 to 11 500)
9600 
(6210 to 13 300)
15·0% 
(11·6 to 18·1)*
–11·5% 
(–13·9 to –9·5)*
·· Ischaemic stroke 110 
(69 to 159)
139 
(87 to 200)
25·8% 
(21·1 to 31·5)*
–6·7% 
(–9·7 to –3·3)*
2380 
(1510 to 3340)
3000 
(1920 to 4220)
26·2% 
(21·7 to 30·6)*
–4·2% 
(–7·4 to –1·0)*
·· Intracerebral haemorrhage 191 
(125 to 270)
205 
(132 to 292)
7·0% 
(2·4 to 10·9)*
–19·4% 
(–22·5 to –16·8)*
4420 
(2920 to 6090)
4470 
(2850 to 6300)
1·0% 
(–4·0 to 5·0)
–22·2% 
(–26·0 to –19·2)*
·· Subarachnoid haemorrhage 23 
(14 to 33)
26 
(16 to 38)
14·8% 
(6·1 to 25·2)*
–12·0% 
(–18·4 to –4·4)*
655 
(387 to 964)
693 
(409 to 1040)
5·9% 
(–1·6 to 14·5)
–16·8% 
(–22·9 to –10·5)*
·· Hypertensive heart disease 66 
(25 to 137)
98 
(33 to 213)
48·0% 
(22·7 to 63·0)*
9·2% 
(–8·9 to 19·8)
1310 
(620 to 2560)
1710 
(725 to 3480)
31·0% 
(12·4 to 45·5)*
0·2% 
(–14·0 to 10·2)
·· Non-rheumatic calcific 
aortic valve disease
2 
(1 to 3)
2 
(1 to 4)
30·7% 
(22·7 to 37·8)*
–5·4% 
(–10·2 to –1·8)*
28 
(16 to 45)
34 
(18 to 54)
20·3% 
(12·8 to 26·9)*
–8·8% 
(–14·1 to –4·7)*
·· Other cardiomyopathy 5 
(3 to 7)
6 
(3 to 9)
22·2% 
(14·6 to 28·8)*
–8·2% 
(–13·4 to –3·7)*
111 
(61 to 176)
126 
(68 to 201)
12·8% 
(4·9 to 19·9)*
–11·8% 
(–18·1 to –6·7)*
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·· Atrial fibrillation and flutter 5 
(3 to 8)
8 
(5 to 11)
48·1% 
(43·4 to 53·0)*
5·2% 
(2·6 to 8·3)*
150 
(91 to 218)
193 
(118 to 283)
29·0% 
(25·3 to 32·5)*
–2·9% 
(–5·2 to –0·8)*
·· Aortic aneurysm 4 
(2 to 5)
4 
(3 to 6)
19·3% 
(13·7 to 24·8)*
–10·3% 
(–14·2 to –6·6)*
75 
(44 to 113)
84 
(48 to 127)
12·5% 
(6·8 to 17·9)*
–13·5% 
(–18·0 to –9·4)*
·· Peripheral vascular disease 1 
(0 to 1)
1 
(0 to 2)
54·1% 
(30·4 to 74·7)*
10·5% 
(–6·0 to 25·2)
19 
(9 to 32)
25 
(12 to 43)
31·2% 
(21·0 to 42·9)*
–1·6% 
(–9·1 to 6·8)
·· Endocarditis 1 
(1 to 2)
2 
(1 to 3)
30·2% 
(19·4 to 36·6)*
–1·4% 
(–8·7 to 2·6)
36 
(19 to 59)
42 
(22 to 67)
17·1% 
(5·9 to 24·4)*
–7·4% 
(–16·0 to –2·3)*
·· Other cardiovascular and 
circulatory diseases
11 
(7 to 16)
13 
(8 to 18)
19·1% 
(12·3 to 24·1)*
–9·7% 
(–14·6 to –6·3)*
347 
(208 to 528)
383 
(227 to 580)
10·2% 
(4·1 to 14·3)*
–13·9% 
(–19·1 to –10·8)*
·· Idiopathic developmental 
intellectual disability
·· ·· ·· ·· 2670 
(1070 to 4880)
2540 
(1000 to 4700)
–4·8% 
(–9·1 to –2·7)*
–13·6% 
(–17·1 to –11·7)*
·· Chronic kidney disease due 
to type 1 diabetes mellitus
3 
(1 to 4)
3 
(2 to 5)
11·2% 
(3·8 to 17·6)*
–12·6% 
(–18·6 to –8·0)*
90 
(48 to 150)
93 
(47 to 159)
2·8% 
(–5·5 to 9·8)
–17·6% 
(–24·1 to –12·5)*
·· Chronic kidney disease due 
to type 2 diabetes mellitus
13 
(8 to 20)
18 
(10 to 27)
34·6% 
(27·8 to 39·0)*
0·4% 
(–4·5 to 3·2)
303 
(179 to 458)
380 
(218 to 578)
25·4% 
(19·4 to 29·6)*
–4·9% 
(–9·2 to –1·8)*
·· Chronic kidney disease due 
to hypertension
12 
(7 to 19)
17 
(10 to 26)
38·2% 
(31·8 to 41·9)*
1·4% 
(–3·2 to 3·9)
255 
(148 to 382)
320 
(187 to 485)
25·6% 
(19·9 to 29·3)*
–4·4% 
(–8·6 to –1·6)*
·· Chronic kidney disease due 
to glomerulonephritis
6 
(3 to 9)
7 
(4 to 12)
25·9% 
(20·3 to 30·2)*
–4·3% 
(–8·2 to –1·6)*
160 
(86 to 260)
177 
(93 to 294)
10·7% 
(5·0 to 15·2)*
–12·6% 
(–17·2 to –9·1)*
·· Chronic kidney disease due 
to other and unspecified 
causes
9 
(5 to 13)
11 
(6 to 17)
27·7% 
(22·2 to 32·1)*
–3·3% 
(–7·3 to –0·6)*
286 
(161 to 454)
327 
(183 to 526)
14·2% 
(9·1 to 18·3)*
–11·0% 
(–15·0 to –8·0)*
2 Occupational risks: all 
causes
1090 
(995 to 1190)
1160 
(1050 to 1280)
6·5% 
(3·5 to 9·4)*
–16·6% 
(–18·7 to –14·7)*
59 800 
(52 300 to 
68 100)
63 700 
(54 900 to 73 200)
6·7% 
(4·1 to 9·3)*
–11·6% 
(–13·7 to –9·4)*
3 Occupational carcinogens: all 
causes
271 
(220 to 322)
334 
(271 to 397)
23·3% 
(19·1 to 27·1)*
–7·4% 
(–10·5 to –4·5)*
5600 
(4560 to 6710)
6750 
(5490 to 8120)
20·6% 
(16·5 to 24·5)*
–8·0% 
(–11·3 to –5·0)*
4 Occupational exposure to 
asbestos: all causes
194 
(148 to 243)
232 
(177 to 289)
19·6% 
(14·6 to 23·6)*
–10·5% 
(–14·2 to –7·5)*
3410 
(2570 to 4310)
3930 
(2980 to 4950)
15·3% 
(9·9 to 19·8)*
–12·7% 
(–16·7 to –9·4)*
·· Larynx cancer 3 
(2 to 5)
4 
(2 to 6)
20·9% 
(13·4 to 27·0)*
–9·6% 
(–15·0 to –5·2)*
63 
(35 to 95)
74 
(41 to 112)
17·1% 
(9·4 to 23·1)*
–11·6% 
(–17·3 to –7·0)*
·· Tracheal, bronchus, and 
lung cancer
161 
(115 to 208)
191 
(137 to 247)
18·5% 
(13·5 to 22·6)*
–11·3% 
(–15·0 to –8·3)*
2740 
(1910 to 3590)
3120 
(2180 to 4110)
14·0% 
(8·7 to 18·4)*
–13·8% 
(–17·8 to –10·6)*
·· Ovarian cancer 5 
(3 to 8)
6 
(3 to 10)
17·4% 
(9·6 to 24·2)*
–14·0% 
(–19·6 to –9·1)*
88 
(44 to 138)
100 
(49 to 156)
14·3% 
(6·4 to 21·4)*
–14·3% 
(–20·1 to –9·2)*
·· Mesothelioma 22 
(21 to 23)
27 
(27 to 28)
27·7% 
(20·5 to 33·7)*
–3·6% 
(–8·8 to 0·7)
464 
(434 to 512)
569 
(542 to 598)
22·4% 
(14·5 to 29·4)*
–6·0% 
(–11·7 to –1·0)*
·· Asbestosis 3 
(2 to 3)
3 
(2 to 4)
23·3% 
(15·2 to 33·9)*
–8·3% 
(–14·1 to –0·4)*
58 
(41 to 70)
69 
(52 to 81)
19·2% 
(11·8 to 30·4)*
–8·5% 
(–14·1 to 0·3)
4 Occupational exposure to 
arsenic: all causes
7 
(1 to 12)
9 
(2 to 16)
33·8% 
(27·3 to 55·2)*
1·9% 
(–3·0 to 18·6)
189 
(43 to 346)
245 
(65 to 436)
29·5% 
(23·2 to 49·0)*
–0·6% 
(–5·5 to 15·1)
·· Tracheal, bronchus, and 
lung cancer
7 
(1 to 12)
9 
(2 to 16)
33·8% 
(27·3 to 55·2)*
1·9% 
(–3·0 to 18·6)
189 
(43 to 346)
245 
(65 to 436)
29·5% 
(23·2 to 49·0)*
–0·6% 
(–5·5 to 15·1)
4 Occupational exposure to 
benzene: all causes
2 
(1 to 3)
2 
(1 to 3)
18·6% 
(13·0 to 24·6)*
0·3% 
(–5·1 to 6·1)
73 
(23 to 120)
84 
(26 to 137)
15·4% 
(10·1 to 21·2)*
–0·2% 
(–5·2 to 5·2)
·· Leukaemia 2 
(1 to 3)
2 
(1 to 3)
18·6% 
(13·0 to 24·6)*
0·3% 
(–5·1 to 6·1)
73 
(23 to 120)
84 
(26 to 137)
15·4% 
(10·1 to 21·2)*
–0·2% 
(–5·2 to 5·2)
·· Acute lymphoid 
leukaemia
0 
(0 to 0)
0 
(0 to 1)
29·4% 
(17·7 to 39·6)*
12·2% 
(2·1 to 21·3)*
14 
(4 to 23)
18 
(5 to 29)
26·3% 
(15·0 to 36·0)*
11·4% 
(1·4 to 20·1)*
·· Chronic lymphoid 
leukaemia
0 
(0 to 0)
0 
(0 to 0)
27·9% 
(16·8 to 45·2)*
2·0% 
(–7·4 to 17·1)
3 
(1 to 4)
4 
(1 to 6)
31·4% 
(19·4 to 48·4)*
7·3% 
(–3·4 to 23·2)
·· Acute myeloid leukaemia 0 
(0 to 1)
1 
(0 to 1)
29·2% 
(20·2 to 39·2)*
8·6% 
(0·4 to 17·8)*
20 
(7 to 33)
25 
(8 to 41)
25·8% 
(16·6 to 35·6)*
8·2% 
(–0·3 to 17·2)
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·· Chronic myeloid 
leukaemia
0 
(0 to 0)
0 
(0 to 0)
7·0% 
(–1·1 to 15·2)
–9·6% 
(–16·8 to –2·3)*
6 
(2 to 10)
7 
(2 to 11)
5·6% 
(–2·4 to 13·7)
–9·0% 
(–16·3 to –1·9)*
·· Other leukaemia 1 
(0 to 1)
1 
(0 to 1)
8·2% 
(3·0 to 14·7)*
–8·4% 
(–13·1 to –2·8)*
30 
(9 to 49)
31 
(10 to 52)
4·1% 
(–1·0 to 10·4)
–9·9% 
(–14·6 to –4·3)*
4 Occupational exposure to 
beryllium: all causes
0 
(0 to 0)
0 
(0 to 0)
45·4% 
(38·9 to 52·2)*
11·0% 
(6·5 to 15·6)*
5 
(5 to 6)
8 
(6 to 9)
40·1% 
(33·4 to 47·3)*
8·0% 
(3·5 to 12·8)*
·· Tracheal, bronchus, and 
lung cancer
0 
(0 to 0)
0 
(0 to 0)
45·4% 
(38·9 to 52·2)*
11·0% 
(6·5 to 15·6)*
5 
(5 to 6)
8 
(6 to 9)
40·1% 
(33·4 to 47·3)*
8·0% 
(3·5 to 12·8)*
4 Occupational exposure to 
cadmium: all causes
0 
(0 to 1)
1 
(1 to 1)
47·7% 
(40·1 to 56·0)*
12·7% 
(7·2 to 18·7)*
13 
(11 to 15)
18 
(15 to 22)
42·4% 
(34·6 to 50·8)*
9·7% 
(4·3 to 15·6)*
·· Tracheal, bronchus, and 
lung cancer
0 
(0 to 1)
1 
(1 to 1)
47·7% 
(40·1 to 56·0)*
12·7% 
(7·2 to 18·7)*
13 
(11 to 15)
18 
(15 to 22)
42·4% 
(34·6 to 50·8)*
9·7% 
(4·3 to 15·6)*
4 Occupational exposure to 
chromium: all causes
1 
(1 to 1)
1 
(1 to 2)
49·3% 
(42·0 to 56·6)*
14·0% 
(9·0 to 19·3)*
27 
(24 to 30)
38 
(34 to 43)
44·1% 
(36·8 to 51·2)*
11·0% 
(6·0 to 16·3)*
·· Tracheal, bronchus, and 
lung cancer
1 
(1 to 1)
1 
(1 to 2)
49·3% 
(42·0 to 56·6)*
14·0% 
(9·0 to 19·3)*
27 
(24 to 30)
38 
(34 to 43)
44·1% 
(36·8 to 51·2)*
11·0% 
(6·0 to 16·3)*
4 Occupational exposure to 
diesel engine exhaust: all 
causes
12 
(11 to 13)
18 
(16 to 20)
48·9% 
(41·6 to 55·4)*
13·5% 
(8·5 to 18·1)*
344 
(304 to 386)
494 
(434 to 559)
43·9% 
(36·8 to 50·5)*
10·8% 
(5·7 to 15·3)*
·· Tracheal, bronchus, and 
lung cancer
12 
(11 to 13)
18 
(16 to 20)
48·9% 
(41·6 to 55·4)*
13·5% 
(8·5 to 18·1)*
344 
(304 to 386)
494 
(434 to 559)
43·9% 
(36·8 to 50·5)*
10·8% 
(5·7 to 15·3)*
4 Occupational exposure to 
formaldehyde: all causes
1 
(1 to 1)
1 
(1 to 1)
20·6% 
(13·4 to 28·5)*
1·3% 
(–3·7 to 7·1)
40 
(33 to 48)
46 
(38 to 56)
16·1% 
(9·4 to 23·6)*
–0·3% 
(–5·4 to 5·4)
·· Nasopharynx cancer 0 
(0 to 1)
0 
(0 to 1)
23·9% 
(10·4 to 39·0)*
2·1% 
(–7·0 to 11·9)
15 
(10 to 21)
18 
(12 to 25)
18·8% 
(5·4 to 34·1)*
–0·1% 
(–9·3 to 10·1)
·· Acute lymphoid leukaemia 0 
(0 to 0)
0 
(0 to 0)
31·7% 
(21·7 to 40·9)*
14·4% 
(6·1 to 22·0)*
5 
(4 to 6)
6 
(5 to 8)
27·8% 
(18·3 to 36·9)*
12·9% 
(4·6 to 20·5)*
·· Chronic lymphoid 
leukaemia
0 
(0 to 0)
0 
(0 to 0)
41·3% 
(32·6 to 51·4)*
14·5% 
(7·3 to 22·2)*
1 
(1 to 1)
1 
(1 to 1)
45·0% 
(34·0 to 57·3)*
20·6% 
(11·8 to 30·2)*
·· Acute myeloid leukaemia 0 
(0 to 0)
0 
(0 to 0)
32·0% 
(24·7 to 38·4)*
12·0% 
(5·9 to 17·3)*
6 
(5 to 7)
8 
(6 to 9)
27·8% 
(20·3 to 34·2)*
10·7% 
(4·3 to 16·3)*
·· Chronic myeloid 
leukaemia
0 
(0 to 0)
0 
(0 to 0)
7·9% 
(2·7 to 13·8)*
–8·3% 
(–12·8 to –3·4)*
2 
(2 to 2)
2 
(2 to 3)
5·6% 
(0·2 to 11·7)*
–8·7% 
(–13·6 to –3·5)*
·· Other leukaemia 0 
(0 to 0)
0 
(0 to 0)
5·9% 
(–1·3 to 15·0)
–10·0% 
(–15·6 to –2·6)*
11 
(9 to 14)
11 
(9 to 14)
1·3% 
(–5·8 to 10·1)
–12·0% 
(–17·9 to –4·7)*
4 Occupational exposure to 
nickel: all causes
7 
(1 to 18)
9 
(1 to 23)
33·9% 
(25·4 to 55·2)*
2·0% 
(–4·5 to 18·6)
184 
(26 to 493)
238 
(36 to 607)
29·5% 
(21·2 to 49·1)*
–0·5% 
(–6·9 to 15·0)
·· Tracheal, bronchus, and 
lung cancer
7 
(1 to 18)
9 
(1 to 23)
33·9% 
(25·4 to 55·2)*
2·0% 
(–4·5 to 18·6)
184 
(26 to 493)
238 
(36 to 607)
29·5% 
(21·2 to 49·1)*
–0·5% 
(–6·9 to 15·0)
4 Occupational exposure to 
polycyclic aromatic 
hydrocarbons: all causes
3 
(3 to 4)
5 
(4 to 6)
48·9% 
(41·4 to 56·4)*
13·7% 
(8·4 to 19·0)*
94 
(80 to 107)
134 
(114 to 156)
43·7% 
(36·4 to 51·2)*
10·8% 
(5·8 to 16·0)*
·· Tracheal, bronchus, and 
lung cancer
3 
(3 to 4)
5 
(4 to 6)
48·9% 
(41·4 to 56·4)*
13·7% 
(8·4 to 19·0)*
94 
(80 to 107)
134 
(114 to 156)
43·7% 
(36·4 to 51·2)*
10·8% 
(5·8 to 16·0)*
4 Occupational exposure to 
silica: all causes
47 
(27 to 69)
60 
(34 to 88)
27·2% 
(20·5 to 33·7)*
–3·5% 
(–8·7 to 1·5)
1280 
(702 to 1880)
1590 
(870 to 2330)
24·6% 
(18·4 to 31·4)*
–4·2% 
(–9·0 to 1·3)
·· Tracheal, bronchus, and 
lung cancer
37 
(17 to 58)
49 
(22 to 77)
31·2% 
(24·3 to 41·4)*
0·0% 
(–5·3 to 7·9)
1050 
(470 to 1630)
1330 
(595 to 2080)
27·1% 
(20·2 to 36·5)*
–2·4% 
(–7·7 to 5·1)
·· Silicosis 10 
(9 to 12)
11 
(10 to 12)
12·0% 
(1·2 to 22·8)*
–15·5% 
(–23·6 to –7·4)*
230 
(205 to 266)
261 
(233 to 286)
13·2% 
(1·2 to 24·1)*
–12·3% 
(–21·6 to –3·9)*
4 Occupational exposure to 
sulphuric acid: all causes
3 
(1 to 6)
4 
(2 to 7)
25·5% 
(19·2 to 32·4)*
–3·8% 
(–8·7 to 1·5)
101 
(43 to 182)
124 
(53 to 224)
22·5% 
(16·1 to 29·5)*
–4·9% 
(–10·0 to 0·4)
·· Larynx cancer 3 
(1 to 6)
4 
(2 to 7)
25·5% 
(19·2 to 32·4)*
–3·8% 
(–8·7 to 1·5)
101 
(43 to 182)
124 
(53 to 224)
22·5% 
(16·1 to 29·5)*
–4·9% 
(–10·0 to 0·4)
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4 Occupational exposure to 
trichloroethylene: all causes
0 
(0 to 0)
0 
(0 to 0)
51·9% 
(46·4 to 59·7)*
16·6% 
(12·4 to 22·5)*
1 
(0 to 2)
2 
(0 to 3)
48·8% 
(43·2 to 56·4)*
15·7% 
(11·4 to 21·7)*
·· Kidney cancer 0 
(0 to 0)
0 
(0 to 0)
51·9% 
(46·4 to 59·7)*
16·6% 
(12·4 to 22·5)*
1 
(0 to 2)
2 
(0 to 3)
48·8% 
(43·2 to 56·4)*
15·7% 
(11·4 to 21·7)*
3 Occupational asthmagens: all 
causes
38 
(21 to 52)
34 
(22 to 47)
–9·4% 
(–16·1 to 0·5)
–28·8% 
(–34·5 to –20·6)*
1930 
(1460 to 2430)
1910 
(1500 to 2410)
–1·2% 
(–6·9 to 6·9)
–18·6% 
(–23·9 to –11·3)*
·· Asthma 38 
(21 to 52)
34 
(22 to 47)
–9·4% 
(–16·1 to 0·5)
–28·8% 
(–34·5 to –20·6)*
1930 
(1460 to 2430)
1910 
(1500 to 2410)
–1·2% 
(–6·9 to 6·9)
–18·6% 
(–23·9 to –11·3)*
3 Occupational particulate 
matter, gases, and fumes: all 
causes
432 
(354 to 510)
488 
(397 to 584)
13·0% 
(9·2 to 17·0)*
–16·2% 
(–18·7 to –13·5)*
10 500 
(9050 to 12 100)
12 100 
(10 200 to 13 900)
14·4% 
(11·1 to 17·8)*
–12·8% 
(–15·2 to –10·5)*
·· Chronic obstructive 
pulmonary disease
425 
(347 to 503)
481 
(391 to 577)
13·1% 
(9·3 to 17·2)*
–16·1% 
(–18·7 to –13·4)*
10 400 
(8870 to 11 900)
11 900 
(10 100 to 13 700)
14·6% 
(11·2 to 18·0)*
–12·7% 
(–15·1 to –10·4)*
·· Coal worker 
pneumoconiosis
3 
(3 to 4)
3 
(3 to 4)
–2·2% 
(–12·0 to 11·7)
–26·6% 
(–33·8 to –16·7)*
81 
(65 to 99)
81 
(69 to 100)
0·1% 
(–8·8 to 12·9)
–23·0% 
(–29·8 to –13·3)*
·· Other pneumoconiosis 3 
(3 to 4)
4 
(3 to 4)
8·8% 
(0·0 to 25·4)*
–17·5% 
(–24·1 to –5·0)*
90 
(74 to 110)
97 
(82 to 117)
7·6% 
(0·6 to 20·4)*
–15·9% 
(–21·4 to –5·5)*
3 Occupational noise: all causes ·· ·· ·· ·· 4830 
(3300 to 6830)
5980 
(4080 to 8430)
23·7% 
(22·4 to 25·0)*
0·7% 
(–0·2 to 1·6)
·· Age-related and other 
hearing loss
·· ·· ·· ·· 4830 
(3300 to 6830)
5980 
(4080 to 8430)
23·7% 
(22·4 to 25·0)*
0·7% 
(–0·2 to 1·6)
3 Occupational injuries: all 
causes
348 
(327 to 370)
304 
(288 to 323)
–12·8% 
(–17·3 to –7·8)*
–24·5% 
(–28·4 to –20·1)*
22 700 
(20 800 to 
24 800)
21 100 
(19 200 to 23 500)
–7·0% 
(–11·8 to –1·4)*
–18·4% 
(–22·7 to –13·5)*
·· Pedestrian road injuries 71 
(64 to 81)
58 
(53 to 66)
–18·1% 
(–24·3 to –11·2)*
–29·6% 
(–35·0 to –23·7)*
3840 
(3460 to 4350)
3190 
(2880 to 3600)
–16·8% 
(–23·0 to –10·0)*
–27·2% 
(–32·6 to –21·3)*
·· Cyclist road injuries 10 
(9 to 12)
10 
(8 to 11)
–8·4% 
(–17·8 to 2·2)
–21·8% 
(–29·8 to –12·6)*
709 
(600 to 821)
705 
(588 to 832)
–0·6% 
(–9·2 to 8·1)
–13·9% 
(–21·4 to –6·1)*
·· Motorcyclist road injuries 45 
(39 to 50)
39 
(34 to 43)
–13·8% 
(–21·5 to –5·8)*
–23·7% 
(–30·5 to –16·7)*
2790 
(2460 to 3110)
2470 
(2190 to 2740)
–11·6% 
(–18·6 to –4·4)*
–21·4% 
(–27·4 to –14·8)*
·· Motor vehicle road injuries 68 
(62 to 76)
62 
(58 to 68)
–9·0% 
(–13·3 to –3·9)*
–20·0% 
(–23·9 to –15·5)*
3860 
(3540 to 4220)
3540 
(3310 to 3860)
–8·1% 
(–12·4 to –3·4)*
–18·3% 
(–22·1 to –14·1)*
·· Other road injuries 2 
(1 to 2)
2 
(1 to 2)
–17·5% 
(–24·5 to 1·9)
–28·6% 
(–34·6 to –12·0)*
162 
(133 to 196)
170 
(136 to 211)
4·9% 
(–3·9 to 17·0)
–8·7% 
(–16·3 to 1·4)
·· Other transport injuries 17 
(15 to 20)
15 
(13 to 18)
–13·5% 
(–20·0 to –6·8)*
–24·5% 
(–30·2 to –18·6)*
1300 
(1130 to 1500)
1200 
(1020 to 1400)
–7·4% 
(–13·8 to –1·1)*
–18·4% 
(–24·2 to –12·8)*
·· Falls 37 
(32 to 41)
36 
(32 to 39)
–3·0% 
(–10·7 to 6·6)
–19·0% 
(–25·5 to –11·0)*
3390 
(2850 to 4090)
3700 
(3030 to 4540)
9·1% 
(2·6 to 16·4)*
–6·6% 
(–12·2 to –0·5)*
·· Drowning 26 
(25 to 28)
23 
(21 to 24)
–13·9% 
(–19·3 to –8·1)*
–24·5% 
(–29·3 to –19·4)*
1380 
(1290 to 1480)
1170 
(1090 to 1260)
–15·3% 
(–20·6 to –9·6)*
–24·2% 
(–29·0 to –19·1)*
·· Fire, heat, and hot 
substances
10 
(8 to 11)
8 
(7 to 9)
–14·2% 
(–18·6 to –5·3)*
–26·3% 
(–30·0 to –18·4)*
898 
(753 to 1060)
878 
(719 to 1070)
–2·1% 
(–7·5 to 4·2)
–14·2% 
(–18·9 to –8·7)*
·· Poisoning by carbon 
monoxide
5 
(4 to 5)
4 
(3 to 4)
–14·8% 
(–23·9 to –4·5)*
–27·0% 
(–34·9 to –18·3)*
230 
(182 to 257)
197 
(147 to 223)
–14·3% 
(–22·8 to –4·4)*
–25·2% 
(–32·6 to –16·6)*
·· Poisoning by other means 4 
(3 to 5)
4 
(3 to 4)
–6·3% 
(–16·3 to 5·4)
–19·4% 
(–28·0 to –9·4)*
234 
(183 to 265)
230 
(174 to 266)
–1·6% 
(–9·8 to 9·1)
–13·6% 
(–20·8 to –4·3)*
·· Unintentional firearm 
injuries
4 
(3 to 4)
3 
(3 to 4)
–10·3% 
(–16·0 to –4·2)*
–20·9% 
(–25·7 to –15·5)*
237 
(210 to 270)
224 
(199 to 256)
–5·3% 
(–10·7 to 0·6)
–15·7% 
(–20·5 to –10·5)*
·· Other exposure to 
mechanical forces
18 
(15 to 19)
15 
(13 to 16)
–17·5% 
(–23·3 to –11·0)*
–28·8% 
(–33·7 to –23·2)*
1420 
(1220 to 1660)
1390 
(1160 to 1690)
–2·0% 
(–9·0 to 5·4)
–14·8% 
(–20·7 to –8·4)*
·· Venomous animal contact 7 
(4 to 8)
6 
(3 to 7)
–19·2% 
(–29·8 to –5·9)*
–30·6% 
(–39·7 to –19·1)*
430 
(269 to 524)
368 
(245 to 440)
–14·3% 
(–25·0 to –2·1)*
–24·6% 
(–34·0 to –14·0)*
·· Non-venomous animal 
contact
1 
(1 to 1)
1 
(1 to 1)
–9·7% 
(–18·5 to 1·3)
–23·1% 
(–30·6 to –13·5)*
93 
(69 to 125)
90 
(68 to 121)
–3·4% 
(–11·0 to 3·5)
–16·0% 
(–22·6 to –10·0)*
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·· Pulmonary aspiration and 
foreign body in airway
5 
(5 to 5)
5 
(5 to 6)
3·5% 
(–0·6 to 7·2)
–12·2% 
(–15·7 to –9·2)*
254 
(241 to 271)
263 
(247 to 281)
3·5% 
(–0·5 to 7·5)
–10·2% 
(–13·6 to –6·8)*
·· Foreign body in other body 
part
1 
(1 to 1)
1 
(1 to 1)
–2·1% 
(–8·5 to 4·0)
–15·4% 
(–20·8 to –10·2)*
109 
(85 to 135)
120 
(92 to 150)
10·9% 
(5·1 to 16·5)*
–3·4% 
(–8·4 to 1·5)
·· Other unintentional 
injuries
18 
(17 to 20)
14 
(13 to 16)
–23·3% 
(–29·2 to –16·8)*
–32·9% 
(–38·0 to –27·1)*
1360 
(1200 to 1550)
1200 
(1030 to 1430)
–11·9% 
(–18·4 to –5·0)*
–22·7% 
(–28·2 to –16·8)*
3 Occupational ergonomic 
factors: all causes
·· ·· ·· ·· 14 200 
(10 000 to 
19 400)
15 900 
(11 200 to 21 800)
12·5% 
(10·6 to 14·5)*
–5·0% 
(–6·3 to –3·6)*
·· Low back pain ·· ·· ·· ·· 14 200 
(10 000 to 
19 400)
15 900 
(11 200 to 21 800)
12·5% 
(10·6 to 14·5)*
–5·0% 
(–6·3 to –3·6)*
1 Behavioural risks: all causes 23 200 
(22 600 to 
23 800)
23 800 
(23 100 to 
24 600)
2·7% 
(1·2 to 4·1)*
–18·7% 
(–19·9 to 
–17·7)*
1 020 000 
(970 000 to 
1 060 000)
913 000 
(863 000 to 
961 000)
–10·1% 
(–11·9 to –8·4)*
–23·1% 
(–24·6 to 
–21·6)*
2 Child and maternal 
malnutrition: all causes
4650 
(4450 to 4880)
3190 
(3020 to 
3360)
–31·4% 
(–34·4 to 
–28·6)*
–34·2% 
(–37·1 to –31·5)*
455 000 
(430 000 to 
482 000)
327 000 
(303 000 to 
352 000)
–28·2% 
(–31·2 to 
–25·3)*
–31·5% 
(–34·3 to 
–28·8)*
3 Suboptimal breastfeeding: all 
causes
270 
(200 to 338)
169 
(132 to 210)
–37·1% 
(–42·4 to –30·9)*
–39·4% 
(–44·4 to –33·4)*
23 800 
(17 700 to 
29 900)
15 000 
(11 700 to 18 600)
–36·8% 
(–42·0 to –30·6)*
–39·0% 
(–44·1 to –33·1)*
4 Non-exclusive 
breastfeeding: all causes
256 
(191 to 324)
161 
(124 to 201)
–37·1% 
(–42·4 to –30·8)*
–39·3% 
(–44·4 to –33·2)*
22 600 
(16 800 to 
28 500)
14 200 
(11 000 to 17 800)
–36·9% 
(–42·1 to –30·6)*
–39·0% 
(–44·1 to –33·0)*
·· Lower respiratory 
infections
97 
(52 to 150)
60 
(34 to 91)
–38·1% 
(–43·0 to –30·8)*
–40·2% 
(–44·9 to –33·1)*
8530 
(4530 to 13 100)
5280 
(2940 to 7960)
–38·1% 
(–43·0 to –30·8)*
–40·2% 
(–44·9 to –33·1)*
·· Diarrhoeal diseases 159 
(118 to 199)
101 
(77 to 127)
–36·5% 
(–44·0 to –28·1)*
–38·7% 
(–45·9 to –30·6)*
14 000 
(10 500 to 
17 600)
8970 
(6850 to 11 300)
–36·1% 
(–43·5 to –27·8)*
–38·4% 
(–45·5 to –30·3)*
4 Discontinued 
breastfeeding: all causes
16 
(5 to 28)
10 
(4 to 18)
–36·7% 
(–46·5 to –25·2)*
–39·9% 
(–49·2 to –28·9)*
1420 
(488 to 2550)
931 
(322 to 1630)
–34·7% 
(–44·2 to –23·1)*
–37·9% 
(–47·0 to –26·9)*
·· Diarrhoeal diseases 16 
(5 to 28)
10 
(4 to 18)
–36·7% 
(–46·5 to –25·2)*
–39·9% 
(–49·2 to –28·9)*
1420 
(488 to 2550)
931 
(322 to 1630)
–34·7% 
(–44·2 to –23·1)*
–37·9% 
(–47·0 to –26·9)*
3 Child growth failure: all 
causes
1980 
(1800 to 2170)
1190 
(1060 to 1300)
–40·1% 
(–43·9 to –36·0)*
–43·6% 
(–47·2 to –39·8)*
170 000 
(155 000 to 
186 000)
100 000 
(89 800 to 
110 000)
–40·9% 
(–44·7 to –37·0)*
–43·8% 
(–47·5 to –40·1)*
4 Child underweight: all 
causes
710 
(606 to 853)
417 
(365 to 498)
–41·3% 
(–45·7 to –36·1)*
–46·2% 
(–50·1 to –41·6)*
58 700 
(49 700 to 
71 300)
32 400 
(28 000 to 39 500)
–44·7% 
(–48·9 to –40·0)*
–47·9% 
(–51·8 to –43·5)*
·· Lower respiratory 
infections
181 
(121 to 310)
93 
(61 to 169)
–48·8% 
(–53·5 to –44·1)*
–51·2% 
(–55·6 to –46·6)*
15 700 
(10 500 to 
26 900)
8050 
(5270 to 14 700)
–48·8% 
(–53·4 to –44·1)*
–51·1% 
(–55·6 to –46·6)*
·· Diarrhoeal diseases 139 
(113 to 177)
66 
(52 to 83)
–53·0% 
(–59·3 to –45·6)*
–55·3% 
(–61·3 to –48·2)*
12 300 
(10 000 to 
15 600)
5860 
(4670 to 7430)
–52·4% 
(–58·7 to –45·2)*
–54·7% 
(–60·7 to –47·8)*
·· Measles 76 
(16 to 199)
27 
(5 to 75)
–64·9% 
(–72·1 to –59·0)*
–66·8% 
(–73·6 to –61·2)*
6560 
(1400 to 17 200)
2300 
(437 to 6480)
–65·0% 
(–72·1 to –59·0)*
–66·8% 
(–73·6 to –61·2)*
·· Protein-energy 
malnutrition
313 
(288 to 339)
232 
(212 to 254)
–26·1% 
(–31·7 to –18·0)*
–34·6% 
(–39·4 to –27·5)*
24 100 
(21 800 to 
26 400)
16 200 
(14 500 to 18 000)
–32·6% 
(–38·3 to –24·7)*
–37·2% 
(–42·5 to –29·7)*
4 Child wasting: all causes 1770 
(1480 to 2020)
1080 
(891 to 1220)
–39·1% 
(–43·1 to –35·0)*
–42·8% 
(–46·6 to 
–38·9)*
152 000 
(127 000 to 
173 000)
91 000 
(75 400 to 104 000)
–40·1% 
(–44·2 to 
–36·0)*
–43·1% 
(–47·1 to –39·2)*
·· Lower respiratory 
infections
700 
(481 to 841)
426 
(281 to 523)
–39·2% 
(–44·2 to –34·6)*
–41·9% 
(–46·7 to –37·5)*
60 900 
(41 800 to 
73 100)
37 000 
(24 500 to 45 500)
–39·1% 
(–44·1 to –34·5)*
–41·8% 
(–46·6 to –37·4)*
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·· Diarrhoeal diseases 680 
(534 to 788)
389 
(288 to 452)
–42·8% 
(–50·5 to –33·8)*
–45·5% 
(–52·9 to –36·9)*
60 300 
(47 200 to 
69 700)
35 100 
(26 000 to 40 800)
–41·8% 
(–49·6 to –33·1)*
–44·6% 
(–52·0 to –36·3)*
·· Measles 76 
(11 to 246)
30 
(4 to 108)
–60·2% 
(–68·0 to –53·9)*
–62·3% 
(–69·6 to –56·4)*
6610 
(942 to 21 400)
2630 
(322 to 9370)
–60·2% 
(–68·0 to –53·9)*
–62·2% 
(–69·6 to –56·4)*
·· Protein-energy 
malnutrition
313 
(288 to 339)
232 
(212 to 254)
–26·1% 
(–31·7 to –18·0)*
–34·6% 
(–39·4 to –27·5)*
24 100 
(21 800 to 
26 400)
16 200 
(14 500 to 18 000)
–32·6% 
(–38·3 to –24·7)*
–37·2% 
(–42·5 to –29·7)*
4 Child stunting: all causes 458 
(237 to 754)
221 
(103 to 395)
–51·8% 
(–57·8 to –46·0)*
–54·2% 
(–59·9 to –48·5)*
40 000 
(20 700 to 
65 700)
19 400 
(9070 to 34 600)
–51·5% 
(–57·3 to –45·8)*
–53·9% 
(–59·5 to –48·3)*
·· Lower respiratory 
infections
229 
(30 to 505)
119 
(13 to 285)
–48·0% 
(–58·0 to –42·3)*
–50·4% 
(–59·9 to –44·9)*
19 900 
(2600 to 43 900)
10 300 
(1120 to 24 800)
–47·9% 
(–57·9 to –42·2)*
–50·3% 
(–59·9 to –44·8)*
·· Diarrhoeal diseases 174 
(69 to 303)
81 
(30 to 149)
–53·3% 
(–61·1 to –44·7)*
–55·5% 
(–63·0 to –47·4)*
15 400 
(6100 to 26 700)
7310 
(2720 to 13 400)
–52·5% 
(–60·3 to –44·2)*
–54·8% 
(–62·3 to –46·9)*
·· Measles 56 
(6 to 158)
20 
(2 to 61)
–63·5% 
(–72·0 to –57·8)*
–65·4% 
(–73·5 to –60·1)*
4810 
(513 to 13 700)
1760 
(168 to 5310)
–63·5% 
(–72·0 to –57·8)*
–65·4% 
(–73·5 to –60·1)*
3 Low birthweight and short 
gestation: all causes
2490 
(2400 to 2570)
1880 
(1790 to 1970)
–24·4% 
(–27·4 to –21·2)*
–26·4% 
(–29·4 to –23·3)*
229 000 
(221 000 to 
237 000)
178 000 
(169 000 to 
187 000)
–22·1% 
(–25·3 to –18·7)*
–24·7% 
(–27·6 to –21·5)*
4 Short gestation for 
birthweight: all causes
1890 
(1820 to 1970)
1430 
(1360 to 1510)
–24·2% 
(–27·4 to –21·0)*
–26·3% 
(–29·4 to –23·1)*
176 000 
(170 000 to 
184 000)
139 000 
(131 000 to 
147 000)
–21·3% 
(–24·4 to –17·6)*
–24·0% 
(–27·0 to –20·6)*
·· Lower respiratory 
infections
186 
(172 to 200)
129 
(117 to 142)
–30·7% 
(–36·5 to –23·8)*
–32·6% 
(–38·3 to –25·9)*
16 300 
(15 100 to 
17 600)
11 300 
(10 300 to 12 400)
–30·7% 
(–36·5 to –23·8)*
–32·6% 
(–38·3 to –25·9)*
·· Upper respiratory 
infections
0 
(0 to 0)
0 
(0 to 0)
–38·4% 
(–48·3 to –21·7)*
–40·2% 
(–49·8 to 
–23·9)*
10 
(5 to 13)
6 
(4 to 9)
–38·4% 
(–48·3 to –21·7)*
–40·2% 
(–49·8 to –23·9)*
·· Otitis media 0 
(0 to 0)
0 
(0 to 0)
–51·6% 
(–70·5 to –22·3)*
–53·0% 
(–71·3 to –24·5)*
3 
(1 to 11)
2 
(1 to 6)
–51·6% 
(–70·5 to –22·3)*
–53·0% 
(–71·3 to –24·5)*
·· Diarrhoeal diseases 48 
(43 to 53)
31 
(27 to 35)
–35·1% 
(–43·6 to –25·9)*
–37·0% 
(–45·2 to –28·0)*
4180 
(3790 to 4620)
2710 
(2410 to 3040)
–35·1% 
(–43·6 to –25·9)*
–37·0% 
(–45·2 to –28·0)*
·· Pneumococcal 
meningitis
2 
(2 to 3)
2 
(1 to 2)
–20·4% 
(–31·4 to –6·9)*
–22·6% 
(–33·3 to –9·4)*
187 
(148 to 224)
149 
(118 to 183)
–20·4% 
(–31·4 to –6·8)*
–22·6% 
(–33·3 to –9·4)*
·· H influenzae type B 
meningitis
4 
(4 to 5)
3 
(2 to 3)
–40·9% 
(–48·8 to –31·0)*
–42·6% 
(–50·2 to –33·0)*
382 
(309 to 462)
225 
(176 to 277)
–40·9% 
(–48·8 to –31·0)*
–42·6% 
(–50·2 to –33·0)*
·· Meningococcal infection 2 
(2 to 3)
2 
(1 to 2)
–34·6% 
(–42·8 to –24·4)*
–36·5% 
(–44·4 to –26·5)*
211 
(175 to 246)
138 
(109 to 167)
–34·6% 
(–42·8 to –24·4)*
–36·4% 
(–44·4 to –26·5)*
·· Other meningitis 7 
(5 to 8)
6 
(5 to 7)
–11·8% 
(–22·6 to 2·5)
–14·2% 
(–24·8 to –0·3)*
573 
(475 to 664)
505 
(413 to 592)
–11·8% 
(–22·6 to 2·5)
–14·2% 
(–24·8 to –0·3)*
·· Encephalitis 1 
(1 to 1)
1 
(1 to 1)
–16·0% 
(–33·2 to –1·7)*
–18·4% 
(–35·1 to –4·4)*
95 
(85 to 107)
80 
(67 to 89)
–16·0% 
(–33·2 to –1·7)*
–18·4% 
(–35·1 to –4·4)*
·· Neonatal preterm birth 879 
(830 to 991)
649 
(605 to 721)
–26·2% 
(–31·3 to –21·5)*
–28·1% 
(–33·2 to –23·6)*
87 700 
(82 100 to 
97 300)
70 200 
(64 400 to 77 200)
–19·9% 
(–25·3 to –14·4)*
–23·3% 
(–28·4 to –18·3)*
·· Neonatal encephalopathy 
due to birth asphyxia and 
trauma
351 
(314 to 379)
281 
(248 to 309)
–20·0% 
(–26·6 to –12·4)*
–22·1% 
(–28·5 to –14·7)*
30 800 
(27 600 to 
33 300)
24 700 
(21 800 to 27 200)
–20·0% 
(–26·6 to –12·4)*
–22·1% 
(–28·5 to –14·7)*
·· Neonatal sepsis and 
other neonatal infections
120 
(106 to 157)
111 
(97 to 144)
–8·1% 
(–17·1 to 2·0)
–10·6% 
(–19·3 to –0·8)*
10 600 
(9280 to 13 800)
9710 
(8540 to 12 700)
–8·1% 
(–17·1 to 2·0)
–10·6% 
(–19·3 to –0·8)*
·· Haemolytic disease and 
other neonatal jaundice
44 
(38 to 50)
28 
(24 to 32)
–36·3% 
(–44·7 to –26·2)*
–38·0% 
(–46·2 to –28·2)*
3840 
(3340 to 4380)
2450 
(2140 to 2810)
–36·3% 
(–44·7 to –26·2)*
–38·0% 
(–46·2 to –28·2)*
·· Other neonatal disorders 242 
(210 to 266)
188 
(160 to 207)
–22·3% 
(–28·9 to –13·9)*
–24·4% 
(–30·8 to –16·1)*
21 300 
(18 400 to 
23 400)
16 500 
(14 000 to 18 200)
–22·3% 
(–28·9 to –13·9)*
–24·4% 
(–30·8 to –16·1)*
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Risk factors and outcomes 2007 deaths 
(thousands)
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DALYs, 
2007–17
Percentage 
change in age-
standardised 
DALY rate, 
2007–17
(Continued from previous page)
·· Sudden infant death 
syndrome
3 
(1 to 5)
2 
(1 to 4)
–20·9% 
(–31·2 to –4·0)*
–23·2% 
(–33·2 to –6·8)*
262 
(103 to 467)
208 
(98 to 351)
–20·9% 
(–31·2 to –4·0)*
–23·2% 
(–33·2 to –6·8)*
4 Low birthweight for 
gestation: all causes
1480 
(1410 to 1570)
1100 
(1040 to 1160)
–25·7% 
(–28·9 to –22·2)*
–27·6% 
(–30·8 to –24·3)*
140 000 
(134 000 to 
148 000)
110 000 
(103 000 to 
117 000)
–21·8% 
(–25·4 to –17·9)*
–24·7% 
(–28·0 to –21·0)*
·· Lower respiratory 
infections
95 
(86 to 105)
63 
(56 to 71)
–33·9% 
(–40·6 to –26·4)*
–35·6% 
(–42·2 to –28·3)*
8350 
(7530 to 9270)
5520 
(4880 to 6260)
–33·8% 
(–40·6 to 
–26·4)*
–35·6% 
(–42·2 to –28·3)*
·· Upper respiratory 
infections
0 
(0 to 0)
0 
(0 to 0)
–45·8% 
(–54·9 to –30·6)*
–47·3% 
(–56·1 to –32·5)*
5 
(3 to 7)
3 
(2 to 4)
–45·8% 
(–54·9 to 
–30·6)*
–47·3% 
(–56·1 to –32·5)*
·· Otitis media 0 
(0 to 0)
0 
(0 to 0)
–48·9% 
(–68·4 to –16·0)*
–50·3% 
(–69·3 to –18·4)*
2 
(0 to 7)
1 
(0 to 4)
–48·9% 
(–68·4 to 
–16·0)*
–50·3% 
(–69·3 to 
–18·4)*
·· Diarrhoeal diseases 18 
(16 to 21)
11 
(10 to 13)
–37·4% 
(–46·1 to –28·8)*
–39·1% 
(–47·5 to –30·7)*
1610 
(1400 to 1830)
1010 
(878 to 1150)
–37·4% 
(–46·1 to 
–28·8)*
–39·1% 
(–47·5 to –30·7)*
·· Pneumococcal 
meningitis
1 
(1 to 1)
1 
(1 to 1)
–28·4% 
(–39·6 to –14·4)*
–30·4% 
(–41·3 to –16·7)*
100 
(76 to 124)
72 
(56 to 89)
–28·4% 
(–39·6 to 
–14·4)*
–30·4% 
(–41·3 to –16·7)*
·· H influenzae type B 
meningitis
2 
(2 to 3)
1 
(1 to 1)
–46·5% 
(–53·9 to –37·0)*
–48·0% 
(–55·2 to –38·7)*
177 
(134 to 227)
95 
(71 to 118)
–46·5% 
(–53·9 to –37·0)*
–48·0% 
(–55·2 to –38·7)*
·· Meningococcal infection 1 
(1 to 1)
1 
(1 to 1)
–37·6% 
(–46·6 to 
–26·6)*
–39·2% 
(–48·0 to 
–28·6)*
104 
(81 to 126)
65 
(50 to 80)
–37·6% 
(–46·6 to 
–26·6)*
–39·2% 
(–48·0 to –28·6)*
·· Other meningitis 3 
(3 to 4)
3 
(2 to 3)
–16·0% 
(–27·6 to –2·3)*
–18·3% 
(–29·5 to –5·0)*
286 
(229 to 340)
240 
(191 to 284)
–16·0% 
(–27·6 to –2·3)*
–18·3% 
(–29·5 to –5·0)*
·· Encephalitis 0 
(0 to 0)
0 
(0 to 0)
–16·7% 
(–32·2 to –3·4)*
–19·0% 
(–34·1 to –6·0)*
38 
(33 to 44)
31 
(27 to 36)
–16·7% 
(–32·2 to –3·4)*
–19·0% 
(–34·1 to –6·0)*
·· Neonatal preterm birth 879 
(830 to 991)
649 
(605 to 721)
–26·2% 
(–31·3 to –21·5)*
–28·1% 
(–33·2 to –23·6)*
87 700 
(82 100 to 
97 300)
70 200 
(64 400 to 77 200)
–19·9% 
(–25·3 to –14·4)*
–23·3% 
(–28·4 to –18·3)*
·· Neonatal 
encephalopathy due to 
birth asphyxia and 
trauma
249 
(221 to 271)
188 
(166 to 207)
–24·6% 
(–30·7 to –17·7)*
–26·6% 
(–32·5 to –19·8)*
21 900 
(19 400 to 
23 800)
16 500 
(14 600 to 18 200)
–24·6% 
(–30·7 to –17·7)*
–26·6% 
(–32·5 to –19·8)*
·· Neonatal sepsis and 
other neonatal infections
64 
(55 to 90)
57 
(49 to 80)
–10·8% 
(–20·3 to 0·0)*
–13·2% 
(–22·4 to –2·7)*
5620 
(4830 to 7910)
5010 
(4320 to 6990)
–10·8% 
(–20·3 to 0·0)*
–13·2% 
(–22·4 to –2·7)*
·· Haemolytic disease and 
other neonatal jaundice
21 
(18 to 24)
13 
(12 to 15)
–35·7% 
(–44·1 to –26·2)*
–37·4% 
(–45·6 to –28·2)*
1810 
(1570 to 2080)
1160 
(1010 to 1330)
–35·7% 
(–44·1 to –26·2)*
–37·4% 
(–45·6 to –28·2)*
·· Other neonatal disorders 141 
(121 to 156)
109 
(92 to 121)
–22·8% 
(–29·7 to –13·9)*
–24·8% 
(–31·5 to –16·2)*
12 400 
(10 600 to 
13 700)
9560 
(8060 to 10 600)
–22·8% 
(–29·7 to 
–13·9)*
–24·8% 
(–31·5 to –16·2)*
·· Sudden infant death 
syndrome
1 
(0 to 1)
1 
(0 to 1)
–22·7% 
(–33·6 to –7·6)*
–24·9% 
(–35·5 to –10·3)*
68 
(32 to 127)
52 
(27 to 93)
–22·7% 
(–33·6 to –7·6)*
–24·9% 
(–35·5 to –10·3)*
3 Iron deficiency: all causes 89 
(36 to 133)
60 
(24 to 91)
–32·6% 
(–37·0 to –28·4)*
–38·5% 
(–42·5 to –34·6)*
37 100 
(25 800 to 
51 300)
33 700 
(23 200 to 47 200)
–9·3% 
(–13·2 to –5·3)*
–17·6% 
(–21·1 to –14·1)*
·· Maternal haemorrhage 28 
(12 to 44)
12 
(5 to 19)
–56·9% 
(–64·0 to –48·6)*
–60·7% 
(–67·3 to –53·2)*
1650 
(670 to 2570)
702 
(281 to 1100)
–57·4% 
(–64·6 to 
–48·7)*
–60·9% 
(–67·6 to –53·1)*
·· Maternal sepsis and other 
pregnancy related infections
11 
(4 to 17)
7 
(3 to 11)
–36·7% 
(–49·0 to –23·8)*
–42·1% 
(–53·2 to –30·3)*
634 
(265 to 1010)
397 
(156 to 635)
–37·4% 
(–49·4 to –24·1)*
–42·3% 
(–53·3 to –30·0)*
·· Maternal hypertensive 
disorders
10 
(4 to 16)
9 
(3 to 14)
–16·0% 
(–32·6 to 2·1)
–22·6% 
(–37·9 to –5·8)*
659 
(262 to 1050)
550 
(212 to 863)
–16·6% 
(–32·7 to 0·5)
–22·7% 
(–37·6 to –6·9)*
·· Maternal obstructed labour 
and uterine rupture
6 
(2 to 10)
4 
(2 to 7)
–26·8% 
(–44·8 to –5·1)*
–33·5% 
(–49·6 to –13·6)*
461 
(188 to 761)
343 
(139 to 561)
–25·6% 
(–40·2 to –10·8)*
–32·1% 
(–45·2 to –18·5)*
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2007–17
(Continued from previous page)
·· Maternal abortive outcome 6 
(3 to 10)
5 
(2 to 9)
–17·0% 
(–32·9 to 0·5)
–24·7% 
(–38·9 to –8·9)*
374 
(152 to 602)
304 
(118 to 484)
–18·7% 
(–35·0 to –0·3)*
–25·5% 
(–40·1 to –9·0)*
·· Ectopic pregnancy 4 
(2 to 9)
3 
(1 to 6)
–21·9% 
(–51·6 to 20·4)
–28·4% 
(–55·1 to 10·5)
263 
(92 to 541)
203 
(75 to 378)
–23·0% 
(–51·4 to 19·5)
–29·0% 
(–55·2 to 9·9)
·· Indirect maternal deaths 12 
(5 to 20)
10 
(4 to 17)
–14·5% 
(–28·4 to –0·6)*
–21·9% 
(–34·7 to –9·5)*
714 
(287 to 1150)
598 
(233 to 956)
–16·2% 
(–30·5 to –1·9)*
–23·0% 
(–36·3 to 
–10·3)*
·· Late maternal deaths 1 
(0 to 2)
1 
(0 to 2)
–13·3% 
(–19·6 to –7·3)*
–20·7% 
(–26·2 to –15·2)*
65 
(26 to 104)
56 
(21 to 92)
–14·3% 
(–20·4 to –8·3)*
–21·2% 
(–26·6 to –15·7)*
·· Maternal deaths 
aggravated by HIV/AIDS
1 
(0 to 1)
0 
(0 to 1)
–30·3% 
(–37·6 to –22·8)*
–37·8% 
(–44·3 to –31·1)*
38 
(15 to 63)
25 
(9 to 44)
–32·8% 
(–39·9 to 
–25·6)*
–39·7% 
(–46·2 to –33·2)*
·· Other maternal disorders 9 
(4 to 15)
8 
(3 to 12)
–18·8% 
(–35·7 to 2·8)
–25·8% 
(–41·4 to –6·0)*
577 
(227 to 936)
470 
(184 to 736)
–18·6% 
(–36·0 to 2·5)
–25·2% 
(–40·9 to –5·8)*
·· Dietary iron deficiency ·· ·· ·· ·· 31 700 
(21 400 to 
45 200)
30 000 
(20 300 to 43 600)
–5·2% 
(–8·4 to –1·9)*
–14·3% 
(–17·2 to –11·4)*
3 Vitamin A deficiency: all 
causes
437 
(339 to 550)
233 
(179 to 294)
–46·8% 
(–51·4 to –42·0)*
–49·2% 
(–53·7 to –44·6)*
48 500 
(38 700 to 
59 900)
29 000 
(23 000 to 35 600)
–40·2% 
(–44·7 to –35·8)*
–43·3% 
(–47·6 to –39·0)*
·· Lower respiratory 
infections
94 
(36 to 161)
53 
(20 to 92)
–43·4% 
(–47·6 to –39·3)*
–45·9% 
(–49·8 to –41·9)*
8130 
(3110 to 14 000)
4600 
(1750 to 8000)
–43·4% 
(–47·6 to –39·3)*
–45·8% 
(–49·8 to –41·9)*
·· Diarrhoeal diseases 263 
(217 to 308)
146 
(120 to 173)
–44·5% 
(–51·0 to –37·1)*
–47·1% 
(–53·3 to –40·0)*
23 300 
(19 300 to 
27 300)
13 100 
(10 800 to 15 500)
–43·7% 
(–50·1 to –36·5)*
–46·3% 
(–52·4 to –39·4)*
·· Measles 81 
(27 to 181)
34 
(11 to 78)
–58·0% 
(–63·3 to –53·0)*
–60·2% 
(–65·2 to –55·4)*
6980 
(2310 to 15 700)
2930 
(961 to 6750)
–58·0% 
(–63·2 to –53·0)*
–60·2% 
(–65·1 to –55·4)*
·· Vitamin A deficiency ·· ·· ·· ·· 10 000 
(6650 to 14 500)
8310 
(5400 to 12 200)
–17·3% 
(–20·8 to –13·6)*
–22·3% 
(–25·7 to –18·8)*
3 Zinc deficiency: all causes 60 
(3 to 157)
29 
(1 to 77)
–52·3% 
(–61·6 to –41·7)*
–55·2% 
(–64·0 to –45·3)*
5290 
(398 to 13 600)
2580 
(235 to 6750)
–51·2% 
(–60·2 to –36·4)*
–54·2% 
(–62·6 to –40·2)*
·· Lower respiratory 
infections
24 
(0 to 98)
12 
(0 to 52)
–49·3% 
(–58·1 to 0)
–57·2% 
(–60·4 to 0)
2100 
(3 to 8430)
1070 
(2 to 4460)
–49·2% 
(–57·9 to –21·2)*
–52·2% 
(–60·4 to –26·0)*
·· Diarrhoeal diseases 36 
(0 to 102)
16 
(0 to 48)
–54·4% 
(–63·4 to 0)
–52·3% 
(–65·6 to 0)
3190 
(132 to 8890)
1510 
(113 to 4270)
–52·6% 
(–61·0 to –12·4)*
–55·4% 
(–63·3 to –17·7)*
2 Tobacco: all causes 7280 
(7010 to 7560)
8100 
(7790 to 
8420)
11·3% 
(9·1 to 13·4)*
–15·9% 
(–17·6 to 
–14·4)*
200 000 
(188 000 to 
212 000)
213 000 
(201 000 to 
227 000)
6·8% 
(4·6 to 9·0)*
–16·8% 
(–18·5 to 
–15·2)*
3 Smoking: all causes 6380 
(6170 to 6590)
7100 
(6830 to 7370)
11·2% 
(8·8 to 13·5)*
–16·2% 
(–18·0 to –14·4)*
169 000 
(160 000 to 
177 000)
182 000 
(173 000 to 
193 000)
8·2% 
(6·0 to 10·3)*
–16·4% 
(–18·1 to –14·7)*
·· Drug-susceptible 
tuberculosis
200 
(163 to 234)
156 
(124 to 188)
–22·1% 
(–29·6 to –14·5)*
–38·7% 
(–44·6 to –32·8)*
6740 
(5450 to 7860)
5210 
(4140 to 6290)
–22·7% 
(–29·7 to –15·3)*
–37·5% 
(–43·1 to –31·7)*
·· Multidrug-resistant 
tuberculosis without 
extensive drug resistance
26 
(20 to 34)
20 
(11 to 32)
–26·0% 
(–54·4 to 16·5)
–41·4% 
(–63·9 to –7·6)*
887 
(671 to 1130)
636 
(368 to 1030)
–28·3% 
(–54·8 to 10·7)
–41·7% 
(–63·2 to –9·8)*
·· Extensively drug-resistant 
tuberculosis
3 
(2 to 4)
3 
(2 to 4)
–2·6% 
(–26·1 to 27·8)
–21·8% 
(–40·8 to 2·5)
110 
(83 to 140)
103 
(74 to 138)
–6·5% 
(–28·6 to 20·6)
–23·1% 
(–41·4 to –1·0)*
·· Lower respiratory 
infections
241 
(180 to 301)
265 
(194 to 338)
9·9% 
(5·2 to 13·8)*
–17·6% 
(–21·0 to –14·8)*
5200 
(3950 to 6410)
5410 
(4020 to 6820)
4·0% 
(–0·6 to 7·9)
–18·9% 
(–22·5 to –15·9)*
·· Lip and oral cavity cancer 48 
(40 to 56)
59 
(48 to 69)
22·2% 
(15·8 to 27·9)*
–7·2% 
(–12·0 to –2·8)*
1270 
(1030 to 1500)
1500 
(1190 to 1780)
17·9% 
(11·3 to 23·6)*
–9·1% 
(–14·1 to –4·6)*
·· Nasopharynx cancer 15 
(11 to 19)
18 
(13 to 23)
19·7% 
(13·9 to 26·5)*
–8·2% 
(–12·5 to –3·0)*
427 
(303 to 541)
492 
(350 to 627)
15·3% 
(9·3 to 22·3)*
–10·0% 
(–14·5 to –4·9)*
·· Other pharynx cancer 39 
(32 to 45)
51 
(41 to 59)
29·9% 
(18·4 to 39·8)*
–1·1% 
(–9·9 to 6·5)
1060 
(867 to 1220)
1330 
(1050 to 1580)
25·7% 
(14·4 to 35·6)*
–3·2% 
(–12·0 to 4·5)
(Table 3 continues on next page)
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1949
Risk factors and outcomes 2007 deaths 
(thousands)
2017 deaths 
(thousands)
Percentage 
change in 
deaths, 
2007–17
Percentage 
change in age-
standardised 
death rate, 
2007–17
2007 DALYs 
(thousands)
2017 DALYs 
(thousands)
Percentage 
change in 
DALYs, 
2007–17
Percentage 
change in age-
standardised 
DALY rate, 
2007–17
(Continued from previous page)
·· Oesophageal cancer 151 
(137 to 164)
170 
(156 to 186)
13·1% 
(8·4 to 18·0)*
–14·4% 
(–17·9 to –10·6)*
3520 
(3170 to 3850)
3810 
(3470 to 4170)
8·3% 
(3·8 to 12·8)*
–17·1% 
(–20·5 to –13·6)*
·· Stomach cancer 147 
(120 to 174)
155 
(126 to 183)
5·1% 
(0·8 to 10·0)*
–20·6% 
(–23·7 to –17·0)*
3220 
(2570 to 3850)
3270 
(2640 to 3890)
1·6% 
(–2·6 to 6·5)
–22·4% 
(–25·6 to –18·8)*
·· Colon and rectum cancer 101 
(68 to 134)
119 
(79 to 160)
18·2% 
(13·6 to 22·6)*
–11·3% 
(–14·9 to –7·8)*
2190 
(1420 to 2870)
2540 
(1620 to 3390)
16·0% 
(11·2 to 20·2)*
–11·8% 
(–15·5 to –8·5)*
·· Liver cancer due to 
hepatitis B
53 
(28 to 78)
64 
(35 to 92)
20·7% 
(9·5 to 38·7)*
–7·1% 
(–15·1 to 5·9)
1520 
(742 to 2250)
1760 
(933 to 2560)
16·0% 
(5·2 to 34·1)*
–9·6% 
(–17·0 to 4·0)
·· Liver cancer due to 
hepatitis C
33 
(19 to 46)
41 
(23 to 58)
25·9% 
(19·2 to 34·1)*
–5·4% 
(–10·1 to 0·4)
712 
(388 to 1020)
880 
(491 to 1260)
23·5% 
(17·0 to 31·7)*
–6·2% 
(–10·7 to –0·5)*
·· Liver cancer due to alcohol 
use
20 
(11 to 30)
26 
(14 to 38)
26·0% 
(19·6 to 33·8)*
–4·1% 
(–8·8 to 1·2)
484 
(266 to 712)
595 
(319 to 888)
23·1% 
(16·4 to 31·1)*
–5·4% 
(–9·9 to 0·1)
·· Liver cancer due to non-
alcoholic steatohepatitis
8 
(4 to 12)
11 
(6 to 16)
39·6% 
(30·5 to 51·3)*
5·3% 
(–1·3 to 13·7)
179 
(96 to 261)
244 
(128 to 353)
36·1% 
(26·8 to 47·9)*
4·1% 
(–2·4 to 12·7)
·· Liver cancer due to other 
causes
8 
(4 to 11)
10 
(5 to 14)
29·8% 
(18·6 to 45·9)*
–0·7% 
(–8·6 to 10·5)
205 
(104 to 304)
255 
(135 to 370)
24·2% 
(13·2 to 41·5)*
–3·4% 
(–10·8 to 8·2)
·· Pancreatic cancer 75 
(67 to 83)
94 
(83 to 105)
24·9% 
(21·1 to 28·4)*
–6·3% 
(–9·3 to –3·6)*
1570 
(1380 to 1750)
1910 
(1670 to 2140)
21·6% 
(17·7 to 24·9)*
–7·6% 
(–10·5 to –5·1)*
·· Larynx cancer 67 
(59 to 73)
77 
(68 to 84)
14·9% 
(11·4 to 18·0)*
–12·7% 
(–15·4 to –10·3)*
1730 
(1540 to 1900)
1930 
(1700 to 2130)
11·3% 
(7·6 to 14·6)*
–14·5% 
(–17·4 to –12·0)*
·· Tracheal, bronchus, and 
lung cancer
965 
(940 to 992)
1190 
(1150 to 1230)
23·3% 
(19·9 to 26·4)*
–6·9% 
(–9·4 to –4·6)*
21 000 
(20 400 to 
21 700)
25 100 
(24 100 to 26 100)
19·3% 
(15·8 to 22·4)*
–9·1% 
(–11·7 to –6·8)*
·· Breast cancer 16 
(12 to 21)
17 
(12 to 22)
5·2% 
(1·9 to 8·4)*
–20·4% 
(–23·1 to –17·7)*
447 
(317 to 582)
451 
(320 to 593)
0·8% 
(–2·5 to 3·8)
–22·0% 
(–24·9 to –19·5)*
·· Cervical cancer 27 
(14 to 43)
27 
(14 to 43)
–0·5% 
(–6·1 to 4·5)
–23·2% 
(–27·6 to –19·0)*
807 
(443 to 1260)
766 
(414 to 1190)
–5·0% 
(–10·0 to –0·4)*
–24·8% 
(–28·9 to –20·7)*
·· Prostate cancer 22 
(10 to 34)
25 
(10 to 40)
15·7% 
(7·1 to 23·3)*
–13·9% 
(–20·1 to –8·4)*
414 
(188 to 640)
475 
(206 to 750)
14·7% 
(6·6 to 22·6)*
–13·6% 
(–19·8 to –7·6)*
·· Kidney cancer 21 
(15 to 27)
26 
(18 to 34)
19·7% 
(14·8 to 24·6)*
–9·8% 
(–13·5 to –6·0)*
482 
(336 to 623)
554 
(378 to 721)
15·0% 
(10·3 to 19·7)*
–12·3% 
(–16·1 to –8·6)*
·· Bladder cancer 56 
(42 to 67)
66 
(50 to 81)
19·5% 
(16·1 to 23·2)*
–10·8% 
(–13·4 to –7·9)*
1130 
(869 to 1350)
1320 
(1010 to 1590)
16·9% 
(13·4 to 20·2)*
–11·2% 
(–14·0 to –8·7)*
·· Acute lymphoid leukaemia 5 
(3 to 8)
7 
(4 to 10)
25·7% 
(16·2 to 33·3)*
–2·7% 
(–9·5 to 2·5)
149 
(78 to 232)
179 
(95 to 279)
20·1% 
(11·1 to 28·0)*
–4·9% 
(–11·8 to 0·3)
·· Chronic lymphoid 
leukaemia
8 
(5 to 12)
9 
(6 to 13)
11·5% 
(6·3 to 17·8)*
–17·4% 
(–21·4 to –12·6)*
168 
(103 to 234)
187 
(116 to 261)
11·3% 
(5·0 to 18·2)*
–16·0% 
(–21·0 to –10·3)*
·· Acute myeloid leukaemia 18 
(11 to 25)
21 
(13 to 30)
18·8% 
(13·7 to 23·2)*
–9·6% 
(–13·7 to –6·0)*
412 
(248 to 595)
471 
(275 to 704)
14·4% 
(9·2 to 18·7)*
–11·3% 
(–16·0 to –7·2)*
·· Chronic myeloid leukaemia 5 
(3 to 7)
5 
(3 to 7)
–6·1% 
(–10·0 to –2·2)*
–28·8% 
(–32·2 to –25·6)*
116 
(67 to 174)
104 
(58 to 157)
–10·4% 
(–14·4 to –6·6)*
–30·3% 
(–34·3 to –27·0)*
·· Other leukaemia 24 
(15 to 34)
26 
(16 to 38)
9·5% 
(4·0 to 16·8)*
–16·9% 
(–20·6 to –11·5)*
565 
(327 to 830)
588 
(346 to 862)
4·2% 
(–1·3 to 13·1)
–19·0% 
(–22·8 to –13·1)*
·· Ischaemic heart disease 1500 
(1440 to 1570)
1620 
(1540 to 1690)
7·8% 
(4·6 to 11·1)*
–17·8% 
(–20·2 to –15·3)*
38 400 
(36 800 to 
40 200)
40 600 
(38 700 to 42 500)
5·6% 
(2·4 to 9·0)*
–18·0% 
(–20·4 to –15·3)*
·· Ischaemic stroke 295 
(276 to 317)
335 
(313 to 361)
13·4% 
(8·6 to 17·8)*
–14·7% 
(–18·2 to –11·4)*
7540 
(6910 to 8260)
9000 
(8170 to 9920)
19·3% 
(14·7 to 23·8)*
–9·0% 
(–12·5 to –5·6)*
·· Intracerebral haemorrhage 470 
(439 to 500)
481 
(450 to 514)
2·3% 
(–2·2 to 6·9)
–21·9% 
(–25·4 to –18·5)*
12 400 
(11 600 to 
13 300)
12 600 
(11 800 to 13 600)
1·5% 
(–2·8 to 5·8)
–21·2% 
(–24·6 to –17·8)*
·· Subarachnoid haemorrhage 67 
(60 to 77)
71 
(63 to 81)
6·2% 
(–1·4 to 14·5)
–17·4% 
(–23·3 to –11·1)*
2190 
(1950 to 2510)
2270 
(2020 to 2560)
3·5% 
(–3·2 to 10·7)
–17·9% 
(–23·2 to –12·4)*
·· Atrial fibrillation and flutter 10 
(6 to 13)
12 
(8 to 16)
27·2% 
(22·5 to 32·3)*
–6·4% 
(–9·8 to –2·9)*
414 
(262 to 591)
502 
(315 to 718)
21·2% 
(17·8 to 24·7)*
–7·5% 
(–9·9 to –5·2)*
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Risk factors and outcomes 2007 deaths 
(thousands)
2017 deaths 
(thousands)
Percentage 
change in 
deaths, 
2007–17
Percentage 
change in age-
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DALYs, 
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change in age-
standardised 
DALY rate, 
2007–17
(Continued from previous page)
·· Aortic aneurysm 51 
(47 to 56)
56 
(51 to 62)
10·4% 
(6·0 to 15·3)*
–16·3% 
(–19·6 to –12·6)*
1160 
(1080 to 1270)
1270 
(1160 to 1400)
9·5% 
(4·9 to 14·7)*
–15·4% 
(–18·9 to –11·4)*
·· Peripheral vascular disease 13 
(8 to 21)
17 
(11 to 29)
31·6% 
(9·2 to 47·5)*
–2·2% 
(–19·0 to 9·8)
376 
(240 to 553)
471 
(298 to 716)
25·1% 
(9·1 to 37·0)*
–5·7% 
(–17·8 to 3·3)
·· Chronic obstructive 
pulmonary disease
1130 
(1030 to 1230)
1230 
(1120 to 1350)
9·5% 
(6·4 to 13·0)*
–19·1% 
(–21·3 to –16·7)*
26 100 
(23 300 to 
28 700)
28 200 
(25 100 to 31 100)
7·8% 
(4·7 to 11·1)*
–18·4% 
(–20·7 to –16·0)*
·· Asthma 69 
(34 to 108)
59 
(29 to 90)
–15·5% 
(–23·9 to –3·8)*
–35·8% 
(–42·2 to –27·0)*
2340 
(1220 to 3350)
2130 
(1100 to 3080)
–9·0% 
(–16·4 to 0·5)
–28·7% 
(–34·7 to –20·9)*
·· Peptic ulcer disease 51 
(44 to 58)
46 
(39 to 54)
–10·1% 
(–15·5 to –3·9)*
–31·5% 
(–35·6 to –26·7)*
1370 
(1180 to 1540)
1200 
(1020 to 1400)
–11·9% 
(–17·0 to –6·8)*
–30·9% 
(–35·0 to –26·8)*
·· Gallbladder and biliary 
diseases
5 
(4 to 6)
6 
(4 to 7)
15·1% 
(9·7 to 22·7)*
–13·6% 
(–17·6 to –7·9)*
106 
(78 to 136)
116 
(84 to 151)
9·6% 
(4·1 to 16·8)*
–14·9% 
(–19·0 to –9·4)*
·· Alzheimer’s disease and 
other dementias
249 
(158 to 338)
318 
(198 to 434)
27·6% 
(21·8 to 32·5)*
–9·5% 
(–13·4 to –6·0)*
3800 
(2410 to 5110)
4650 
(2900 to 6310)
22·4% 
(17·2 to 26·7)*
–10·0% 
(–13·6 to –6·6)*
·· Parkinson’s disease –24 
(–38 to –12)
–29 
(–46 to –14)
20·0% 
(10·5 to 28·2)*
–10·4% 
(–17·3 to –4·4)*
–481 
(–750 to –239)
–567 
(–890 to –281)
17·9% 
(9·1 to 26·2)*
–10·5% 
(–17·1 to –4·3)*
·· Multiple sclerosis 2 
(2 to 3)
3 
(2 to 3)
12·1% 
(–1·6 to 19·2)
–11·4% 
(–21·9 to –5·7)*
132 
(101 to 165)
143 
(107 to 179)
8·2% 
(0·3 to 14·5)*
–12·0% 
(–18·3 to –6·8)*
·· Type 2 diabetes mellitus 65 
(53 to 78)
83 
(67 to 100)
27·3% 
(22·6 to 32·2)*
–4·6% 
(–8·1 to –0·9)*
4710 
(3450 to 6160)
5680 
(4140 to 7530)
20·6% 
(15·2 to 26·2)*
–5·6% 
(–9·6 to –1·4)*
·· Cataract ·· ·· ·· ·· 534 
(362 to 747)
610 
(408 to 860)
14·3% 
(8·7 to 19·5)*
–13·0% 
(–17·1 to –8·9)*
·· Age-related macular 
degeneration
·· ·· ·· ·· 48 
(20 to 79)
56 
(24 to 95)
17·0% 
(9·3 to 23·4)*
–12·7% 
(–18·4 to –8·0)*
·· Rheumatoid arthritis 3 
(1 to 6)
4 
(1 to 6)
10·4% 
(2·4 to 20·2)*
–16·8% 
(–22·8 to –9·3)*
245 
(72 to 443)
285 
(82 to 519)
16·4% 
(10·0 to 21·8)*
–9·0% 
(–13·9 to –4·8)*
·· Low back pain ·· ·· ·· ·· 9350 
(6160 to 13 000)
10 100 
(6700 to 14 100)
8·1% 
(5·4 to 10·7)*
–12·6% 
(–14·7 to –10·9)*
·· Pedestrian road injuries 4 
(3 to 5)
4 
(3 to 5)
0·9% 
(–8·3 to 7·2)
–22·2% 
(–29·4 to –17·2)*
126 
(91 to 167)
126 
(90 to 169)
–0·4% 
(–7·7 to 5·0)
–21·1% 
(–27·0 to –16·9)*
·· Cyclist road injuries 1 
(0 to 1)
1 
(0 to 1)
13·2% 
(3·4 to 23·5)*
–12·0% 
(–19·7 to –4·3)*
25 
(17 to 34)
29 
(20 to 40)
16·8% 
(10·0 to 23·7)*
–8·1% 
(–13·2 to –2·7)*
·· Motorcyclist road injuries 1 
(1 to 2)
1 
(1 to 2)
6·7% 
(–7·3 to 16·4)
–14·0% 
(–25·5 to –6·2)*
71 
(48 to 96)
76 
(51 to 105)
6·9% 
(–2·7 to 13·7)
–13·3% 
(–21·1 to –7·9)*
·· Motor vehicle road injuries 3 
(2 to 4)
3 
(2 to 3)
–1·9% 
(–9·8 to 2·7)
–22·5% 
(–28·8 to –18·8)*
105 
(71 to 143)
103 
(69 to 140)
–2·0% 
(–7·4 to 1·7)
–21·2% 
(–25·7 to –18·3)*
·· Other road injuries 0 
(0 to 0)
0 
(0 to 0)
–2·7% 
(–12·4 to 16·6)
–24·9% 
(–32·5 to –10·6)*
8 
(6 to 12)
10 
(7 to 15)
26·6% 
(19·1 to 34·2)*
–1·8% 
(–7·3 to 4·0)
·· Other transport injuries 1 
(1 to 2)
1 
(1 to 2)
3·3% 
(–2·3 to 10·4)
–19·5% 
(–23·9 to –14·1)*
71 
(52 to 94)
77 
(55 to 104)
8·6% 
(4·3 to 13·2)*
–14·5% 
(–17·7 to –11·1)*
·· Falls 15 
(11 to 20)
19 
(13 to 25)
23·6% 
(15·1 to 34·6)*
–10·5% 
(–16·9 to –2·4)*
508 
(365 to 694)
630 
(443 to 870)
23·9% 
(19·2 to 29·2)*
–6·4% 
(–9·9 to –2·5)*
·· Other exposure to 
mechanical forces
1 
(1 to 1)
1 
(1 to 1)
1·6% 
(–3·8 to 6·7)
–21·3% 
(–25·2 to –17·5)*
64 
(45 to 88)
71 
(50 to 102)
12·3% 
(7·5 to 16·4)*
–11·7% 
(–15·1 to –8·9)*
·· Non-venomous animal 
contact
0 
(0 to 0)
0 
(0 to 0)
–0·4% 
(–11·7 to 15·6)
–23·6% 
(–32·3 to –11·3)*
5 
(3 to 7)
5 
(3 to 8)
5·3% 
(–0·8 to 12·3)
–18·4% 
(–23·0 to –12·9)*
·· Assault by other means 0 
(0 to 0)
0 
(0 to 0)
–8·1% 
(–15·2 to –0·8)*
–27·5% 
(–33·1 to –21·8)*
17 
(12 to 23)
16 
(12 to 22)
–2·0% 
(–6·9 to 2·5)
–22·2% 
(–25·9 to –18·7)*
3 Chewing tobacco: all causes 59 
(48 to 70)
76 
(62 to 91)
29·5% 
(22·0 to 38·3)*
–1·6% 
(–7·3 to 5·2)
1490 
(1220 to 1790)
1890 
(1530 to 2270)
26·6% 
(19·5 to 35·1)*
–1·9% 
(–7·5 to 4·8)
·· Lip and oral cavity cancer 31 
(24 to 38)
44 
(35 to 54)
41·3% 
(31·8 to 51·6)*
8·1% 
(0·9 to 16·0)*
853 
(661 to 1050)
1160 
(892 to 1440)
36·0% 
(26·2 to 46·3)*
6·3% 
(–1·3 to 14·4)
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·· Oesophageal cancer 27 
(20 to 36)
32 
(22 to 41)
16·0% 
(6·0 to 27·2)*
–12·4% 
(–20·2 to –4·0)*
641 
(455 to 833)
731 
(507 to 948)
14·0% 
(5·2 to 24·4)*
–12·6% 
(–19·5 to –5·1)*
3 Second-hand smoke: all 
causes
1110 
(888 to 1370)
1220 
(984 to 1500)
10·2% 
(6·9 to 13·5)*
–15·9% 
(–18·2 to –13·6)*
36 600 
(28 600 to 
46 000)
36 300 
(28 600 to 45 100)
–0·9% 
(–5·6 to 4·5)
–20·0% 
(–23·0 to –16·5)*
·· Lower respiratory 
infections
208 
(123 to 302)
179 
(107 to 261)
–13·6% 
(–16·3 to –10·5)*
–27·8% 
(–30·0 to –25·4)*
11 900 
(6940 to 17 400)
7960 
(4630 to 11 600)
–33·2% 
(–36·4 to 
–29·8)*
–39·0% 
(–42·0 to –35·7)*
·· Otitis media 0 
(0 to 0)
0 
(0 to 0)
–60·5% 
(–72·8 to 
–40·3)*
–62·4% 
(–74·1 to –43·1)*
127 
(69 to 209)
119 
(63 to 199)
–6·1% 
(–10·8 to –2·6)*
–11·6% 
(–15·9 to –8·2)*
·· Tracheal, bronchus, and 
lung cancer
78 
(44 to 117)
100 
(57 to 149)
28·3% 
(22·5 to 33·8)*
–2·5% 
(–6·7 to 1·6)
1830 
(1050 to 2750)
2240 
(1300 to 3360)
22·7% 
(17·6 to 28·1)*
–5·5% 
(–9·4 to –1·4)*
·· Breast cancer 12 
(3 to 21)
15 
(4 to 26)
21·2% 
(14·3 to 26·9)*
–5·4% 
(–10·6 to –1·0)*
404 
(98 to 688)
478 
(118 to 829)
18·5% 
(11·6 to 24·6)*
–4·9% 
(–10·4 to –0·2)*
·· Ischaemic heart disease 330 
(269 to 399)
382 
(311 to 463)
16·0% 
(12·8 to 19·3)*
–12·1% 
(–14·1 to –10·0)*
7890 
(6440 to 9490)
8850 
(7180 to 10 700)
12·2% 
(9·2 to 15·3)*
–12·4% 
(–14·5 to –10·2)*
·· Ischaemic stroke 65 
(48 to 85)
74 
(55 to 98)
14·6% 
(9·6 to 20·4)*
–14·6% 
(–17·4 to –11·3)*
1430 
(1070 to 1850)
1670 
(1250 to 2190)
17·4% 
(11·9 to 22·6)*
–10·3% 
(–13·8 to –6·9)*
·· Intracerebral haemorrhage 96 
(73 to 124)
102 
(76 to 132)
5·9% 
(1·1 to 10·9)*
–19·4% 
(–22·4 to –16·1)*
2460 
(1840 to 3160)
2550 
(1880 to 3290)
3·8% 
(–0·9 to 8·5)
–18·9% 
(–21·9 to –15·8)*
·· Subarachnoid haemorrhage 14 
(11 to 19)
16 
(12 to 21)
10·9% 
(5·5 to 16·9)*
–13·4% 
(–17·1 to –9·2)*
467 
(337 to 616)
500 
(360 to 656)
7·1% 
(2·2 to 12·6)*
–14·0% 
(–17·2 to –10·3)*
·· Chronic obstructive 
pulmonary disease
244 
(126 to 363)
266 
(136 to 405)
9·0% 
(3·5 to 14·6)*
–20·0% 
(–23·9 to –15·8)*
6230 
(3190 to 9260)
6910 
(3540 to 10 400)
10·8% 
(6·3 to 15·2)*
–15·3% 
(–18·8 to –12·0)*
·· Type 2 diabetes mellitus 61 
(23 to 92)
86 
(33 to 131)
41·1% 
(37·5 to 45·0)*
5·3% 
(2·7 to 8·1)*
3890 
(1390 to 6340)
5040 
(1810 to 8230)
29·3% 
(25·1 to 33·8)*
1·3% 
(–2·0 to 4·8)
2 Alcohol use: all causes 2560 
(2230 to 2910)
2840 
(2440 to 
3250)
11·0% 
(3·2 to 19·1)*
–11·7% 
(–18·1 to –4·8)*
102 000 
(92 400 to 
114 000)
108 000 
(96 200 to 
120 000)
5·5% 
(0·5 to 10·7)*
–13·1% 
(–17·2 to –8·7)*
·· Drug-susceptible 
tuberculosis
338 
(247 to 415)
287 
(209 to 361)
–15·0% 
(–22·8 to –7·7)*
–32·0% 
(–38·1 to –25·9)*
12 600 
(9340 to 15 400)
10 500 
(7730 to 13 100)
–16·6% 
(–23·9 to –9·9)*
–30·9% 
(–37·0 to –25·3)*
·· Multidrug-resistant 
tuberculosis without 
extensive drug resistance
45 
(32 to 60)
38 
(20 to 64)
–16·0% 
(–50·5 to 31·4)
–32·5% 
(–60·3 to 5·5)
1650 
(1170 to 2170)
1330 
(697 to 2260)
–19·2% 
(–51·4 to 24·6)
–33·0% 
(–59·7 to 3·5)
·· Extensively drug-resistant 
tuberculosis
5 
(3 to 6)
5 
(3 to 7)
6·1% 
(–20·2 to 43·2)
–13·8% 
(–35·2 to 16·2)
178 
(128 to 225)
178 
(124 to 254)
–0·4% 
(–24·4 to 32·7)
–16·9% 
(–36·8 to 10·7)
·· Lower respiratory 
infections
96 
(36 to 154)
114 
(39 to 186)
19·1% 
(–0·6 to 31·4)
–8·2% 
(–20·9 to 2·8)
2630 
(1310 to 3830)
2840 
(1380 to 4230)
8·0% 
(–5·2 to 18·0)
–13·2% 
(–22·7 to –5·2)*
·· Lip and oral cavity cancer 59 
(51 to 66)
78 
(66 to 89)
32·8% 
(25·1 to 40·2)*
2·1% 
(–3·8 to 7·8)
1710 
(1490 to 1910)
2200 
(1900 to 2490)
28·6% 
(20·6 to 35·9)*
1·1% 
(–5·3 to 6·8)
·· Nasopharynx cancer 25 
(21 to 29)
32 
(26 to 37)
25·7% 
(17·7 to 34·3)*
–2·2% 
(–8·4 to 4·3)
790 
(662 to 900)
956 
(801 to 1100)
21·1% 
(13·1 to 29·7)*
–3·6% 
(–9·7 to 3·1)
·· Other pharynx cancer 38 
(31 to 44)
52 
(42 to 62)
38·0% 
(25·3 to 49·5)*
6·1% 
(–3·7 to 14·9)
1110 
(912 to 1290)
1490 
(1190 to 1770)
34·2% 
(21·6 to 45·3)*
4·9% 
(–5·0 to 13·5)
·· Oesophageal cancer 120 
(97 to 143)
139 
(110 to 166)
15·6% 
(7·8 to 24·5)*
–12·1% 
(–18·2 to –5·3)*
2980 
(2430 to 3510)
3310 
(2650 to 3910)
10·9% 
(3·9 to 18·7)*
–14·7% 
(–20·2 to –8·6)*
·· Colon and rectum cancer 103 
(83 to 124)
126 
(98 to 155)
22·3% 
(14·0 to 31·0)*
–7·9% 
(–14·1 to –1·3)*
2410 
(1970 to 2870)
2900 
(2290 to 3500)
20·5% 
(12·2 to 29·3)*
–7·2% 
(–13·6 to –0·4)*
·· Liver cancer due to alcohol 
use
98 
(87 to 112)
129 
(115 to 147)
31·7% 
(26·8 to 37·3)*
0·6% 
(–3·0 to 4·8)
2400 
(2100 to 2790)
3080 
(2680 to 3590)
27·9% 
(22·5 to 34·0)*
–0·5% 
(–4·4 to 4·0)
·· Larynx cancer 32 
(21 to 40)
38 
(25 to 48)
17·6% 
(11·3 to 24·4)*
–10·2% 
(–15·1 to –4·8)*
886 
(594 to 1100)
1010 
(683 to 1270)
14·4% 
(8·5 to 20·8)*
–11·5% 
(–16·1 to –6·6)*
·· Breast cancer 54 
(46 to 62)
59 
(49 to 69)
9·7% 
(4·3 to 14·1)*
–16·3% 
(–20·4 to –13·0)*
1560 
(1320 to 1790)
1670 
(1390 to 1940)
7·0% 
(2·0 to 11·3)*
–15·9% 
(–19·9 to –12·3)*
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·· Ischaemic heart disease –129 
(–342 to 78)
–112 
(–364 to 123)
–13·4% 
(–192·5 to 327·3)
–38·7% 
(–304·3 to 136·6)
–384 
(–4880 to 4100)
343 
(–4690 to 5200)
–189·5% 
(–502·2 to 
832·6)
–111·5% 
(–487·6 to 
473·6)
·· Ischaemic stroke 74 
(11 to 143)
102 
(28 to 181)
38·3% 
(–1·6 to 154·7)
9·2% 
(–32·8 to 220·5)
2070 
(771 to 3370)
2870 
(1210 to 4520)
38·2% 
(11·8 to 88·8)*
7·2% 
(–14·3 to 53·9)
·· Intracerebral haemorrhage 399 
(292 to 503)
462 
(338 to 592)
15·7% 
(3·0 to 31·2)*
–12·1% 
(–21·8 to –0·3)*
9910 
(7550 to 12 200)
11 200 
(8440 to 14 000)
13·3% 
(2·4 to 27·2)*
–11·9% 
(–20·5 to –1·0)*
·· Hypertensive heart disease 93 
(63 to 120)
134 
(84 to 179)
43·9% 
(21·8 to 61·4)*
6·5% 
(–9·2 to 19·1)
2000 
(1410 to 2570)
2680 
(1760 to 3520)
34·3% 
(15·8 to 49·2)*
3·3% 
(–10·9 to 14·9)
·· Alcoholic cardiomyopathy 119 
(91 to 125)
89 
(81 to 96)
–25·3% 
(–29·5 to –8·3)*
–40·5% 
(–43·7 to –27·6)*
4230 
(3190 to 4450)
2990 
(2720 to 3210)
–29·4% 
(–33·5 to –11·1)*
–42·2% 
(–45·6 to –27·5)*
·· Atrial fibrillation and flutter 20 
(15 to 26)
28 
(20 to 36)
40·1% 
(28·9 to 51·6)*
–1·0% 
(–8·7 to 7·1)
567 
(408 to 738)
740 
(536 to 966)
30·4% 
(21·0 to 41·2)*
–2·3% 
(–9·6 to 5·6)
·· Cirrhosis and other chronic 
liver diseases due to alcohol 
use
284 
(260 to 309)
332 
(303 to 373)
16·9% 
(11·2 to 23·7)*
–8·8% 
(–13·2 to –3·4)*
9000 
(8290 to 9790)
10 200 
(9310 to 11 300)
13·1% 
(8·1 to 18·9)*
–9·3% 
(–13·4 to –4·8)*
·· Pancreatitis 31 
(24 to 38)
36 
(29 to 45)
17·6% 
(7·5 to 27·4)*
–6·2% 
(–14·2 to 1·8)
1150 
(929 to 1390)
1300 
(1050 to 1590)
13·0% 
(3·4 to 22·1)*
–6·9% 
(–14·8 to 0·6)
·· Epilepsy 23 
(17 to 29)
25 
(19 to 32)
8·4% 
(2·1 to 16·0)*
–9·6% 
(–15·0 to –2·9)*
2050 
(1460 to 2760)
2240 
(1550 to 3100)
9·0% 
(0·4 to 17·7)*
–6·3% 
(–13·7 to 1·2)
·· Alcohol use disorders 180 
(163 to 184)
185 
(167 to 193)
2·7% 
(–2·2 to 7·7)
–16·5% 
(–20·4 to –12·4)*
16 600 
(13 600 to 
20 400)
17 500 
(14 100 to 21 600)
5·0% 
(2·4 to 7·4)*
–10·2% 
(–12·7 to –8·1)*
·· Type 2 diabetes mellitus –4 
(–24 to 15)
–3 
(–28 to 23)
–41·1% 
(–486·6 to 
318·0)
–52·3% 
(–365·2 to 
347·8)
240 
(–1140 to 1620)
363 
(–1460 to 2260)
51·2% 
(–291·8 to 
254·2)
41·4% 
(–236·8 to 
207·0)
·· Pedestrian road injuries 42 
(25 to 59)
40 
(23 to 56)
–4·4% 
(–13·2 to 6·4)
–19·7% 
(–26·9 to –10·7)*
2000 
(1180 to 2820)
1880 
(1120 to 2630)
–6·0% 
(–13·7 to 4·2)
–17·6% 
(–24·3 to –8·9)*
·· Cyclist road injuries 6 
(3 to 8)
6 
(3 to 9)
9·5% 
(–1·0 to 22·8)
–7·6% 
(–16·2 to 3·4)
365 
(221 to 528)
404 
(246 to 573)
10·6% 
(2·5 to 21·6)*
–4·3% 
(–11·2 to 5·1)
·· Motorcyclist road injuries 23 
(14 to 33)
24 
(14 to 34)
2·5% 
(–8·5 to 14·5)
–9·0% 
(–18·7 to 1·4)
1450 
(887 to 2050)
1480 
(896 to 2070)
1·9% 
(–7·1 to 12·7)
–8·6% 
(–16·5 to 0·8)
·· Motor vehicle road injuries 43 
(25 to 60)
40 
(24 to 56)
–6·6% 
(–11·6 to –0·8)*
–18·6% 
(–23·0 to –13·6)*
2380 
(1430 to 3320)
2190 
(1340 to 3030)
–8·2% 
(–12·6 to –2·6)*
–18·0% 
(–21·9 to –13·0)*
·· Other road injuries 1 
(1 to 2)
1 
(1 to 1)
–8·8% 
(–16·0 to 7·3)
–22·4% 
(–28·6 to –8·8)*
81 
(47 to 117)
85 
(51 to 124)
5·4% 
(–2·6 to 16·8)
–8·7% 
(–15·4 to 1·1)
·· Other transport injuries 8 
(5 to 12)
8 
(5 to 11)
–3·8% 
(–10·1 to 4·0)
–17·1% 
(–22·7 to –10·5)*
565 
(338 to 803)
577 
(345 to 823)
2·1% 
(–4·1 to 9·7)
–10·2% 
(–15·5 to –3·7)*
·· Falls 38 
(17 to 62)
48 
(22 to 80)
25·9% 
(16·3 to 39·2)*
–3·7% 
(–11·1 to 6·8)
2540 
(1150 to 4230)
2990 
(1370 to 4980)
17·9% 
(11·8 to 27·0)*
–4·6% 
(–9·4 to 3·1)
·· Drowning 17 
(7 to 28)
16 
(7 to 27)
–2·3% 
(–8·4 to 6·8)
–18·0% 
(–23·0 to –10·3)*
732 
(322 to 1220)
669 
(284 to 1100)
–8·6% 
(–14·2 to 0·2)
–20·5% 
(–25·2 to –13·5)*
·· Fire, heat, and hot 
substances
8 
(4 to 13)
7 
(3 to 12)
–11·6% 
(–17·9 to –5·0)*
–28·9% 
(–33·6 to –23·9)*
464 
(202 to 766)
440 
(192 to 743)
–5·1% 
(–11·8 to 2·0)
–20·4% 
(–25·9 to –14·4)*
·· Poisoning by carbon 
monoxide
4 
(2 to 7)
3 
(1 to 6)
–21·4% 
(–31·1 to –11·3)*
–35·1% 
(–42·9 to –26·8)*
177 
(77 to 283)
132 
(59 to 215)
–25·3% 
(–33·4 to –16·5)*
–36·6% 
(–43·4 to –29·4)*
·· Poisoning by other means 2 
(1 to 3)
2 
(1 to 4)
12·4% 
(–2·0 to 31·6)
–7·6% 
(–19·3 to 7·9)
106 
(48 to 176)
116 
(53 to 197)
9·5% 
(0·6 to 23·0)*
–7·1% 
(–14·4 to 4·1)
·· Unintentional firearm 
injuries
2 
(1 to 3)
2 
(1 to 3)
–9·0% 
(–14·8 to –2·7)*
–22·8% 
(–28·0 to –17·6)*
111 
(50 to 192)
105 
(47 to 179)
–5·7% 
(–11·0 to 0·1)
–18·1% 
(–23·0 to –13·3)*
·· Venomous animal contact 3 
(1 to 5)
3 
(1 to 6)
14·0% 
(–1·1 to 35·6)
–6·8% 
(–19·3 to 10·9)
140 
(56 to 246)
157 
(63 to 285)
11·7% 
(–0·8 to 29·8)
–5·6% 
(–15·9 to 9·1)
·· Non-venomous animal 
contact
1 
(0 to 1)
1 
(0 to 1)
2·6% 
(–7·3 to 16·5)
–16·9% 
(–25·0 to –5·5)*
42 
(18 to 70)
45 
(20 to 77)
6·9% 
(–0·2 to 16·8)
–11·1% 
(–16·9 to –3·1)*
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·· Environmental heat and 
cold exposure
7 
(3 to 12)
5 
(2 to 9)
–23·9% 
(–32·6 to –15·9)*
–38·3% 
(–45·0 to –31·8)*
354 
(154 to 572)
297 
(130 to 498)
–16·1% 
(–23·2 to –8·3)*
–30·2% 
(–36·1 to –23·6)*
·· Exposure to forces of 
nature
1 
(0 to 1)
1 
(0 to 1)
4·6% 
(–7·6 to 25·0)
–11·1% 
(–21·6 to 5·9)
42 
(19 to 72)
57 
(24 to 100)
34·9% 
(21·8 to 50·6)*
17·5% 
(6·5 to 31·1)*
·· Other unintentional 
injuries
9 
(4 to 14)
8 
(3 to 13)
–8·2% 
(–16·0 to 4·6)
–22·1% 
(–28·5 to –11·6)*
670 
(287 to 1120)
683 
(297 to 1130)
1·9% 
(–4·7 to 10·6)
–14·0% 
(–19·3 to –6·8)*
·· Self-harm by firearm 16 
(9 to 23)
17 
(9 to 25)
5·7% 
(–6·8 to 18·1)
–11·8% 
(–22·0 to –1·5)*
691 
(389 to 995)
709 
(399 to 1020)
2·6% 
(–8·9 to 14·5)
–11·3% 
(–21·3 to –1·0)*
·· Self-harm by other 
specified means
157 
(96 to 214)
161 
(99 to 225)
2·8% 
(–4·7 to 11·0)
–14·3% 
(–20·6 to –7·2)*
6730 
(4120 to 9190)
6700 
(4150 to 9310)
–0·4% 
(–7·7 to 7·8)
–14·5% 
(–20·9 to –7·7)*
·· Assault by firearm 34 
(22 to 46)
36 
(23 to 49)
6·6% 
(–0·6 to 13·3)
–5·2% 
(–11·7 to 1·1)
1840 
(1220 to 2510)
1940 
(1270 to 2650)
5·2% 
(–2·1 to 11·8)
–5·0% 
(–11·8 to 1·1)
·· Assault by sharp object 20 
(13 to 29)
18 
(11 to 24)
–14·4% 
(–20·1 to –8·4)*
–25·6% 
(–30·7 to –20·3)*
1100 
(702 to 1550)
944 
(598 to 1310)
–14·4% 
(–19·5 to –8·9)*
–24·4% 
(–29·2 to –19·5)*
·· Sexual violence ·· ·· ·· ·· 114 
(50 to 200)
131 
(58 to 228)
15·0% 
(6·7 to 26·4)*
1·5% 
(–5·8 to 10·6)
·· Assault by other means 21 
(14 to 29)
22 
(14 to 31)
4·1% 
(–3·5 to 11·1)
–11·0% 
(–17·6 to –4·6)*
1260 
(792 to 1770)
1340 
(854 to 1880)
6·9% 
(–0·4 to 12·9)
–7·5% 
(–14·1 to –2·2)*
2 Drug use: all causes 459 
(416 to 501)
585 
(535 to 635)
27·6% 
(24·0 to 31·4)*
4·1% 
(1·2 to 7·0)*
34 900 
(29 800 to 
40 400)
41 700 
(35 300 to 48 200)
19·2% 
(16·8 to 21·6)*
3·2% 
(0·9 to 5·4)*
·· HIV/AIDS and drug-
susceptible tuberculosis 
co-infection
14 
(9 to 20)
8 
(5 to 12)
–42·6% 
(–47·6 to –37·9)*
–50·7% 
(–55·2 to –46·9)*
700 
(455 to 993)
412 
(276 to 582)
–41·1% 
(–45·9 to –36·2)*
–48·8% 
(–53·0 to –44·7)*
·· HIV/AIDS and multidrug-
resistant tuberculosis 
without extensive drug 
resistance co-infection
2 
(1 to 4)
1 
(1 to 2)
–44·0% 
(–58·8 to –22·3)*
–51·8% 
(–64·5 to –33·4)*
113 
(68 to 176)
63 
(36 to 103)
–43·9% 
(–58·6 to –23·6)*
–51·2% 
(–63·9 to –33·7)*
·· HIV/AIDS and extensively 
drug-resistant tuberculosis 
co-infection
0 
(0 to 0)
0 
(0 to 0)
4·1% 
(–19·4 to 33·5)
–9·6% 
(–30·3 to 16·0)
14 
(8 to 22)
14 
(8 to 23)
3·5% 
(–20·2 to 33·2)
–9·4% 
(–30·0 to 16·4)
·· HIV/AIDS resulting in other 
diseases
71 
(58 to 88)
56 
(46 to 70)
–20·7% 
(–26·5 to –11·3)*
–31·5% 
(–36·4 to –23·4)*
3630 
(2920 to 4520)
2880 
(2340 to 3630)
–20·8% 
(–26·0 to –11·4)*
–30·9% 
(–35·5 to –22·8)*
·· Acute hepatitis B 1 
(0 to 1)
1 
(0 to 1)
26·1% 
(13·9 to 41·6)*
0·8% 
(–8·8 to 13·1)
19 
(14 to 25)
23 
(17 to 30)
17·8% 
(6·3 to 31·3)*
–3·0% 
(–12·2 to 7·9)
·· Acute hepatitis C 0 
(0 to 1)
1 
(0 to 1)
19·9% 
(2·2 to 41·8)*
–6·3% 
(–20·3 to 10·9)
15 
(8 to 29)
17 
(9 to 33)
13·2% 
(–2·4 to 33·2)
–7·6% 
(–19·6 to 7·1)
·· Liver cancer due to 
hepatitis B
3 
(2 to 3)
4 
(3 to 5)
44·0% 
(35·2 to 55·2)*
13·2% 
(6·4 to 21·4)*
85 
(68 to 104)
112 
(90 to 138)
32·2% 
(23·5 to 42·1)*
5·8% 
(–1·1 to 13·9)
·· Liver cancer due to 
hepatitis C
84 
(72 to 97)
127 
(110 to 144)
51·0% 
(44·1 to 59·6)*
14·6% 
(9·4 to 21·4)*
2040 
(1760 to 2320)
2930 
(2560 to 3310)
43·9% 
(37·8 to 51·0)*
10·9% 
(6·2 to 16·5)*
·· Cirrhosis and other chronic 
liver diseases due to 
hepatitis B
3 
(2 to 4)
4 
(3 to 4)
25·6% 
(17·6 to 35·0)*
0·3% 
(–6·4 to 8·0)
103 
(82 to 131)
121 
(96 to 152)
17·4% 
(9·7 to 25·7)*
–3·9% 
(–10·2 to 3·1)
·· Cirrhosis and other chronic 
liver diseases due to 
hepatitis C
137 
(115 to 160)
175 
(150 to 204)
28·4% 
(22·3 to 35·0)*
1·7% 
(–3·1 to 7·2)
4730 
(3970 to 5520)
5800 
(4920 to 6760)
22·5% 
(17·0 to 28·5)*
–0·6% 
(–4·8 to 4·2)
·· Opioid use disorders 62 
(58 to 65)
110 
(106 to 114)
77·0% 
(68·8 to 88·5)*
49·4% 
(42·5 to 59·2)*
16 400 
(12 400 to 
20 800)
21 500 
(16 300 to 27 100)
30·8% 
(27·5 to 34·4)*
15·3% 
(12·4 to 18·3)*
·· Cocaine use disorders 5 
(5 to 6)
7 
(7 to 8)
42·2% 
(30·1 to 58·3)*
19·6% 
(9·2 to 33·0)*
833 
(620 to 1090)
992 
(747 to 1290)
19·0% 
(15·5 to 24·2)*
4·9% 
(1·9 to 9·3)*
·· Amphetamine use 
disorders
4 
(3 to 4)
5 
(3 to 5)
27·2% 
(0·8 to 41·0)*
8·6% 
(–14·0 to 20·6)
1120 
(708 to 1670)
1180 
(757 to 1740)
5·5% 
(1·5 to 9·4)*
–2·5% 
(–6·2 to 0·4)
·· Cannabis use disorders ·· ·· ·· ·· 496 
(314 to 727)
518 
(329 to 766)
4·4% 
(2·2 to 6·6)*
–3·7% 
(–5·7 to –1·8)*
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·· Other drug use disorders 34 
(32 to 37)
45 
(43 to 48)
35·2% 
(22·8 to 46·1)*
11·3% 
(1·2 to 19·9)*
2560 
(2130 to 3090)
3010 
(2550 to 3540)
17·5% 
(10·9 to 24·0)*
3·5% 
(–2·2 to 8·9)
·· Self-harm by firearm 5 
(3 to 7)
6 
(3 to 9)
24·2% 
(16·4 to 31·8)*
8·2% 
(1·5 to 14·7)*
232 
(137 to 378)
277 
(165 to 441)
19·3% 
(11·8 to 27·0)*
6·7% 
(0·1 to 13·5)*
·· Self-harm by other 
specified means
35 
(19 to 60)
36 
(19 to 64)
3·1% 
(–1·8 to 7·1)
–10·0% 
(–14·0 to –6·6)*
1820 
(1010 to 3100)
1820 
(980 to 3180)
0·1% 
(–4·7 to 4·1)
–10·7% 
(–14·6 to –7·3)*
2 Dietary risks: all causes 9160 
(8510 to 9810)
10 900 
(10 100 to 
11 700)
18·9% 
(17·0 to 20·7)*
–11·2% 
(–12·6 to –9·8)*
219 000 
(203 000 to 
235 000)
255 000 
(234 000 to 
274 000)
16·4% 
(14·6 to 18·1)*
–9·9% 
(–11·3 to –8·6)*
3 Diet low in fruits: all causes 2220 
(1410 to 3180)
2420 
(1480 to 3530)
9·0% 
(4·5 to 12·3)*
–17·4% 
(–20·6 to –15·1)*
60 200 
(38 600 to 
84 000)
64 800 
(40 600 to 92 000)
7·7% 
(3·2 to 11·1)*
–15·7% 
(–19·0 to –13·1)*
·· Lip and oral cavity cancer 10 
(0 to 21)
12 
(0 to 26)
25·3% 
(17·0 to 
1318·4)*
–3·7% 
(–10·0 to 
1002·4)
269 
(0 to 582)
325 
(0 to 709)
21·0% 
(12·2 to 
1198·1)*
–4·7% 
(–11·5 to 879·6)
·· Nasopharynx cancer 4 
(0 to 8)
4 
(0 to 10)
12·9% 
(5·1 to 1008·3)*
–12·1% 
(–18·1 to 739·6)
118 
(0 to 259)
128 
(0 to 284)
8·6% 
(1·0 to 946·6)*
–13·5% 
(–19·3 to 712·2)
·· Other pharynx cancer 6 
(0 to 13)
7 
(0 to 16)
28·4% 
(15·0 to 42·0)*
–1·3% 
(–11·5 to 9·0)
163 
(0 to 373)
204 
(0 to 458)
24·8% 
(11·9 to 38·3)*
–2·3% 
(–12·3 to 8·1)
·· Oesophageal cancer 82 
(18 to 146)
83 
(18 to 152)
1·7% 
(–5·1 to 6·4)
–22·9% 
(–27·9 to –19·4)*
1900 
(430 to 3400)
1860 
(399 to 3390)
–1·8% 
(–8·4 to 2·8)
–24·4% 
(–29·4 to –21·0)*
·· Larynx cancer 7 
(0 to 15)
8 
(0 to 17)
11·4% 
(5·2 to 218·8)*
–14·9% 
(–19·5 to 127·1)
183 
(0 to 403)
199 
(0 to 436)
8·4% 
(2·3 to 189·4)*
–16·0% 
(–20·5 to 104·4)
·· Tracheal, bronchus, and 
lung cancer
152 
(64 to 261)
185 
(77 to 320)
21·8% 
(16·2 to 25·8)*
–7·6% 
(–11·8 to –4·6)*
3470 
(1460 to 5920)
4050 
(1680 to 6950)
16·6% 
(10·9 to 20·6)*
–10·2% 
(–14·4 to –7·1)*
·· Ischaemic heart disease 822 
(280 to 1440)
916 
(306 to 1650)
11·4% 
(7·5 to 14·5)*
–16·1% 
(–18·8 to –14·0)*
19 500 
(6770 to 33 700)
20 800 
(7110 to 36 600)
7·0% 
(2·9 to 10·0)*
–16·2% 
(–19·1 to –13·9)*
·· Ischaemic stroke 376 
(195 to 573)
406 
(206 to 631)
8·1% 
(2·9 to 11·9)*
–18·8% 
(–22·6 to –16·1)*
9860 
(5310 to 14 600)
11 200 
(5800 to 16 900)
13·6% 
(7·8 to 18·1)*
–12·4% 
(–16·7 to –9·1)*
·· Intracerebral haemorrhage 615 
(338 to 933)
624 
(331 to 972)
1·4% 
(–3·8 to 5·2)
–22·3% 
(–26·2 to –19·5)*
16 700 
(9480 to 24 800)
16 800 
(9210 to 25 400)
0·4% 
(–4·6 to 4·0)
–21·2% 
(–24·8 to –18·5)*
·· Subarachnoid haemorrhage 92 
(50 to 138)
99 
(53 to 152)
7·5% 
(1·2 to 13·4)*
–15·8% 
(–20·4 to –11·2)*
3160 
(1770 to 4650)
3330 
(1820 to 5020)
5·2% 
(–0·2 to 10·5)
–15·1% 
(–19·3 to –11·0)*
·· Type 2 diabetes mellitus 60 
(12 to 112)
80 
(15 to 151)
32·1% 
(27·1 to 36·2)*
–0·6% 
(–4·2 to 2·4)
4880 
(928 to 9240)
5900 
(1090 to 11 300)
21·0% 
(15·1 to 26·1)*
–3·5% 
(–7·9 to 0·4)
3 Diet low in vegetables: all 
causes
1390 
(715 to 2240)
1460 
(732 to 2400)
5·3% 
(–0·8 to 9·7)
–20·7% 
(–25·2 to –17·7)*
33 600 
(17 900 to 
53 300)
34 200 
(17 700 to 55 700)
1·8% 
(–4·0 to 6·1)
–20·4% 
(–24·8 to –17·3)*
·· Ischaemic heart disease 947 
(370 to 1660)
1020 
(396 to 1830)
8·2% 
(3·0 to 12·0)*
–19·1% 
(–23·0 to –16·3)*
21 400 
(8520 to 37 400)
22 100 
(8730 to 39 400)
3·2% 
(–2·2 to 7·2)
–19·5% 
(–23·5 to –16·4)*
·· Ischaemic stroke 150 
(36 to 280)
154 
(36 to 297)
3·1% 
(–3·3 to 8·1)
–22·6% 
(–27·4 to –19·0)*
3920 
(970 to 7330)
4170 
(1010 to 8090)
6·2% 
(–0·9 to 12·0)
–17·9% 
(–23·3 to –13·6)*
·· Intracerebral haemorrhage 252 
(71 to 474)
243 
(66 to 469)
–3·6% 
(–10·4 to 1·4)
–26·1% 
(–31·2 to –22·4)*
6910 
(1970 to 12 900)
6550 
(1800 to 12 500)
–5·2% 
(–11·5 to –0·5)*
–25·4% 
(–30·3 to –21·9)*
·· Subarachnoid haemorrhage 39 
(11 to 73)
41 
(11 to 78)
3·3% 
(–3·2 to 9·3)
–18·8% 
(–23·8 to –14·2)*
1360 
(381 to 2530)
1380 
(371 to 2580)
1·0% 
(–4·9 to 6·4)
–18·4% 
(–22·9 to –14·1)*
3 Diet low in legumes: all 
causes
481 
(192 to 819)
535 
(214 to 909)
11·2% 
(9·2 to 13·0)*
–17·3% 
(–18·8 to –16·0)*
10 600 
(4280 to 18 000)
11 000 
(4390 to 18 700)
3·3% 
(0·9 to 5·5)*
–19·3% 
(–21·1 to –17·6)*
·· Ischaemic heart disease 481 
(192 to 819)
535 
(214 to 909)
11·2% 
(9·2 to 13·0)*
–17·3% 
(–18·8 to –16·0)*
10 600 
(4280 to 18 000)
11 000 
(4390 to 18 700)
3·3% 
(0·9 to 5·5)*
–19·3% 
(–21·1 to –17·6)*
3 Diet low in whole grains: all 
causes
2630 
(1820 to 3490)
3070 
(2110 to 4120)
16·7% 
(14·6 to 18·5)*
–12·2% 
(–13·6 to –10·8)*
71 500 
(51 300 to 
93 800)
82 500 
(59 000 to 
109 000)
15·5% 
(13·2 to 17·6)*
–9·7% 
(–11·4 to –8·1)*
·· Ischaemic heart disease 1510 
(890 to 2170)
1780 
(1050 to 2570)
18·4% 
(16·4 to 20·2)*
–11·5% 
(–12·9 to –10·2)*
34 300 
(20 600 to 
48 800)
39 100 
(23 300 to 55 700)
13·9% 
(11·9 to 15·9)*
–11·2% 
(–12·8 to –9·7)*
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·· Ischaemic stroke 363 
(241 to 501)
418 
(276 to 580)
15·1% 
(12·5 to 17·6)*
–13·6% 
(–15·5 to –11·8)*
9870 
(6680 to 13 500)
12 000 
(8050 to 16 400)
21·3% 
(18·0 to 24·4)*
–6·4% 
(–9·0 to –4·0)*
·· Intracerebral haemorrhage 550 
(368 to 745)
597 
(401 to 813)
8·5% 
(5·5 to 11·2)*
–16·9% 
(–19·2 to –14·9)*
14 900 
(10 100 to 
20 100)
16 000 
(10 800 to 21 400)
7·0% 
(4·1 to 9·7)*
–16·0% 
(–18·3 to 
–14·0)*
·· Subarachnoid haemorrhage 86 
(58 to 118)
98 
(66 to 134)
13·6% 
(8·2 to 19·1)*
–11·1% 
(–15·3 to –7·0)*
2960 
(2010 to 3950)
3280 
(2240 to 4410)
11·0% 
(6·5 to 15·6)*
–10·7% 
(–14·3 to –7·1)*
·· Type 2 diabetes mellitus 122 
(69 to 186)
169 
(95 to 259)
38·4% 
(35·1 to 41·4)*
3·7% 
(1·4 to 5·9)*
9400 
(4980 to 15 100)
12 200 
(6400 to 19 400)
29·7% 
(25·6 to 33·9)*
2·8% 
(–0·4 to 6·0)
3 Diet low in nuts and seeds: all 
causes
1740 
(1130 to 2410)
2060 
(1330 to 2880)
18·7% 
(16·6 to 20·6)*
–11·2% 
(–12·7 to –9·9)*
43 300 
(28 800 to 
58 800)
49 900 
(33 100 to 68 000)
15·2% 
(12·9 to 17·3)*
–10·0% 
(–11·8 to –8·3)*
·· Ischaemic heart disease 1660 
(1070 to 2330)
1960 
(1230 to 2750)
17·8% 
(15·7 to 19·7)*
–11·9% 
(–13·4 to –10·6)*
37 600 
(24 500 to 
51 800)
42 600 
(27 300 to 58 700)
13·2% 
(10·9 to 15·2)*
–11·8% 
(–13·4 to –10·3)*
·· Type 2 diabetes mellitus 74 
(36 to 116)
103 
(50 to 160)
38·4% 
(35·4 to 41·3)*
3·9% 
(1·8 to 6·1)*
5700 
(2640 to 9390)
7310 
(3410 to 12 100)
28·2% 
(24·1 to 32·4)*
1·8% 
(–1·4 to 4·9)
3 Diet low in milk: all causes 96 
(34 to 171)
126 
(45 to 220)
30·6% 
(26·0 to 34·8)*
–1·9% 
(–5·2 to 1·2)
2140 
(757 to 3770)
2720 
(965 to 4730)
27·0% 
(21·9 to 31·5)*
–2·0% 
(–6·0 to 1·4)
·· Colon and rectum cancer 96 
(34 to 171)
126 
(45 to 220)
30·6% 
(26·0 to 34·8)*
–1·9% 
(–5·2 to 1·2)
2140 
(757 to 3770)
2720 
(965 to 4730)
27·0% 
(21·9 to 31·5)*
–2·0% 
(–6·0 to 1·4)
3 Diet high in red meat: all 
causes
17 
(7 to 28)
25 
(11 to 40)
47·5% 
(36·9 to 59·6)*
11·2% 
(3·0 to 20·4)*
880 
(352 to 1520)
1310 
(508 to 2250)
49·2% 
(36·7 to 63·8)*
17·8% 
(7·9 to 29·5)*
·· Colon and rectum cancer 11 
(3 to 20)
16 
(4 to 29)
45·7% 
(34·3 to 58·4)*
9·8% 
(1·4 to 19·6)*
262 
(63 to 472)
378 
(89 to 678)
44·3% 
(32·7 to 57·6)*
11·2% 
(2·6 to 21·2)*
·· Type 2 diabetes mellitus 6 
(1 to 11)
9 
(1 to 17)
50·8% 
(40·3 to 62·8)*
13·6% 
(5·8 to 23·1)*
618 
(77 to 1200)
934 
(113 to 1830)
51·2% 
(37·6 to 66·6)*
20·8% 
(10·1 to 32·9)*
3 Diet high in processed meat: 
all causes
125 
(24 to 239)
130 
(26 to 265)
4·3% 
(–5·0 to 13·2)
–22·3% 
(–28·9 to –15·6)*
3360 
(1050 to 6120)
3570 
(1260 to 6770)
6·1% 
(–4·4 to 19·4)
–17·9% 
(–25·9 to –6·9)*
·· Colon and rectum cancer 9 
(5 to 15)
11 
(5 to 18)
13·8% 
(6·4 to 20·3)*
–14·9% 
(–20·4 to –10·1)*
205 
(107 to 330)
227 
(114 to 373)
10·6% 
(3·0 to 16·9)*
–15·4% 
(–21·1 to –10·5)*
·· Ischaemic heart disease 105 
(5 to 213)
107 
(5 to 230)
2·0% 
(–9·8 to 10·2)
–24·0% 
(–32·5 to –18·0)*
2320 
(120 to 4650)
2270 
(111 to 4860)
–2·2% 
(–13·8 to 6·3)
–24·5% 
(–33·3 to –17·8)*
·· Type 2 diabetes mellitus 10 
(5 to 17)
12 
(6 to 21)
18·6% 
(6·0 to 29·7)*
–11·3% 
(–20·6 to –2·9)*
838 
(404 to 1430)
1070 
(490 to 1900)
28·0% 
(16·3 to 37·0)*
0·2% 
(–8·9 to 7·6)
3 Diet high in sugar-sweetened 
beverages: all causes
105 
(13 to 206)
137 
(20 to 264)
30·4% 
(23·2 to 52·7)*
–2·5% 
(–8·2 to 14·4)
3350 
(981 to 5910)
4450 
(1490 to 7700)
32·8% 
(24·7 to 54·4)*
4·7% 
(–1·8 to 23·1)
·· Ischaemic heart disease 92 
(0 to 189)
117 
(0 to 242)
27·4% 
(0 to 34·2)
–4·7% 
(–10·2 to 1·1)
2270 
(0 to 4620)
2810 
(0 to 5700)
23·7% 
(0 to 30·2)
–2·9% 
(–7·8 to 2·4)
·· Type 2 diabetes mellitus 14 
(7 to 20)
21 
(11 to 30)
50·5% 
(39·9 to 62·8)*
12·5% 
(4·6 to 21·7)*
1080 
(570 to 1670)
1650 
(852 to 2520)
52·0% 
(43·2 to 62·5)*
21·1% 
(14·0 to 29·3)*
3 Diet low in fibre: all causes 737 
(433 to 1110)
873 
(510 to 1330)
18·6% 
(15·9 to 20·7)*
–11·2% 
(–13·2 to –9·6)*
17 700 
(10 400 to 
26 500)
19 900 
(11 600 to 30 400)
12·6% 
(9·5 to 15·0)*
–11·4% 
(–13·7 to –9·6)*
·· Colon and rectum cancer 84 
(44 to 131)
106 
(54 to 167)
26·0% 
(21·7 to 29·8)*
–5·8% 
(–8·9 to –3·0)*
1800 
(926 to 2800)
2200 
(1140 to 3470)
22·2% 
(17·2 to 26·4)*
–5·8% 
(–9·5 to –2·7)*
·· Ischaemic heart disease 653 
(368 to 1010)
768 
(429 to 1210)
17·6% 
(14·9 to 19·8)*
–11·9% 
(–13·9 to –10·4)*
15 900 
(9030 to 24 400)
17 700 
(9940 to 27 700)
11·5% 
(8·3 to 14·0)*
–12·0% 
(–14·3 to –10·1)*
3 Diet low in calcium: all causes 145 
(91 to 205)
185 
(116 to 262)
27·4% 
(22·5 to 31·2)*
–4·5% 
(–8·0 to –1·8)*
3150 
(1990 to 4420)
3890 
(2450 to 5480)
23·7% 
(18·1 to 27·9)*
–4·7% 
(–8·9 to –1·5)*
·· Colon and rectum cancer 145 
(91 to 205)
185 
(116 to 262)
27·4% 
(22·5 to 31·2)*
–4·5% 
(–8·0 to –1·8)*
3150 
(1990 to 4420)
3890 
(2450 to 5480)
23·7% 
(18·1 to 27·9)*
–4·7% 
(–8·9 to –1·5)*
3 Diet low in seafood omega 3 
fatty acids: all causes
1220 
(565 to 2000)
1440 
(667 to 2380)
18·4% 
(16·3 to 20·2)*
–10·8% 
(–12·4 to –9·5)*
28 200 
(13 300 to 
45 600)
32 400 
(15 200 to 52 700)
14·9% 
(12·8 to 17·0)*
–10·3% 
(–12·0 to –8·8)*
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·· Ischaemic heart disease 1220 
(565 to 2000)
1440 
(667 to 2380)
18·4% 
(16·3 to 20·2)*
–10·8% 
(–12·4 to –9·5)*
28 200 
(13 300 to 
45 600)
32 400 
(15 200 to 52 700)
14·9% 
(12·8 to 17·0)*
–10·3% 
(–12·0 to –8·8)*
3 Diet low in polyunsaturated 
fatty acids: all causes
676 
(288 to 1110)
799 
(343 to 1310)
18·3% 
(15·7 to 20·8)*
–11·3% 
(–13·1 to –9·5)*
15 700 
(6740 to 25 500)
17 900 
(7770 to 29 000)
13·7% 
(11·3 to 16·2)*
–11·0% 
(–12·8 to –9·1)*
·· Ischaemic heart disease 676 
(288 to 1110)
799 
(343 to 1310)
18·3% 
(15·7 to 20·8)*
–11·3% 
(–13·1 to –9·5)*
15 700 
(6740 to 25 500)
17 900 
(7770 to 29 000)
13·7% 
(11·3 to 16·2)*
–11·0% 
(–12·8 to –9·1)*
3 Diet high in trans fatty acids: 
all causes
250 
(93 to 519)
258 
(80 to 577)
3·2% 
(–14·0 to 10·5)
–23·1% 
(–36·5 to –17·4)*
6050 
(2180 to 12 800)
6160 
(1870 to 13 800)
1·9% 
(–14·3 to 8·6)
–20·3% 
(–33·2 to –15·0)*
·· Ischaemic heart disease 250 
(93 to 519)
258 
(80 to 577)
3·2% 
(–14·0 to 10·5)
–23·1% 
(–36·5 to –17·4)*
6050 
(2180 to 12 800)
6160 
(1870 to 13 800)
1·9% 
(–14·3 to 8·6)
–20·3% 
(–33·2 to –15·0)*
3 Diet high in sodium: all 
causes
2520 
(1070 to 4370)
3200 
(1420 to 5450)
26·6% 
(21·5 to 38·3)*
–5·4% 
(–9·4 to 4·4)
57 400 
(26 500 to 
97 000)
70 400 
(33 600 to 118 000)
22·7% 
(18·0 to 32·2)*
–5·9% 
(–9·4 to 1·7)
·· Stomach cancer 295 
(158 to 460)
327 
(175 to 506)
10·9% 
(3·1 to 19·9)*
–15·8% 
(–20·4 to –9·2)*
6950 
(3880 to 10 500)
7350 
(4120 to 11 100)
5·8% 
(–2·1 to 14·9)
–18·2% 
(–23·3 to –12·0)*
·· Rheumatic heart disease 19 
(7 to 37)
18 
(7 to 37)
–0·8% 
(–10·5 to 6·8)
–23·9% 
(–30·6 to –18·7)*
583 
(240 to 1130)
554 
(222 to 1100)
–5·0% 
(–13·4 to 1·2)
–24·3% 
(–30·6 to –19·9)*
·· Ischaemic heart disease 963 
(336 to 1870)
1250 
(472 to 2350)
29·8% 
(24·0 to 47·4)*
–3·8% 
(–8·1 to 10·4)
20 000 
(7450 to 37 200)
25 000 
(10 300 to 45 300)
25·3% 
(20·2 to 40·6)*
–4·2% 
(–8·2 to 7·9)
·· Ischaemic stroke 318 
(120 to 582)
421 
(179 to 744)
32·5% 
(24·5 to 52·5)*
–2·1% 
(–8·2 to 13·6)
7270 
(3110 to 12 300)
10 300 
(4840 to 16 700)
41·2% 
(31·8 to 61·4)*
6·7% 
(–0·3 to 22·5)
·· Intracerebral haemorrhage 547 
(261 to 912)
629 
(305 to 1040)
14·9% 
(8·8 to 23·1)*
–13·4% 
(–17·8 to –6·7)*
13 000 
(6660 to 
20 900)
14 500 
(7450 to 23 300)
11·5% 
(5·8 to 18·6)*
–14·2% 
(–18·4 to –8·4)*
·· Subarachnoid haemorrhage 66 
(28 to 116)
82 
(36 to 143)
24·0% 
(13·7 to 37·3)*
–5·6% 
(–13·3 to 4·6)
1900 
(837 to 3310)
2240 
(1020 to 3850)
18·1% 
(8·5 to 29·0)*
–7·8% 
(–15·2 to 0·3)
·· Hypertensive heart disease 147 
(43 to 330)
236 
(67 to 512)
60·1% 
(26·0 to 91·2)*
17·7% 
(–7·0 to 41·5)
3000 
(1060 to 6130)
4380 
(1590 to 8810)
46·3% 
(20·5 to 71·3)*
11·4% 
(–8·5 to 30·6)
·· Non-rheumatic calcific 
aortic valve disease
4 
(1 to 10)
6 
(1 to 14)
39·4% 
(29·6 to 48·8)*
0·3% 
(–5·3 to 7·3)
81 
(22 to 172)
107 
(29 to 225)
32·1% 
(24·2 to 40·3)*
–0·4% 
(–5·5 to 6·2)
·· Other cardiomyopathy 12 
(3 to 24)
15 
(4 to 32)
29·8% 
(21·3 to 35·7)*
–3·2% 
(–8·0 to 1·5)
292 
(83 to 611)
366 
(100 to 774)
25·6% 
(16·7 to 31·4)*
–2·2% 
(–8·8 to 2·5)
·· Atrial fibrillation and flutter 15 
(4 to 30)
22 
(7 to 45)
51·5% 
(45·3 to 67·2)*
7·7% 
(3·2 to 21·1)*
446 
(165 to 848)
628 
(244 to 1170)
40·9% 
(35·9 to 53·2)*
5·8% 
(1·9 to 16·2)*
·· Aortic aneurysm 11 
(3 to 22)
14 
(5 to 28)
27·8% 
(21·8 to 40·3)*
–4·4% 
(–8·7 to 5·6)
225 
(75 to 447)
280 
(98 to 552)
24·5% 
(17·8 to 37·2)*
–4·6% 
(–9·6 to 5·3)
·· Peripheral vascular disease 2 
(0 to 5)
3 
(1 to 8)
60·6% 
(34·7 to 93·7)*
15·8% 
(–2·4 to 42·0)
64 
(18 to 139)
91 
(26 to 195)
42·4% 
(29·0 to 57·9)*
6·5% 
(–3·2 to 18·2)
·· Endocarditis 4 
(1 to 9)
6 
(2 to 12)
36·0% 
(25·7 to 43·2)*
2·2% 
(–4·7 to 8·0)
103 
(31 to 212)
132 
(40 to 272)
28·3% 
(18·6 to 35·5)*
0·6% 
(–6·7 to 5·6)
·· Other cardiovascular and 
circulatory diseases
23 
(7 to 48)
30 
(9 to 60)
27·1% 
(21·5 to 41·6)*
–4·3% 
(–8·3 to 7·1)
832 
(275 to 1680)
1020 
(350 to 2040)
23·2% 
(18·7 to 31·0)*
–4·3% 
(–7·6 to 1·7)
·· Chronic kidney disease due 
to type 1 diabetes mellitus
6 
(2 to 13)
8 
(3 to 16)
19·7% 
(7·3 to 26·9)*
–5·8% 
(–14·3 to –1·4)*
231 
(88 to 467)
262 
(95 to 552)
13·2% 
(0·6 to 21·0)*
–9·0% 
(–18·4 to –3·8)*
·· Chronic kidney disease due 
to type 2 diabetes mellitus
31 
(11 to 62)
44 
(16 to 89)
42·0% 
(34·4 to 49·7)*
5·3% 
(0·1 to 11·4)*
743 
(282 to 1460)
1000 
(383 to 1990)
35·0% 
(27·8 to 41·0)*
2·2% 
(–2·9 to 6·7)
·· Chronic kidney disease due 
to hypertension
29 
(10 to 58)
42 
(15 to 84)
46·1% 
(38·9 to 56·9)*
6·9% 
(1·7 to 16·3)*
619 
(223 to 1230)
847 
(318 to 1650)
36·9% 
(30·2 to 45·0)*
3·8% 
(–0·8 to 10·4)
·· Chronic kidney disease due 
to glomerulonephritis
13 
(4 to 27)
17 
(5 to 36)
34·2% 
(27·5 to 42·0)*
1·7% 
(–2·7 to 8·4)
372 
(126 to 756)
460 
(156 to 946)
23·7% 
(16·5 to 30·2)*
–2·6% 
(–7·6 to 1·7)
·· Chronic kidney disease due 
to other and unspecified 
causes
19 
(6 to 38)
25 
(8 to 52)
36·3% 
(29·0 to 44·6)*
2·7% 
(–2·3 to 9·0)
664 
(240 to 1340)
837 
(304 to 1700)
26·1% 
(19·5 to 32·5)*
–2·1% 
(–6·6 to 2·3)
(Table 3 continues on next page)
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1957
Risk factors and outcomes 2007 deaths 
(thousands)
2017 deaths 
(thousands)
Percentage 
change in 
deaths, 
2007–17
Percentage 
change in age-
standardised 
death rate, 
2007–17
2007 DALYs 
(thousands)
2017 DALYs 
(thousands)
Percentage 
change in 
DALYs, 
2007–17
Percentage 
change in age-
standardised 
DALY rate, 
2007–17
(Continued from previous page)
2 Intimate partner violence: 
all causes
151 
(95 to 217)
71 
(49 to 97)
–53·2% 
(–56·6 to 
–47·9)*
–59·3% 
(–62·4 to 
–54·6)*
10 300 
(7270 to 
14 000)
6700 
(5150 to 8580)
–35·0% 
(–41·8 to 
–25·1)*
–43·0% 
(–49·0 to 
–34·3)*
·· HIV/AIDS and drug-
susceptible tuberculosis 
co-infection
27 
(13 to 44)
10 
(5 to 16)
–63·0% 
(–66·7 to –58·0)*
–68·3% 
(–71·7 to –64·1)*
1280 
(615 to 2110)
500 
(248 to 802)
–61·0% 
(–65·0 to –55·5)*
–66·1% 
(–69·6 to –61·2)*
·· HIV/AIDS and multidrug-
resistant tuberculosis 
without extensive drug 
resistance co-infection
3 
(1 to 5)
1 
(0 to 2)
–59·6% 
(–73·0 to –42·6)*
–65·4% 
(–76·9 to –51·0)*
127 
(50 to 230)
53 
(23 to 94)
–58·0% 
(–71·7 to –39·8)*
–63·4% 
(–75·4 to –47·8)*
·· HIV/AIDS and extensively 
drug-resistant tuberculosis 
co-infection
0 
(0 to 0)
0 
(0 to 0)
–19·2% 
(–39·7 to 4·2)
–30·7% 
(–48·4 to –10·4)*
2 
(1 to 4)
2 
(1 to 3)
–18·7% 
(–39·5 to 4·3)
–29·3% 
(–47·3 to –9·1)*
·· HIV/AIDS resulting in other 
diseases
96 
(51 to 148)
37 
(20 to 58)
–61·3% 
(–64·4 to –58·2)*
–66·5% 
(–69·3 to –63·8)*
4890 
(2580 to 7620)
1990 
(1050 to 3100)
–59·2% 
(–62·4 to –56·0)*
–64·3% 
(–67·2 to –61·5)*
·· Maternal abortive outcome 3 
(2 to 4)
3 
(2 to 4)
–9·2% 
(–25·8 to 11·4)
–18·4% 
(–32·9 to 0·7)
162 
(99 to 241)
144 
(90 to 212)
–10·7% 
(–26·8 to 9·4)
–19·1% 
(–33·6 to –0·1)*
·· Major depressive disorder ·· ·· ·· ·· 1760 
(1080 to 2660)
2000 
(1240 to 3030)
13·7% 
(10·2 to 17·8)*
–2·9% 
(–4·9 to –1·0)*
·· Assault by firearm 5 
(4 to 6)
5 
(4 to 6)
–4·8% 
(–9·7 to 3·0)
–15·7% 
(–20·1 to –8·8)*
270 
(209 to 328)
251 
(203 to 309)
–7·1% 
(–11·7 to 1·0)
–15·9% 
(–20·2 to –8·5)*
·· Assault by sharp object 7 
(5 to 8)
5 
(4 to 6)
–17·2% 
(–21·1 to –10·6)*
–27·5% 
(–30·8 to –21·8)*
368 
(291 to 421)
302 
(244 to 352)
–18·0% 
(–22·1 to –10·6)*
–26·8% 
(–30·6 to –20·4)*
·· Sexual violence ·· ·· ·· ·· 712 
(469 to 1040)
787 
(520 to 1150)
10·7% 
(5·2 to 16·0)*
–0·8% 
(–5·3 to 3·5)
·· Assault by other means 11 
(8 to 13)
10 
(8 to 12)
–11·9% 
(–16·6 to –4·4)*
–22·6% 
(–26·7 to –16·2)*
733 
(576 to 871)
669 
(561 to 806)
–8·7% 
(–13·4 to –0·9)*
–19·0% 
(–22·9 to –12·2)*
2 Childhood maltreatment: 
all causes
7 
(6 to 10)
8 
(6 to 10)
6·6% 
(–0·6 to 13·9)
–12·6% 
(–18·5 to –6·9)*
4670 
(3280 to 6460)
5210 
(3660 to 7220)
11·6% 
(9·9 to 13·5)*
1·7% 
(0·3 to 3·0)*
3 Childhood sexual abuse: all 
causes
7 
(6 to 10)
8 
(6 to 10)
6·6% 
(–0·6 to 13·9)
–12·6% 
(–18·5 to –6·9)*
2380 
(1670 to 3230)
2700 
(1900 to 3690)
13·3% 
(11·2 to 15·6)*
–2·4% 
(–4·3 to –0·7)*
·· Major depressive disorder ·· ·· ·· ·· 1620 
(1080 to 2300)
1860 
(1250 to 2640)
14·9% 
(12·8 to 17·2)*
–1·0% 
(–2·9 to 0·8)
·· Alcohol use disorders 7 
(6 to 10)
8 
(6 to 10)
6·6% 
(–0·6 to 13·9)
–12·6% 
(–18·5 to –6·9)*
760 
(528 to 1050)
836 
(583 to 1170)
10·0% 
(6·2 to 13·6)*
–5·2% 
(–8·7 to –2·2)*
3 Bullying victimisation: all 
causes
·· ·· ·· ·· 2340 
(1380 to 3660)
2570 
(1540 to 3970)
9·9% 
(8·1 to 12·5)*
6·3% 
(4·5 to 8·8)*
·· Major depressive disorder ·· ·· ·· ·· 1110 
(624 to 1800)
1210 
(689 to 1940)
9·5% 
(6·9 to 12·6)*
6·0% 
(3·3 to 9·0)*
·· Anxiety disorders ·· ·· ·· ·· 1230 
(732 to 1950)
1360 
(815 to 2130)
10·2% 
(8·1 to 12·6)*
6·6% 
(4·6 to 9·0)*
2 Unsafe sex: all causes 1750 
(1680 to 1830)
1030 
(980 to 1080)
–41·2% 
(–43·2 to 
–39·2)*
–49·8% 
(–51·4 to 
–48·1)*
86 100 
(81 700 to 
90 600)
50 200 
(47 100 to 53 400)
–41·7% 
(–43·8 to 
–39·4)*
–49·2% 
(–51·0 to 
–47·2)*
·· HIV/AIDS and drug-
susceptible tuberculosis 
co-infection
330 
(223 to 440)
153 
(108 to 202)
–53·6% 
(–56·9 to –49·1)*
–59·9% 
(–62·8 to –56·2)*
16 000 
(10 700 to 
21 400)
7900 
(5640 to 10 300)
–50·7% 
(–54·5 to –45·7)*
–56·6% 
(–60·0 to –52·2)*
·· HIV/AIDS and multidrug-
resistant tuberculosis 
without extensive drug 
resistance co-infection
35 
(20 to 55)
17 
(10 to 26)
–51·2% 
(–66·3 to –31·0)*
–57·9% 
(–70·9 to –40·6)*
1690 
(952 to 2650)
865 
(513 to 1310)
–48·8% 
(–64·4 to 
–28·1)*
–54·9% 
(–68·6 to –36·8)*
·· HIV/AIDS and extensively 
drug-resistant tuberculosis 
co-infection
1 
(1 to 1)
1 
(0 to 1)
–8·7% 
(–29·5 to 16·7)
–21·3% 
(–39·4 to 0·4)
43 
(26 to 65)
40 
(24 to 59)
–8·8% 
(–28·7 to 16·7)
–20·1% 
(–37·6 to 2·0)
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Risk factors and outcomes 2007 deaths 
(thousands)
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2017 DALYs 
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Percentage 
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DALYs, 
2007–17
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change in age-
standardised 
DALY rate, 
2007–17
(Continued from previous page)
·· HIV/AIDS resulting in other 
diseases
1160 
(1020 to 1290)
590 
(526 to 656)
–49·0% 
(–51·5 to –46·2)*
–55·7% 
(–58·0 to –53·3)*
59 800 
(52 700 to 
67 100)
31 700 
(28 300 to 35 400)
–47·1% 
(–49·9 to 
–44·2)*
–53·4% 
(–55·9 to –50·9)*
·· Syphilis 2 
(1 to 2)
2 
(1 to 2)
2·9% 
(–11·3 to 18·4)
–17·6% 
(–28·9 to –5·0)*
124 
(101 to 151)
132 
(108 to 162)
7·1% 
(–0·1 to 14·1)
–11·2% 
(–17·2 to –5·6)*
·· Chlamydial infection 1 
(1 to 1)
1 
(1 to 1)
2·5% 
(–4·4 to 11·3)
–15·2% 
(–21·0 to –8·4)*
329 
(205 to 555)
355 
(219 to 606)
8·1% 
(5·1 to 10·6)*
–3·0% 
(–5·9 to –0·8)*
·· Gonococcal infection 3 
(2 to 3)
3 
(2 to 3)
3·7% 
(–3·4 to 12·5)
–15·0% 
(–20·8 to –8·2)*
290 
(206 to 437)
303 
(216 to 468)
4·5% 
(0·1 to 8·6)*
–6·1% 
(–10·7 to –2·1)*
·· Trichomoniasis ·· ·· ·· ·· 209 
(84 to 454)
243 
(98 to 524)
16·0% 
(14·2 to 17·7)*
2·2% 
(1·1 to 3·2)*
·· Genital herpes ·· ·· ·· ·· 207 
(68 to 492)
247 
(80 to 594)
19·8% 
(18·1 to 21·0)*
1·5% 
(0·8 to 2·3)*
·· Other sexually transmitted 
infections
2 
(1 to 2)
2 
(1 to 2)
0·2% 
(–6·4 to 8·4)
–15·9% 
(–21·6 to –9·5)*
385 
(257 to 604)
416 
(276 to 659)
8·1% 
(5·9 to 10·1)*
–2·6% 
(–5·0 to –0·7)*
·· Cervical cancer 219 
(204 to 231)
260 
(241 to 269)
18·8% 
(12·9 to 22·8)*
–7·2% 
(–11·6 to –4·0)*
7000 
(6500 to 7340)
8060 
(7530 to 8400)
15·2% 
(9·5 to 19·2)*
–7·0% 
(–11·6 to –3·8)*
2 Low physical activity: all 
causes
1030 
(557 to 1640)
1260 
(681 to 2010)
22·0% 
(20·4 to 23·7)*
–10·8% 
(–12·1 to –9·5)*
19 700 
(10 500 to 
31 300)
23 700 
(12 500 to 37 300)
20·1% 
(18·0 to 22·1)*
–8·9% 
(–10·7 to –7·2)*
·· Colon and rectum cancer 26 
(3 to 61)
33 
(4 to 77)
27·3% 
(23·8 to 31·3)*
–5·2% 
(–7·9 to –1·8)*
525 
(70 to 1230)
652 
(89 to 1540)
24·1% 
(20·1 to 28·5)*
–5·1% 
(–8·2 to –1·2)*
·· Breast cancer 7 
(0 to 17)
9 
(0 to 21)
25·9% 
(20·8 to 30·5)*
–4·4% 
(–8·1 to –0·5)*
205 
(4 to 470)
253 
(5 to 575)
23·4% 
(17·7 to 28·5)*
–3·2% 
(–7·5 to 1·3)
·· Ischaemic heart disease 730 
(346 to 1220)
889 
(416 to 1480)
21·8% 
(20·1 to 23·3)*
–10·9% 
(–12·1 to –9·6)*
13 200 
(6020 to 21 900)
15 400 
(7120 to 25 700)
17·0% 
(15·2 to 18·7)*
–11·1% 
(–12·5 to –9·7)*
·· Ischaemic stroke 246 
(86 to 456)
295 
(103 to 547)
20·1% 
(17·9 to 22·4)*
–13·0% 
(–14·7 to –11·2)*
4410 
(1520 to 8280)
5460 
(1870 to 10 200)
23·8% 
(20·7 to 27·1)*
–7·4% 
(–9·8 to –4·7)*
·· Type 2 diabetes mellitus 26 
(6 to 48)
36 
(8 to 69)
42·5% 
(39·8 to 45·2)*
5·3% 
(3·3 to 7·2)*
1380 
(300 to 2710)
1870 
(410 to 3660)
35·8% 
(32·1 to 40·0)*
5·2% 
(2·4 to 8·3)*
1 Metabolic risks: all causes 14 100 
(12 900 to 
15 100)
17 600 
(16 100 to 
18 900)
25·0% 
(23·3 to 26·6)*
–7·3% 
(–8·5 to –6·1)*
346 000 
(317 000 to 
376 000)
423 000 
(386 000 to 
462 000)
22·2% 
(20·7 to 23·9)*
–5·4% 
(–6·6 to –4·1)*
2 High fasting plasma 
glucose: all causes
5140 
(4150 to 6490)
6530 
(5230 to 
8230)
27·1% 
(22·5 to 31·7)*
–6·0% 
(–9·4 to –2·9)*
136 000 
(115 000 to 
160 000)
171 000 
(144 000 to 
201 000)
25·5% 
(21·8 to 29·5)*
–3·2% 
(–6·1 to 0·0)
·· Drug-susceptible 
tuberculosis
125 
(80 to 176)
118 
(73 to 166)
–6·1% 
(–14·1 to 2·4)
–26·6% 
(–32·6 to –20·1)*
4060 
(2680 to 5580)
3740 
(2400 to 5200)
–8·0% 
(–15·6 to 0·1)
–26·0% 
(–31·9 to –19·6)*
·· Multidrug-resistant 
tuberculosis without 
extensive drug resistance
14 
(9 to 22)
14 
(7 to 25)
–4·3% 
(–43·5 to 50·2)
–24·9% 
(–55·9 to 17·7)
464 
(285 to 672)
428 
(210 to 757)
–7·8% 
(–44·8 to 44·5)
–25·7% 
(–55·7 to 16·6)
·· Extensively drug-resistant 
tuberculosis
1 
(1 to 2)
1 
(1 to 2)
21·5% 
(–12·2 to 68·0)
–3·6% 
(–30·3 to 33·2)
40 
(24 to 58)
46 
(26 to 73)
14·3% 
(–16·3 to 56·9)
–7·0% 
(–31·9 to 27·2)
·· Colon and rectum cancer 60 
(15 to 129)
80 
(19 to 172)
32·6% 
(25·5 to 41·0)*
–1·7% 
(–7·0 to 4·5)
1130 
(269 to 2450)
1470 
(352 to 3200)
29·8% 
(22·4 to 38·2)*
–1·8% 
(–7·3 to 4·5)
·· Liver cancer due to non-
alcoholic steatohepatitis
4 
(1 to 8)
5 
(1 to 12)
44·0% 
(35·8 to 52·6)*
8·0% 
(1·8 to 14·7)*
74 
(18 to 163)
105 
(25 to 230)
40·8% 
(33·1 to 49·3)*
7·2% 
(1·2 to 13·9)*
·· Liver cancer due to other 
causes
3 
(1 to 7)
4 
(1 to 9)
26·5% 
(18·8 to 34·8)*
–3·9% 
(–9·7 to 2·4)
81 
(19 to 174)
99 
(24 to 217)
22·4% 
(15·2 to 30·7)*
–5·3% 
(–10·8 to 1·1)
·· Pancreatic cancer 27 
(6 to 57)
39 
(9 to 84)
46·3% 
(38·6 to 55·0)*
8·8% 
(3·1 to 15·1)*
502 
(115 to 1090)
717 
(163 to 1570)
42·9% 
(35·3 to 51·4)*
8·0% 
(2·4 to 14·5)*
·· Tracheal, bronchus, and 
lung cancer
119 
(27 to 257)
154 
(34 to 336)
29·6% 
(23·0 to 36·9)*
–2·5% 
(–7·6 to 2·8)
2420 
(544 to 5270)
3050 
(674 to 6710)
26·4% 
(19·8 to 33·6)*
–4·1% 
(–9·1 to 1·3)
·· Breast cancer 33 
(6 to 73)
44 
(9 to 99)
35·2% 
(27·9 to 43·9)*
1·3% 
(–4·2 to 7·6)
805 
(153 to 1800)
1070 
(205 to 2430)
33·5% 
(25·4 to 42·4)*
2·8% 
(–3·2 to 9·5)
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·· Ovarian cancer 10 
(2 to 23)
14 
(3 to 32)
38·1% 
(31·3 to 46·3)*
3·1% 
(–1·9 to 9·3)
222 
(43 to 521)
307 
(61 to 718)
38·6% 
(31·6 to 46·9)*
5·6% 
(0·3 to 11·8)*
·· Bladder cancer 14 
(3 to 31)
19 
(4 to 42)
34·8% 
(28·0 to 42·5)*
–0·8% 
(–5·7 to 5·0)
246 
(50 to 538)
320 
(65 to 697)
30·1% 
(23·8 to 37·6)*
–2·2% 
(–6·9 to 3·4)
·· Ischaemic heart disease 1820 
(1070 to 2930)
2270 
(1340 to 3570)
24·9% 
(18·6 to 31·5)*
–8·7% 
(–12·8 to –4·2)*
32 500 
(20 800 to 
49 400)
39 800 
(25 900 to 60 000)
22·7% 
(17·6 to 28·7)*
–7·2% 
(–11·3 to –2·5)*
·· Ischaemic stroke 504 
(243 to 1010)
594 
(301 to 1210)
17·8% 
(11·0 to 25·2)*
–13·8% 
(–18·0 to –9·1)*
9580 
(5110 to 16 800)
11 800 
(6500 to 20 100)
23·0% 
(16·2 to 31·1)*
–7·7% 
(–12·8 to –1·4)*
·· Intracerebral haemorrhage 529 
(329 to 813)
591 
(368 to 878)
11·7% 
(5·1 to 18·4)*
–16·3% 
(–21·3 to –11·4)*
11 300 
(7280 to 16 500)
12 700 
(8210 to 18 000)
12·9% 
(6·0 to 19·1)*
–13·9% 
(–19·4 to –8·6)*
·· Subarachnoid haemorrhage 72 
(46 to 107)
88 
(57 to 129)
23·0% 
(16·3 to 30·4)*
–7·0% 
(–12·3 to –1·3)*
1850 
(1190 to 2730)
2280 
(1460 to 3230)
23·1% 
(16·5 to 30·3)*
–4·6% 
(–9·7 to 0·9)
·· Peripheral vascular disease 12 
(7 to 20)
19 
(11 to 34)
61·8% 
(34·4 to 84·1)*
15·9% 
(–3·4 to 31·8)
278 
(188 to 409)
402 
(269 to 605)
44·8% 
(28·0 to 60·2)*
7·9% 
(–4·7 to 19·3)
·· Alzheimer’s disease and 
other dementias
164 
(37 to 353)
249 
(58 to 532)
52·0% 
(44·2 to 60·8)*
4·6% 
(–0·9 to 11·0)
2060 
(462 to 4440)
2940 
(681 to 6340)
42·8% 
(35·7 to 50·9)*
2·5% 
(–2·6 to 8·4)
·· Type 1 diabetes mellitus 300 
(276 to 326)
346 
(319 to 371)
15·1% 
(10·5 to 19·0)*
–11·0% 
(–14·6 to –7·8)*
9370 
(8720 to 10 100)
10 400 
(9790 to 11 100)
11·4% 
(7·9 to 14·5)*
–9·8% 
(–12·8 to –7·2)*
·· Type 2 diabetes mellitus 716 
(686 to 748)
1020 
(986 to 1070)
43·0% 
(40·4 to 45·8)*
5·9% 
(4·1 to 8·0)*
42 900 
(33 400 to 
53 700)
57 400 
(45 000 to 71 900)
34·0% 
(30·3 to 38·1)*
5·1% 
(2·3 to 8·1)*
·· Chronic kidney disease due 
to type 1 diabetes mellitus
63 
(51 to 76)
77 
(62 to 95)
23·2% 
(19·0 to 27·4)*
–1·2% 
(–4·0 to 1·2)
2440 
(2010 to 2950)
2890 
(2370 to 3500)
18·2% 
(14·3 to 22·3)*
–2·6% 
(–5·1 to –0·3)*
·· Chronic kidney disease due 
to type 2 diabetes mellitus
248 
(219 to 282)
349 
(307 to 396)
40·5% 
(36·4 to 43·6)*
4·2% 
(1·4 to 6·2)*
6050 
(5290 to 6850)
8120 
(7120 to 9250)
34·3% 
(30·9 to 37·2)*
2·3% 
(–0·2 to 4·2)
·· Chronic kidney disease due 
to hypertension
143 
(100 to 181)
208 
(150 to 255)
45·0% 
(37·7 to 53·6)*
4·8% 
(–0·2 to 10·9)
2670 
(1880 to 3420)
3710 
(2690 to 4650)
39·2% 
(32·0 to 47·4)*
4·4% 
(–0·8 to 10·4)
·· Chronic kidney disease due 
to glomerulonephritis
66 
(46 to 85)
91 
(66 to 116)
38·6% 
(31·3 to 47·4)*
3·6% 
(–1·5 to 9·7)
1600 
(1100 to 2110)
2140 
(1520 to 2730)
33·5% 
(26·6 to 41·2)*
3·7% 
(–1·4 to 9·6)
·· Chronic kidney disease due 
to other and unspecified 
causes
93 
(64 to 121)
130 
(93 to 165)
40·4% 
(33·1 to 48·9)*
4·2% 
(–0·8 to 10·3)
2800 
(1920 to 3740)
3760 
(2640 to 4880)
34·3% 
(27·0 to 42·4)*
2·8% 
(–2·6 to 9·0)
·· Glaucoma ·· ·· ·· ·· 46 
(11 to 105)
61 
(14 to 141)
32·7% 
(27·1 to 39·4)*
–1·1% 
(–5·4 to 3·8)
·· Cataract ·· ·· ·· ·· 503 
(112 to 1170)
687 
(153 to 1580)
36·7% 
(31·0 to 43·1)*
2·4% 
(–2·0 to 7·1)
2 High low-density 
lipoprotein cholesterol: all 
causes
3570 
(2780 to 4450)
4320 
(3330 to 
5440)
20·8% 
(18·2 to 23·2)*
–10·6% 
(–11·8 to –9·4)*
81 000 
(67 800 to 
95 700)
94 900 
(78 800 to 
112 000)
17·2% 
(15·3 to 19·1)*
–9·3% 
(–10·6 to –7·9)*
·· Ischaemic heart disease 3140 
(2430 to 3900)
3790 
(2890 to 4730)
20·7% 
(17·9 to 23·3)*
–10·4% 
(–11·6 to –9·1)*
70 800 
(59 400 to 
82 400)
82 200 
(68 600 to 96 400)
16·1% 
(14·3 to 17·8)*
–9·9% 
(–11·3 to –8·6)*
·· Ischaemic stroke 439 
(177 to 893)
532 
(211 to 1080)
21·2% 
(16·4 to 24·7)*
–12·1% 
(–13·6 to –10·2)*
10 200 
(6160 to 16 900)
12 700 
(7610 to 21 200)
25·0% 
(21·6 to 28·1)*
–5·0% 
(–7·5 to –2·1)*
2 High systolic blood 
pressure: all causes
8500 
(7640 to 9340)
10 400 
(9390 to 
11 500)
22·8% 
(20·5 to 24·7)*
–9·0% 
(–10·6 to –7·6)*
182 000 
(164 000 to 
198 000)
218 000 
(198 000 to 
237 000)
20·0% 
(18·0 to 21·8)*
–8·0% 
(–9·5 to –6·7)*
·· Rheumatic heart disease 69 
(46 to 106)
72 
(48 to 113)
4·5% 
(–1·9 to 11·0)
–20·1% 
(–24·2 to –16·1)*
2070 
(1420 to 3130)
2100 
(1450 to 3260)
1·6% 
(–4·0 to 7·2)
–18·8% 
(–23·0 to –15·0)*
·· Ischaemic heart disease 4030 
(3350 to 4740)
4890 
(4030 to 5760)
21·2% 
(19·0 to 23·0)*
–10·4% 
(–11·6 to –9·2)*
80 500 
(69 200 to 
91 400)
94 800 
(81 100 to 108 000)
17·7% 
(15·9 to 19·4)*
–10·0% 
(–11·4 to –8·7)*
·· Ischaemic stroke 1150 
(900 to 1390)
1370 
(1060 to 
1680)
19·4% 
(16·5 to 22·7)*
–12·3% 
(–14·0 to –10·6)*
23 500 
(18 700 to 
27 700)
29 400 
(23 400 to 34 700)
25·1% 
(21·9 to 28·4)*
–5·7% 
(–8·1 to –3·2)*
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change in age-
standardised 
DALY rate, 
2007–17
(Continued from previous page)
·· Intracerebral haemorrhage 1530 
(1230 to 1800)
1730 
(1400 to 2050)
13·5% 
(10·5 to 16·6)*
–14·9% 
(–17·0 to –12·8)*
34 700 
(29 000 to 
40 100)
38 900 
(32 400 to 44 800)
12·0% 
(9·2 to 14·8)*
–13·8% 
(–16·0 to –11·7)*
·· Subarachnoid haemorrhage 215 
(175 to 258)
258 
(211 to 311)
19·7% 
(14·4 to 26·0)*
–8·8% 
(–12·8 to –4·4)*
6120 
(5000 to 7240)
7140 
(5900 to 8480)
16·7% 
(12·4 to 22·0)*
–8·4% 
(–11·8 to –4·3)*
·· Hypertensive heart disease 632 
(516 to 676)
926 
(681 to 995)
46·6% 
(26·3 to 59·3)*
7·5% 
(–7·3 to 16·3)
12 200 
(10 100 to 
13 200)
16 500 
(12 700 to 17 900)
35·6% 
(20·5 to 46·6)*
3·7% 
(–7·9 to 11·8)
·· Non-rheumatic calcific 
aortic valve disease
24 
(17 to 34)
33 
(23 to 47)
35·5% 
(28·7 to 41·4)*
–3·2% 
(–7·4 to 0·0)
408 
(317 to 514)
528 
(410 to 670)
29·6% 
(24·4 to 34·3)*
–2·9% 
(–6·1 to 0·2)
·· Other cardiomyopathy 61 
(47 to 76)
80 
(62 to 101)
31·6% 
(27·0 to 35·9)*
–2·3% 
(–5·8 to 1·1)
1460 
(1150 to 1770)
1890 
(1490 to 2290)
29·5% 
(23·8 to 34·0)*
1·1% 
(–3·3 to 4·8)
·· Atrial fibrillation and flutter 70 
(56 to 83)
100 
(80 to 121)
43·8% 
(40·2 to 47·0)*
1·4% 
(–0·7 to 3·4)
1800 
(1450 to 2210)
2410 
(1930 to 2950)
33·8% 
(31·9 to 35·7)*
–0·2% 
(–1·4 to 1·1)
·· Aortic aneurysm 49 
(39 to 59)
59 
(47 to 72)
21·3% 
(17·2 to 25·5)*
–9·6% 
(–12·5 to –6·6)*
968 
(801 to 1140)
1150 
(952 to 1360)
18·8% 
(14·4 to 23·5)*
–9·0% 
(–12·5 to –5·4)*
·· Peripheral vascular disease 12 
(7 to 22)
18 
(10 to 33)
49·1% 
(24·9 to 66·2)*
7·2% 
(–9·4 to 19·7)
300 
(186 to 457)
410 
(257 to 632)
36·8% 
(22·9 to 49·1)*
2·1% 
(–8·0 to 10·7)
·· Endocarditis 20 
(15 to 25)
27 
(21 to 34)
36·5% 
(29·4 to 41·4)*
2·4% 
(–2·5 to 6·6)
478 
(375 to 589)
629 
(499 to 762)
31·6% 
(24·3 to 36·8)*
3·9% 
(–1·4 to 7·8)
·· Other cardiovascular and 
circulatory diseases
117 
(100 to 137)
143 
(122 to 167)
22·8% 
(18·5 to 26·0)*
–7·6% 
(–10·7 to –5·3)*
3840 
(3170 to 4680)
4680 
(3850 to 5660)
21·8% 
(18·8 to 24·2)*
–5·3% 
(–7·5 to –3·5)*
·· Chronic kidney disease due 
to type 1 diabetes mellitus
23 
(16 to 33)
30 
(20 to 42)
29·1% 
(24·8 to 33·1)*
1·0% 
(–2·0 to 3·4)
799 
(524 to 1130)
999 
(660 to 1410)
25·1% 
(20·6 to 29·2)*
0·4% 
(–2·4 to 2·9)
·· Chronic kidney disease due 
to type 2 diabetes mellitus
119 
(85 to 154)
168 
(120 to 217)
41·4% 
(37·3 to 44·6)*
4·4% 
(1·6 to 6·5)*
2710 
(1930 to 3550)
3700 
(2640 to 4840)
36·5% 
(33·1 to 39·4)*
3·0% 
(0·4 to 5·0)*
·· Chronic kidney disease due 
to hypertension
246 
(216 to 276)
347 
(305 to 391)
41·4% 
(37·4 to 44·2)*
3·2% 
(0·4 to 5·2)*
5550 
(4900 to 6230)
7350 
(6450 to 8220)
32·4% 
(29·0 to 35·0)*
2·1% 
(–0·3 to 4·1)
·· Chronic kidney disease due 
to glomerulonephritis
57 
(40 to 77)
77 
(54 to 103)
34·2% 
(30·8 to 37·5)*
1·4% 
(–0·9 to 3·3)
1560 
(1060 to 2110)
1990 
(1350 to 2690)
27·1% 
(24·0 to 30·1)*
0·1% 
(–1·8 to 1·9)
·· Chronic kidney disease due 
to other and unspecified 
causes
80 
(56 to 103)
109 
(76 to 142)
36·7% 
(32·6 to 40·3)*
2·4% 
(–0·3 to 4·6)
2670 
(1850 to 3560)
3450 
(2410 to 4620)
29·0% 
(25·8 to 32·2)*
–0·1% 
(–2·4 to 2·0)
2 High body-mass index: all 
causes
3470 
(2110 to 5030)
4720 
(2990 to 
6700)
36·3% 
(31·9 to 42·5)*
2·3% 
(–0·9 to 7·2)
108 000 
(69 000 to 
153 000)
148 000 
(98 600 to 
202 000)
36·7% 
(31·5 to 44·5)*
6·8% 
(2·6 to 13·0)*
·· Oesophageal cancer 61 
(20 to 121)
81 
(27 to 153)
32·7% 
(24·0 to 45·1)*
0·3% 
(–6·4 to 9·8)
1470 
(464 to 2860)
1900 
(622 to 3530)
29·7% 
(20·9 to 42·0)*
–0·5% 
(–7·3 to 9·0)
·· Colon and rectum cancer 54 
(29 to 84)
73 
(41 to 114)
36·4% 
(32·2 to 41·7)*
2·4% 
(–0·8 to 6·4)
1210 
(662 to 1880)
1640 
(920 to 2500)
35·4% 
(30·6 to 41·1)*
3·9% 
(0·3 to 8·2)*
·· Liver cancer due to 
hepatitis B
26 
(9 to 55)
40 
(15 to 79)
56·1% 
(42·2 to 86·2)*
21·5% 
(10·8 to 44·8)*
794 
(264 to 1690)
1210 
(429 to 2390)
51·8% 
(37·3 to 82·8)*
20·7% 
(9·1 to 45·2)*
·· Liver cancer due to 
hepatitis C
21 
(8 to 40)
31 
(12 to 58)
52·0% 
(44·1 to 64·6)*
14·0% 
(8·0 to 23·3)*
467 
(181 to 895)
705 
(286 to 1310)
51·0% 
(42·5 to 64·4)*
15·2% 
(8·7 to 25·3)*
·· Liver cancer due to alcohol 
use
13 
(5 to 25)
19 
(8 to 37)
50·8% 
(43·4 to 61·8)*
15·0% 
(9·2 to 23·2)*
317 
(123 to 630)
471 
(189 to 905)
48·9% 
(40·6 to 61·0)*
15·4% 
(9·2 to 24·6)*
·· Liver cancer due to other 
causes
5 
(2 to 10)
8 
(3 to 15)
59·4% 
(47·8 to 80·2)*
22·7% 
(13·8 to 38·2)*
142 
(52 to 285)
220 
(85 to 413)
54·7% 
(42·4 to 77·2)*
22·0% 
(12·5 to 39·1)*
·· Gallbladder and biliary tract 
cancer
20 
(10 to 34)
27 
(14 to 44)
32·7% 
(27·8 to 39·0)*
–1·2% 
(–4·9 to 3·5)
422 
(219 to 694)
561 
(299 to 897)
33·0% 
(27·0 to 39·9)*
1·3% 
(–3·2 to 6·6)
·· Pancreatic cancer 19 
(7 to 35)
27 
(11 to 51)
47·2% 
(43·5 to 51·8)*
10·0% 
(7·1 to 13·6)*
398 
(153 to 758)
577 
(225 to 1090)
45·2% 
(41·2 to 49·9)*
10·7% 
(7·7 to 14·3)*
·· Breast cancer 26 
(10 to 48)
40 
(16 to 71)
54·8% 
(39·2 to 88·4)*
11·1% 
(–0·3 to 30·8)
487 
(125 to 983)
817 
(267 to 1530)
67·7% 
(45·5 to 153·1)*
16·2% 
(1·2 to 52·4)*
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·· Uterine cancer 25 
(17 to 34)
33 
(23 to 44)
30·8% 
(25·9 to 37·6)*
–1·7% 
(–5·3 to 3·2)
642 
(426 to 869)
842 
(584 to 1120)
31·2% 
(25·5 to 38·8)*
0·7% 
(–3·5 to 6·3)
·· Ovarian cancer 4 
(0 to 10)
6 
(0 to 13)
34·5% 
(22·4 to 39·8)*
1·8% 
(–5·1 to 5·8)
111 
(0 to 251)
149 
(0 to 334)
35·1% 
(22·6 to 41·2)*
4·9% 
(–4·4 to 9·5)
·· Kidney cancer 20 
(12 to 30)
27 
(16 to 40)
36·7% 
(32·4 to 42·0)*
3·0% 
(–0·3 to 7·0)
464 
(275 to 690)
619 
(370 to 911)
33·5% 
(29·0 to 39·3)*
2·6% 
(–0·8 to 7·1)
·· Thyroid cancer 3 
(1 to 5)
4 
(2 to 7)
43·9% 
(37·0 to 51·7)*
9·3% 
(3·9 to 15·2)*
81 
(39 to 136)
116 
(57 to 191)
43·1% 
(35·6 to 51·8)*
12·2% 
(6·3 to 18·8)*
·· Non-Hodgkin lymphoma 9 
(4 to 17)
13 
(6 to 24)
40·2% 
(36·2 to 46·1)*
6·4% 
(3·1 to 11·2)*
238 
(100 to 427)
330 
(144 to 591)
38·9% 
(34·5 to 44·6)*
9·0% 
(5·6 to 13·6)*
·· Multiple myeloma 5 
(2 to 10)
8 
(3 to 13)
41·2% 
(35·8 to 47·8)*
5·7% 
(1·6 to 10·9)*
119 
(52 to 210)
168 
(75 to 291)
41·0% 
(35·4 to 47·9)*
7·7% 
(3·4 to 13·2)*
·· Acute lymphoid leukaemia 2 
(1 to 3)
2 
(1 to 4)
44·4% 
(35·2 to 52·4)*
15·2% 
(8·0 to 21·4)*
56 
(26 to 98)
79 
(39 to 135)
40·9% 
(31·9 to 49·9)*
17·0% 
(9·6 to 24·2)*
·· Chronic lymphoid 
leukaemia
2 
(1 to 4)
3 
(2 to 5)
25·5% 
(21·2 to 30·2)*
–7·8% 
(–10·9 to –4·2)*
48 
(24 to 79)
60 
(31 to 98)
25·9% 
(21·8 to 30·5)*
–4·9% 
(–8·0 to –1·4)*
·· Acute myeloid leukaemia 5 
(3 to 9)
7 
(4 to 12)
36·3% 
(31·4 to 42·2)*
4·7% 
(0·9 to 9·2)*
138 
(67 to 231)
184 
(92 to 303)
33·3% 
(27·8 to 39·6)*
6·2% 
(2·0 to 11·1)*
·· Chronic myeloid leukaemia 2 
(1 to 3)
2 
(1 to 3)
10·2% 
(6·3 to 15·6)*
–15·9% 
(–18·8 to –11·7)*
40 
(19 to 68)
43 
(21 to 72)
8·9% 
(4·5 to 15·0)*
–13·2% 
(–16·6 to –8·5)*
·· Other leukaemia 7 
(3 to 12)
8 
(4 to 14)
26·6% 
(21·2 to 34·8)*
–3·1% 
(–7·0 to 2·7)
175 
(80 to 311)
215 
(103 to 364)
22·9% 
(16·1 to 32·8)*
–1·8% 
(–6·9 to 5·6)
·· Ischaemic heart disease 1270 
(750 to 1890)
1630 
(985 to 2380)
28·0% 
(24·4 to 32·6)*
–3·7% 
(–6·1 to 0·0)
30 800 
(19 100 to 
44 100)
39 300 
(25 300 to 55 000)
27·6% 
(23·6 to 33·4)*
–0·6% 
(–3·7 to 4·2)
·· Ischaemic stroke 259 
(143 to 394)
324 
(184 to 493)
25·3% 
(20·9 to 30·2)*
–5·4% 
(–8·2 to –1·8)*
7410 
(4430 to 10 900)
10 100 
(6190 to 14 600)
36·4% 
(31·2 to 43·2)*
5·3% 
(1·3 to 10·5)*
·· Intracerebral haemorrhage 487 
(279 to 736)
622 
(380 to 907)
27·7% 
(20·8 to 37·3)*
–1·2% 
(–6·5 to 6·4)
14 900 
(8960 to 21 400)
18 900 
(12 000 to 26 000)
27·0% 
(19·9 to 37·1)*
0·5% 
(–5·3 to 8·6)
·· Subarachnoid haemorrhage 93 
(59 to 132)
119 
(79 to 164)
27·6% 
(21·7 to 34·5)*
1·0% 
(–3·8 to 6·6)
3510 
(2300 to 4800)
4420 
(3010 to 5900)
26·0% 
(20·4 to 33·2)*
2·2% 
(–2·6 to 8·1)
·· Hypertensive heart disease 213 
(118 to 332)
327 
(176 to 522)
53·8% 
(36·3 to 65·3)*
13·7% 
(1·6 to 21·2)*
4690 
(2930 to 6620)
6830 
(4290 to 9600)
45·7% 
(32·0 to 56·2)*
12·3% 
(1·9 to 20·2)*
·· Atrial fibrillation and flutter 39 
(22 to 61)
60 
(34 to 93)
53·5% 
(49·2 to 59·2)*
6·6% 
(3·5 to 11·0)*
907 
(487 to 1450)
1310 
(712 to 2070)
44·6% 
(41·3 to 49·1)*
6·8% 
(4·3 to 10·3)*
·· Asthma 58 
(28 to 106)
72 
(38 to 126)
23·9% 
(13·7 to 38·8)*
–5·4% 
(–13·3 to 6·4)
2800 
(1540 to 4510)
3550 
(2050 to 5580)
27·0% 
(19·4 to 36·1)*
3·3% 
(–3·8 to 11·6)
·· Gallbladder and biliary 
diseases
24 
(15 to 35)
34 
(22 to 49)
41·8% 
(36·7 to 49·6)*
3·6% 
(–0·2 to 9·4)
453 
(282 to 653)
611 
(391 to 866)
35·0% 
(28·5 to 44·2)*
4·0% 
(–0·9 to 10·9)
·· Alzheimer’s disease and 
other dementias
207 
(77 to 395)
319 
(121 to 599)
54·1% 
(49·4 to 61·7)*
5·8% 
(2·0 to 11·7)*
2640 
(1030 to 5050)
3900 
(1580 to 7270)
47·6% 
(43·1 to 54·7)*
5·9% 
(2·4 to 11·6)*
·· Type 1 diabetes mellitus 271 
(186 to 363)
422 
(299 to 552)
55·7% 
(49·7 to 64·0)*
16·6% 
(12·0 to 23·0)*
20 600 
(13 500 to 
29 500)
31 100 
(21 400 to 43 000)
50·7% 
(42·7 to 61·5)*
19·3% 
(13·0 to 27·8)*
·· Chronic kidney disease due 
to type 2 diabetes mellitus
67 
(32 to 112)
109 
(54 to 177)
62·3% 
(52·2 to 75·4)*
20·2% 
(13·8 to 29·2)*
1800 
(857 to 2940)
2840 
(1400 to 4450)
58·2% 
(48·9 to 71·5)*
19·4% 
(13·3 to 27·9)*
·· Chronic kidney disease due 
to hypertension
63 
(27 to 116)
100 
(44 to 180)
59·0% 
(50·2 to 70·2)*
15·9% 
(10·3 to 26·0)*
1510 
(725 to 2590)
2330 
(1180 to 3780)
54·7% 
(45·4 to 67·0)*
17·4% 
(11·4 to 26·3)*
·· Chronic kidney disease due 
to glomerulonephritis
37 
(17 to 62)
55 
(26 to 90)
47·0% 
(38·4 to 58·2)*
11·9% 
(7·5 to 18·0)*
1160 
(451 to 2030)
1650 
(692 to 2760)
42·0% 
(33·8 to 54·8)*
12·3% 
(7·8 to 18·7)*
·· Chronic kidney disease due 
to other and unspecified 
causes
48 
(22 to 80)
75 
(35 to 120)
53·7% 
(44·5 to 66·6)*
16·0% 
(10·4 to 24·2)*
1850 
(806 to 3110)
2710 
(1260 to 4380)
46·9% 
(38·5 to 59·5)*
14·4% 
(8·7 to 22·4)*
·· Cataract ·· ·· ·· ·· 304 
(130 to 581)
456 
(207 to 847)
49·9% 
(43·0 to 61·0)*
13·2% 
(7·9 to 21·8)*
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·· Osteoarthritis ·· ·· ·· ·· 1360 
(520 to 2920)
2030 
(801 to 4370)
49·2% 
(43·8 to 58·0)*
14·3% 
(10·2 to 21·0)*
·· Low back pain ·· ·· ·· ·· 3250 
(1690 to 5610)
4370 
(2350 to 7400)
34·4% 
(30·1 to 40·1)*
9·1% 
(5·8 to 13·4)*
·· Gout ·· ·· ·· ·· 284 
(142 to 490)
419 
(216 to 706)
47·8% 
(42·8 to 55·0)*
15·6% 
(11·8 to 21·2)*
2 Low bone mineral density: 
all causes
245 
(226 to 256)
327 
(308 to 347)
33·7% 
(27·2 to 41·0)*
–2·7% 
(–7·3 to 2·6)
7850 
(6660 to 9210)
10 300 
(8690 to 12 200)
31·5% 
(28·1 to 34·8)*
–0·9% 
(–3·3 to 1·5)
·· Pedestrian road injuries 29 
(28 to 32)
33 
(31 to 36)
13·9% 
(5·3 to 19·6)*
–14·5% 
(–21·1 to –10·2)*
780 
(704 to 857)
886 
(792 to 981)
13·6% 
(6·5 to 18·8)*
–12·5% 
(–18·1 to –8·7)*
·· Cyclist road injuries 3 
(3 to 4)
4 
(4 to 4)
27·6% 
(17·0 to 36·2)*
–2·4% 
(–10·7 to 4·1)
166 
(135 to 198)
218 
(177 to 263)
31·6% 
(25·8 to 36·5)*
1·4% 
(–2·9 to 5·0)
·· Motorcyclist road injuries 6 
(5 to 7)
8 
(7 to 9)
25·9% 
(7·9 to 36·3)*
–1·5% 
(–15·6 to 6·7)
319 
(269 to 373)
406 
(334 to 483)
27·2% 
(16·4 to 33·6)*
0·3% 
(–8·2 to 5·1)
·· Motor vehicle road injuries 18 
(17 to 20)
22 
(19 to 24)
17·1% 
(8·4 to 21·8)*
–10·8% 
(–17·6 to –7·3)*
610 
(534 to 683)
709 
(615 to 800)
16·3% 
(9·9 to 20·1)*
–9·6% 
(–14·6 to –6·9)*
·· Other road injuries 1 
(1 to 1)
1 
(1 to 1)
18·1% 
(7·6 to 36·0)*
–10·9% 
(–19·0 to 2·2)
84 
(64 to 109)
132 
(99 to 175)
57·0% 
(51·0 to 62·7)*
19·2% 
(14·8 to 23·3)*
·· Other transport injuries 8 
(7 to 9)
9 
(8 to 10)
18·6% 
(13·6 to 27·6)*
–9·4% 
(–13·3 to –2·5)*
481 
(397 to 585)
616 
(500 to 762)
28·1% 
(24·6 to 32·0)*
–1·1% 
(–3·6 to 1·8)
·· Falls 169 
(154 to 176)
238 
(223 to 256)
41·1% 
(32·6 to 52·0)*
0·6% 
(–5·3 to 8·2)
4810 
(4010 to 5760)
6590 
(5500 to 7860)
37·0% 
(32·6 to 42·2)*
1·5% 
(–1·6 to 5·3)
·· Other exposure to 
mechanical forces
7 
(6 to 8)
9 
(7 to 10)
21·4% 
(15·6 to 27·3)*
–9·0% 
(–13·2 to –4·4)*
443 
(347 to 562)
582 
(447 to 752)
31·5% 
(27·8 to 34·8)*
0·9% 
(–1·6 to 3·2)
·· Non-venomous animal 
contact
1 
(0 to 1)
1 
(1 to 1)
17·9% 
(4·3 to 37·3)*
–11·3% 
(–21·4 to 3·2)
50 
(36 to 69)
62 
(44 to 88)
24·1% 
(17·5 to 30·2)*
–5·9% 
(–10·7 to –1·2)*
·· Assault by other means 3 
(2 to 3)
3 
(3 to 3)
7·2% 
(–1·0 to 13·8)
–17·8% 
(–24·0 to –12·7)*
114 
(97 to 134)
132 
(109 to 158)
16·1% 
(10·9 to 20·0)*
–10·6% 
(–14·3 to –7·7)*
2 Impaired kidney function: 
all causes
2040 
(1880 to 2210)
2590 
(2390 to 
2800)
26·6% 
(23·6 to 29·7)*
–5·8% 
(–7·9 to –3·7)*
51 000 
(47 300 to 
54 900)
61 300 
(56 900 to 66 100)
20·3% 
(17·9 to 22·9)*
–5·4% 
(–7·3 to –3·5)*
·· Ischaemic heart disease 716 
(593 to 844)
882 
(726 to 1050)
23·2% 
(17·7 to 28·8)*
–10·5% 
(–14·1 to –6·8)*
12 500 
(10 700 to 
14 400)
14 900 
(12 800 to 17 200)
18·9% 
(14·6 to 23·8)*
–9·7% 
(–12·9 to –6·1)*
·· Ischaemic stroke 187 
(137 to 239)
223 
(162 to 288)
19·0% 
(13·2 to 24·8)*
–12·9% 
(–15·9 to –9·9)*
3760 
(3010 to 4550)
4650 
(3750 to 5700)
23·7% 
(19·0 to 28·9)*
–6·6% 
(–9·9 to –3·2)*
·· Intracerebral haemorrhage 214 
(175 to 257)
243 
(199 to 293)
13·7% 
(9·2 to 18·0)*
–14·3% 
(–17·2 to –11·5)*
4970 
(4090 to 5860)
5530 
(4580 to 6550)
11·4% 
(7·6 to 15·4)*
–13·9% 
(–16·6 to –11·4)*
·· Peripheral vascular disease 6 
(4 to 11)
10 
(5 to 18)
52·4% 
(25·2 to 73·7)*
11·5% 
(–7·5 to 26·5)
184 
(121 to 278)
257 
(166 to 398)
39·9% 
(23·4 to 55·0)*
5·7% 
(–6·6 to 16·8)
·· Chronic kidney disease due 
to type 1 diabetes mellitus
63 
(51 to 76)
77 
(62 to 95)
23·2% 
(19·0 to 27·4)*
–1·2% 
(–4·0 to 1·2)
2440 
(2010 to 2950)
2890 
(2370 to 3500)
18·2% 
(14·3 to 22·3)*
–2·6% 
(–5·1 to –0·3)*
·· Chronic kidney disease due 
to type 2 diabetes mellitus
248 
(219 to 282)
349 
(307 to 396)
40·5% 
(36·4 to 43·6)*
4·2% 
(1·4 to 6·2)*
6050 
(5290 to 6850)
8120 
(7120 to 9250)
34·3% 
(30·9 to 37·2)*
2·3% 
(–0·2 to 4·2)
·· Chronic kidney disease due 
to hypertension
246 
(216 to 276)
347 
(305 to 391)
41·4% 
(37·4 to 44·2)*
3·2% 
(0·4 to 5·2)*
5550 
(4900 to 6230)
7350 
(6450 to 8220)
32·4% 
(29·0 to 35·0)*
2·1% 
(–0·3 to 4·1)
·· Chronic kidney disease due 
to glomerulonephritis
151 
(132 to 172)
190 
(165 to 217)
25·5% 
(22·1 to 28·8)*
–1·3% 
(–3·2 to 0·7)
5800 
(5180 to 6450)
6600 
(5860 to 7420)
13·8% 
(11·0 to 17.0)*
–4·4% 
(–6·3 to –2·4)*
·· Chronic kidney disease due 
to other and unspecified 
causes
212 
(186 to 239)
267 
(233 to 304)
25·9% 
(22·4 to 29·4)*
–1·4% 
(–3·7 to 0·6)
9580 
(8570 to 10 700)
10 900 
(9660 to 12 200)
13·3% 
(10·4 to 16·2)*
–6·0% 
(–8·0 to –4·1)*
·· Gout ·· ·· ·· ·· 135 
(91 to 187)
191 
(130 to 265)
41·5% 
(35·7 to 47·7)*
6·3% 
(2·1 to 10·7)*
Results are for both sexes combined. Data in parentheses are 95% uncertainty intervals. *Statistically significant increase or decrease. DALYs=disability-adjusted life-years. 
Table 3: Global all-age attributable deaths and DALYs, 2007–17, and percentage change of deaths and DALYs and age-standardised death rates and DALY rates, 2007–17, for all 
risk-outcome pairs
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1963
Among injuries, 1·09 million (0·99–1·19) deaths and 
55·9 million (49·6–62·5) DALYs were attributable to 
risks in 2017. The five leading injury causes of risk-
attributable DALYs were falls, self-harm by other 
specified means, motor vehicle road injuries, pedestrian 
road injuries, and motorcyclist road injuries. In 2017, 
34·1% (95% UI 30·7–38·2) of DALYs and 43·4% 
(40·6–46·6) of deaths from falls were risk attributable, 
resulting in 12·2 million (9·93–15·0) risk-attributable 
DALYs and 302 000 (275 000–330 000) risk-attributable 
deaths from falls. Self-harm by other specified means 
had 8·07 million (5·50–10·7) risk-attributable DALYs 
(25·7% [17·6–33·9] of all DALYs from self-harm by other 
specified means), motor vehicle road injuries had 
5·95 million (5·19–6·70; 24·2% [21·3–27·0] of all motor 
vehicle road injury DALYs), pedestrian road injuries 
had 5·50 million (4·76–6·28; 23·4% [20·8–26·1] of 
pedestrian road injury DALYs), and motorcyclist road 
injuries had 4·05 million (3·46–4·64; 29·0% [25·3–32·4] 
of motorcyclist road injury DALYs).
Levels and trends in the burden attributable to risk 
factors
In 2017, 34·1 million (95% UI 33·3–35·0) deaths and 
1·21 billion (1·14–1·28) DALYs were attributable to 
GBD risk factors (table 3). Between 2007 and 2017, the 
number of all-age risk-attributable YLLs declined from 
1·04 billion (1·02–1·07) to 944 million (922–968), and age-
standardised YLL rates declined from 16 359 (16 005–16 748) 
per 100 000 to 12 509 (12 205–12 837) per 100 000. Age-
standardised risk-attri butable death rates declined from 
531 (520–544) per 100 000 in 2007 to 448 (437–460) per 
100 000 in 2017. Conversely, during that period, the absolute 
number of risk-attributable deaths increased from 
31·5 million (30·9–32·2) to 34·1 million (33·3–35·0). 
During the same period, there was no significant trend in 
risk-attributable non-fatal burden because there was no 
statistically significant trend in non-fatal burden: age-
standard ised risk-attributable YLD rates were 3442 
(2593–4374) per 100 000 in 2007 and 3357 (2528–4275) 
per 100 000 in 2017; and the absolute numbers of risk-
attributable YLDs were 227 million (170–288) in 2007 and 
263 million (198–336) in 2017. The largest percentage 
declines in the number of risk-attributable DALYs are for 
measles; the largest per centage increases are for 
osteoarthritis. Globally in 2017, high SBP was the leading 
risk factor, accounting for 10·4 million (9·39–11·5) deaths 
and 218 million (198–237) DALYs, followed by smoking 
(7·10 million [6·83–7·37] deaths and 182 million [173–193] 
DALYs), high FPG (6·53 million [5·23–8·23] deaths and 
171 million [144–201] DALYs), high BMI (4·72 million 
[2·99–6·70] deaths and 148 million [98·6–202] DALYs), 
and short gestation (1·43 million [1·36–1·51] deaths and 
139 million [131–147] DALYs; table 3).
Behavioural risk factors accounted for 43·6% (95% UI 
41·7–45·5) of all DALYs in 1990, followed by environ-
mental and occupational risk factors at 17·4% (15·9–19·0) 
and metabolic at 10·3% (9·63–11·1). Between 1990 
and 2017, these percentages declined by 16·2% for 
behavioural risk factors, which accounted for 36·5% 
(34·7–38·4) of all DALYs in 2017, and 29·3% for environ-
mental and occupational risks, which accounted for 
12·3% (11·5–13·3) in 2017. Proportions increased by 
63·7% for metabolic risks, which accounted for 16·9% 
(15·6–18·3) of all DALYs in 2017.
The proportion of all DALYs attributable to each Level 1 
risk also varies with SDI (appendix 2). Metabolic risks 
accounted for increasingly large proportions of DALYs 
with increasing levels of SDI, up to high-middle SDI: 
metabolic risks accounted for 8·31% (95% UI 7·69–9·00) 
of DALYs in low SDI, 13·6% (12·6–14·7) in low-middle 
SDI, 21·3% (19·6–23·0) in middle SDI, 24·8% 
(22·7–27·2) in high-middle SDI, and 20·7% (18·4–23·1) 
in high SDI countries. Conversely, both behavioural and 
environmental and occupational risks accounted for 
smaller proportions of DALYs in higher SDI regions. 
Behavioural risks accounted for 38·8% (37·2–40·4) of 
DALYs in low SDI, 38·5% (36·8–40·2) in low-middle 
SDI, 35·2% (33·2–37·2) in middle SDI, 37·4% 
(34·9–39·7) in high-middle SDI, and 30·2% (28·1–32·4) 
in high SDI countries. Environmental and occupational 
risks accounted for 16·9% (15·6–18·3) of DALYs in 
low SDI, 14·1% (13·0–15·3) in low-middle SDI, 11·1% 
(10·2–12·0) in middle SDI, 9·61% (8·85–10·4) in high-
middle SDI, and 6·56% (5·92–7·23) in high SDI 
countries (appendix 2).
Changes in leading risk factors
Between 1990 and 2017, high SBP was consistently 
responsible for the largest number of all-cause deaths, 
followed by smoking then high FPG. The fourth leading 
risk for mortality in 1990 was child wasting, which was in 
21st position in 2017. The fourth leading risk for mortality 
in 2017 was high BMI, which increased in rank from 
1990 when it was ninth. High LDL cholesterol remained 
the fifth leading cause of risk-attributable deaths in 1990 
and 2017. These rankings and trends differ for DALYs. In 
1990, the five leading risks for DALYs were child wasting, 
short gestation, low birthweight, smoking, and high 
SBP, whereas in 2017, the leading five risks were high 
SBP, smoking, high FPG, high BMI, and short gestation 
(figure 2A).
Leading risks differ for males and females. For males, 
the leading risks in 2017 were (in order of descending 
rank) smoking, high SBP, high FPG, alcohol use, and 
short gestation; the leading risks for females were high 
SBP, high FPG, high BMI, short gestation, and low 
birthweight. Three of the five leading risks for males 
were behavioural risks, whereas three of the five leading 
risks for females were metabolic risks (figure 2B, C).
DALY-based ranks for all metabolic risks increased 
between 1990 and 2017 for both males and females, 
whereas changes in ranks were more heterogeneous for 
environmental and occupational and behavioural risks. In 
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Leading risks 1990 Leading risks 2007 Leading risks 2017
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1 High systolic blood pressure
2 Smoking
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12 High sodium
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2 Short gestation for birthweight
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1990, six of the ten leading risks were behavioural risks, 
three were environmental, and one was metabolic. Of 
the ten leading risks in 2017 for both sexes, five were 
behavioural, four were metabolic, and only one was 
environ mental. Broadly, in terms of their relative impor-
tance, metabolic risks rose in rank whereas environ-
mental and occupational risks fell. Within behavioural 
risks, 13 of the 15 dietary risks increased rank. Appendix 2 
shows trends in leading risk factors within each SDI 
quintile and trends in leading risk factors for deaths and 
DALYs by location.
Drivers of changes in risk-attributable burden
Changes in the absolute number of DALYs over time are 
the result of changes in six underlying components: 
(1) population growth; (2) population ageing; (3) changes 
in exposure to environmental and occupational risks; 
(4) changes in exposure to behavioural risks; (5) changes in 
exposure to metabolic risks; and (6) changes due to all 
other (ie, risk-deleted or residual) factors. Figure 3 shows 
the changes in these components for each Level 1 cause, 
and for all causes combined (for Level 2 causes, see 
appendix 2). Broadly, in the absence of demographic 
changes, changes in risk exposure and risk-deleted DALYs 
would have led to a 23·5% decline in DALYs between 2007 
and 2017 in both sexes. Conversely, in the absence of 
changes in risk exposure and risk-deleted DALYs, 
demographic changes would have led to an 18·6% increase 
in DALYs during that period. Comparing drivers of change 
for males and females, females have generally had greater 
declines in risk exposure: the aggregate effect of changes 
in exposure across all risks would have led to a 6·93% 
decline in DALYs from all causes for males, versus a 9·08% 
decline for females (figure 3).
Of all individual risk categories, changes in exposure 
to behavioural risks have driven the largest change in 
burden: declines in exposure to these risks would have 
resulted in a 7·41% decline in DALYs from all causes in 
both sexes combined. For both males and females, 
changing exposures to behavioural risks drove declines 
for NCDs and CMNNDs and increases for injuries 
(figure 3). Changes in exposure to environmental and 
occupational risks would have resulted a 2·59% decline 
in DALYs from all causes for both sexes, and it is the 
only risk category that was a driver of decline for all 
cause groups and both sexes. Conversely, in the absence 
of changes from other drivers, changes in metabolic 
risks would have resulted in a 2·15% increase in all-
cause DALYs for both sexes.
Among the three cause groups, CMNNDs are the only 
Level 1 cause group for which combined effects of 
improve ments in risk exposure and risk-deleted burden 
have outweighed the effects of demographic changes 
for both males and females. Declines in risk exposure 
would have resulted in a 12·0% decline in DALYs 
from CMNNDs among males and a 14·8% decline in 
females. For NCDs, increasing exposure to metabolic 
risks has largely offset health gains from improvements 
in environ mental and behavioural risks. In aggregate, 
changes in risk exposure would have resulted in a 
2·83% decline in DALYs from NCDs in males and a 
2·29% decline in females. Among both males and 
females, changes in exposure to environ mental risks, 
behavioural risks, and all risks combined would have 
resulted in reduced injury burden.
Drivers of changes in risk-attributable DALYs were 
spatially heterogeneous (figure 4). Broadly, population 
Figure 2: Leading 15 Level 4 risk factors by attributable DALYs at the global 
level, 1990, 2007, and 2017, for both sexes (A), females (B), and males (C)
Risks are connected by lines between time periods; solid lines are increases and 
dashed lines are decreases. Statistically significant increases or decreases are 
shown in bold (p<0·05). DALYs=disability-adjusted life-years. LDL=low-density 
lipoprotein.
Figure 3: Percentage change in risk-attributable DALYs at the global level in 2007–17, due to population 
growth, population ageing, changes in exposure to Level 1 risk factors, and changes in risk-deleted DALY 
rates, for females, males, and both sexes
Results are shown for all causes combined, CMNNDs, NCDs, and injuries. The black dot on each bar shows total 
percentage change. The risk-deleted DALY rate is the expected DALY rate if the exposure level for all risk factors 
were reduced to the theoretical minimum risk exposure level. Changes in the risk-deleted rate might result from 
changes in risks and risk–outcome pairs that are not currently included in the Global Burden of Diseases, Injuries, 
and Risk Factors Study or changes in other factors such as treatment. The change in CMNNDs and injuries due to 
metabolic risk exposure for both males and females is not zero but is too small to visualise because of the small 
number of risk–outcome pairs. CMNNDs=communicable, maternal, neonatal, and nutritional diseases. 
DALYs=disability-adjusted life-years. NCDs=non-communicable diseases.
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growth has driven increases in risk-attributable DALYs 
across most locations except for Eastern Europe, Cuba, 
Greenland, Guyana, Japan, and Portugal. Population 
ageing has driven increases in most locations, with notable 
exceptions in central, eastern, and western sub-Saharan 
Africa, and parts of the Middle East and south and southeast 
Asia. Conversely, all-cause risk-deleted DALY rates have 
declined across most locations; however, they have 
increased in a number of subnational locations in Brazil, 
China, the UK, India, Mexico, and the USA. Broadly, 
DALYs attributable to metabolic risk exposure have 
increased in most locations and DALYs attributable to 
environmental and occupational and behavioural risks 
have largely declined.
Observed versus expected summary exposure values
Estimating the expected SEV for a given risk factor at a 
given level of SDI, a comparison can be made between 
observed exposure levels in a given place and time and 
their expected levels based on SDI. An observed to 
expected ratio (O/E ratio) of 1·0 indicates that observed 
exposure levels equal our expectation; O/E ratios less 
than 1·0 indicate that observed exposures are better than 
expected (ie, at levels associated with lower risk); 
and O/E ratios greater than 1·0 indicate that observed 
exposures are worse than expected (ie, at levels associated 
with greater risk).
Across leading environmental risks, O/E ratios for 
ambient particulate matter pollution showed no 
consistent trends across regions, whereas there were 
nearly univer sal increases in O/E ratios for household air 
pollution and unsafe water (figure 5A). In 2017, O/E ratios 
for ambient particulate matter pollution were notably 
high in north Africa and Middle East (2·03) and south 
Asia (1·81). O/E ratios for household air pollution were 
notably high in southeast Asia, east Asia, and Oceania 
(3·05) and central Europe, eastern Europe, and central 
Asia (1·73). Between 1990 and 2017, O/ E ratios for unsafe 
water increased across all super-regions, with the largest 
changes in southeast Asia, east Asia, and Oceania (85·6% 
increase; ratio of 1·75 in 2017), north Africa and Middle 
East (57·8% increase; ratio of 1·02 in 2017), and south 
Asia (55·5% increase; ratio of 1·41 in 2017).
Among the leading behavioural risks between 1990 
and 2017, there were near universal declines in O/E ratios 
for both smoking and alcohol use, and incon sistent 
trends in O/E ratios for low birthweight (figure 5B). 
The range of O/E ratios between regions is especially 
broad for alcohol use. These ratios were consis tently 
high in sub-Saharan Africa (O/E ratios declined from 
2·10 to 1·49 between 1990 and 2017), Latin America and 
the Caribbean (ratios declined from 1·83 to 1·54), and 
central Europe, eastern Europe, and central Asia (ratios 
declined from 1·82 to 1·68). O/E ratios for alcohol use 
were consistently the lowest in north Africa and the 
Middle East, declining from 0·38 to 0·21 between 1990 
and 2017.
Trends in O/E ratios for leading metabolic risks 
were hetero geneous across super-regions (figure 5C). 
For high SBP, O/E ratios improved by more than 5% 
between 1990 and 2017 for two super-regions: 27·1% 
decrease in the high-income region and 8·05% in the 
central Europe, eastern Europe, and central Asia region. 
By contrast, ratios for high SBP increased by more than 
5% in three super-regions: 22·0% in sub-Saharan 
Africa, 16·4% in southeast Asia, east Asia, and Oceania, 
and 9·67% in south Asia. In 2017, ratios for high SBP 
were highest in sub-Saharan Africa (1·19) and central 
Europe, eastern Europe, and central Asia (1·19) and 
were lowest in the high-income region (0·77). O/E 
ratios increased for both high FPG and high BMI across 
all super-regions between 1990 and 2017. The north 
Africa and Middle East region stands out as having the 
highest O/E ratios for both high FPG and high BMI 
across many years.
Expected attributable burden
Broadly, total expected risk-attributable burden declines 
with increasing SDI (figure 6). At an SDI of 0·1, we 
expect 101 000 risk-attributable DALYs per 100 000 males 
and 90 600 per 100 000 females; at an SDI of 0·5, we 
expect 20 200 per 100 000 males and 16 300 per 
100 000 females; and at an SDI of 0·9, we expect 
15 900 per 100 000 among males and 9640 per 100 000 
among females.
Increasing SDI was associated with dramatic declines 
in the expected burden attributable to environmental 
risks in both sexes: the expected burden attributable to 
environ mental risks declines from 41 600 DALYs 
per 100 000 people (31·6% of total burden) with an SDI of 
0·1 to 1870 DALYs per 100 000 people (10·6% of total 
burden) with an SDI of 0·9. The pat tern for behavioural 
risks was more complex and heterogeneous. Although 
the expected burden attribu table to malnutrition declined 
with increasing SDI, the expected burden attributable to 
tobacco use, drug use, alcohol use, and most dietary risks 
generally increased with increasing SDI. At an SDI value 
of 0·1, behavioural risks accounted for 65·0% of the total 
expected risk-attributable burden, at an SDI of 0·75 they 
accounted for 51·5%, and at an SDI of 0·9 they accounted 
Figure 4: Percentage change in the absolute number of all-cause 
risk-attributable DALYs for both sexes, by location, 2007–17
Changes due to population growth (A), population ageing (B), changes in 
risk-deleted DALY rates (C), changes in exposure to environmental and 
occupational risk factors (D), changes in exposure to behavioural risk factors (E), 
and changes in exposure to metabolic risk factors (F). The risk-deleted DALY rate 
is the expected DALY rate if the exposure level for all risk factors were reduced to 
the theoretical minimum risk exposure level. Changes in the risk-deleted rate 
might result from changes in risks and risk–outcome pairs not included in the 
Global Burden of Diseases, Injuries, and Risk Factors Study or changes in other 
factors such as treatment. ATG=Antigua and Barbuda. DALYs=disability-adjusted 
life-years. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. 
TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the 
Grenadines.
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for 52·9%. The expected burden attributable to metabolic 
risks increased with increasing SDI up to an SDI of 0·65, 
then declines with increasing SDI above that level. At an 
SDI value of 0·1, metabolic risks accounted for 3·44% of 
the total expected risk-attributable burden, at an SDI of 
0·75 they accounted for 37·6%, and at an SDI of 0·9 they 
accounted for 36·4%.
Observed versus expected attributable burden
In males, the two leading risk factors were smoking and 
high SBP (in varying order) in four of the seven super-
regions (figure 7; appendix 2). The three exceptions were 
sub-Saharan Africa (unsafe sex was the leading risk with 
an O/E ratio of 14·9 followed by child wasting with a ratio 
of 0·71), Latin American and the Caribbean (alcohol use 
with a ratio of 1·19 then high FPG with a ratio of 0·78), 
and the high-income super-region (smoking with a ratio 
of 0·65 then high BMI with a ratio of 0·83). In females, 
the leading risk factors were either high BMI or high 
SBP in four of the seven super-regions (figure 7; 
appendix 2). The three exceptions were sub-Saharan 
Africa (as for males, unsafe sex was the leading risk 
among females, with an O/E ratio of 5·51, followed by 
child wasting with a ratio of 0·63), south Asia (short 
gestation with a ratio of 0·79, followed by high SBP with 
a ratio of 0·79), and the high-income super-region 
(smoking with a ratio of 0·98 followed by high BMI 
with a ratio of 0·91). High FPG was the second leading 
Figure 5: Trends in the ratios of observed SEVs to SEVs expected based on SDI, by super-region, for both sexes, 1990–2017
Trends are for three of the top environmental (A), behavioural (B), and metabolic (C) risk factors by number of attributable DALYs globally. Observed to expected 
ratios are based on age-standardised SEVs. y-axes are on a log scale with the range scaled appropriately for each risk factor. DALYs=disability-adjusted life-years. 
SDI=Socio-demographic Index. SEV=summary exposure value.
1990 201720102000
0·80
1·00
1·25
1990 201720102000
0·50
1·00
1·25
1990 201720102000
0·50
1·00
1·25
Ra
tio
 o
f o
bs
er
ve
d 
to
 e
xp
ec
te
d 
SE
Vs
0·8
1·0
2·0
0·80
1·25
1·00
1·00
0·25
2·00
Ra
tio
 o
f o
bs
er
ve
d 
to
 e
xp
ec
te
d 
SE
Vs
Year Year Year
C Metabolic
B Behavioural
Global Southeast Asia, east Asia, and OceaniaCentral Europe, eastern Europe, and central Asia
High income
Latin America and Caribbean
North Africa and Middle East
South Asia
Sub-Saharan Africa
1·0
0·8
2·0
0·50
1·25
1·00
1·0
0·5
3·0
Ra
tio
 o
f o
bs
er
ve
d 
to
 e
xp
ec
te
d 
SE
Vs
Super-region
Ambient particulate matter pollution Unsafe water source Household air pollution from solid fuels
Smoking Low birthweight for gestation Alcohol use
High systolic blood pressure High body-mass index High fasting plasma glucose
A Environmental and occupational
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1971
risk factor in southeast Asia, east Asia, and Oceania 
(O/E ratio of 0·78) and Latin America and the Caribbean 
(O/E ratio of 0·84) for females. Notably, the O/E ratios 
exceed one for all five leading risk factors for males for 
the central Europe, eastern Europe, and central Asia 
regions, and for nearly all countries within those regions.
The highest O/E ratios for environmental and occu-
pational risks were in southern sub-Saharan Africa and 
south Asia, driven largely by air pollution and unsafe 
water, sanitation, and handwashing in both regions 
(figure 8). For behavioural risks, high O/E ratios were 
recorded in southern sub-Saharan Africa, driven largely 
by higher than expected unsafe sex and intimate partner 
violence, and eastern Europe, largely due to higher than 
expected alcohol and drug use. The burden attributable 
to metabolic risks was higher than expected in Oceania 
and much of the central Europe, eastern Europe, and 
central Asia super-region.
New risks, leading risks, and risks with significant 
changes in GBD 2017
Globally, bullying victimisation is the leading risk factor 
for mental disorder DALYs in 2017 (other risks factors are 
lead exposure, intimate partner violence, and childhood 
sexual abuse) and the 35th leading risk factor of all 
54 risks for all NCDs. However, for major depressive 
disorder, bullying accounts for fewer DALYs than 
childhood sexual abuse or intimate partner violence. In 
2017, 2·57 million (95% UI 1·54–3·97) DALYs were 
attributable to bullying victim isation, by peers, of 
children and adolescents attending school. This was 
distributed relatively evenly between anxiety disorders 
(1·36 million DALYs [0·81–2·13]) and major depressive 
disorder (1·21 million DALYs [0·69–1·94]). Globally, 
bullying victimisation accounted for 5·01% (3·40–6·83) 
of all anxiety disorder DALYs and 3·68% (2·37–5·21) of 
all major depressive disorder DALYs.
In 2017, high SBP was the leading risk factor globally, 
accounting for 10·4 million (95% UI 9·39–11·5) deaths 
and 218 million (198–237) DALYs. Overall, 8·74% 
(7·78–9·68) of total DALYs were attributable to high SBP. 
Most of the burden attributable to high SBP was due to 
ischaemic heart disease and stroke, and high SBP 
accounted for 55·7% (48·1–63·1) of DALYs due to 
ischaemic heart disease and 57·1% (49·4–63·8) of DALYs 
due to stroke. Globally, age-standardised DALY rates 
attributable to high SBP declined between 1990 and 2017 
(25·8% decrease [24·3–27·5]). Notable declines occurred 
in the high-income (54·5% [53·1–56·0] decline), north 
Africa and Middle East (32·6% [28·7–35·7]), and Latin 
America and Caribbean (32·4% [30·7–34·1]) super-
regions.
In 2017, smoking was the second leading risk for both 
deaths and DALYs. It was responsible for 7·10 million 
(95% UI 6·83–7·37) deaths (12·7% [12·2–13·2] of all 
deaths globally) and accounted for 182 million (173–193) 
DALYs (7·31% [6·81–7·80] of all DALYs globally). 
Although smoking-attributable age-standardised mort-
ality rates declined 38·2% (36·4–40·0) between 1990 and 
2017, the total number of smoking-attributable deaths 
has increased by 24·9% (21·3–28·6). In 2017, smoking 
accounted for a larger proportion of deaths among men 
Figure 6: Expected relationship between all-age, all-cause risk-attributable DALY rates and SDI for each GBD Level 2 risk, 1990–2017
Stacked curves show males (left) and females (right) after adjusting for mediation, scaling to account for overlapping risks, and aggregating so that total expected 
DALY rates reflect the true all-cause total expected DALY rates attributable to all risk factors. The y-axis shows lowest SDI (0·09) to highest SDI (0·92) for all 
GBD countries and territories, 1990–2017. Coloured regions are the proportion of the total attributable DALY rate corresponding to that risk factor. 
DALYs=disability-adjusted life-years. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. LDL=low-density lipoprotein. SDI=Socio-demographic Index.
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in high-middle SDI countries (27·1% [26·3–27·9]) than 
in low SDI countries (10·2% [9·23–11·0]; appendix 2). 
Between 1990 and 2017, among men, the percentage of 
all-cause all-age deaths attributable to smoking in high 
SDI countries decreased, whereas it increased in all other 
SDI groups. Levels and trends in smoking prevalence 
and attributable burden vary by gender. As a risk factor 
for all-cause all-age deaths, smoking ranks first among 
men and eighth among women, reflecting both the lower 
prevalence and lower intensity of smoking among 
women. In 2017, the four Level 3 causes with the largest 
number of deaths attributable to smoking were ischaemic 
heart disease (1·62 million [1·54–1·69] deaths), COPD 
(1·23 million [1·12–1·35] deaths), tracheal, bronchus, 
and lung cancer (1·19 million [1·15–1·23] deaths), and 
stroke (887 000 [833 000–944 000] deaths), and together 
account for 69·4% of total smoking-attributable deaths 
(table 3). For lung cancer and COPD, changing from 
Figure 7: Leading five risk factors for DALYs with the ratio of observed to expected DALYs based on Socio-demographic Index, by super-region and region, and by sex, 2017
Number below each risk factor is its observed to expected ratio. Ratios are based on age-standardised DALY rates. BMI=body-mass index. DALYs=disability-adjusted life-years. Ergonomic=occupational 
ergonomic factors. FPG=fasting plasma glucose. LDL=low-density lipoprotein. Household air=household air pollution from solid fuels. Kidney=impaired kidney function. Low birthweight=low 
birthweight for gestation. PM=particulate matter pollution. SBP=systolic blood pressure. Short gestation=short gestation for birthweight. Wasting=child wasting. Water=unsafe water source. *Round 
brackets indicate excluded endpoints whereas square brackets indicate included endpoints.
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indirect estimation using the smoking impact ratio to 
direct estimation using measures of cumulative lifetime 
exposure resulted in large changes in smoking-
attributable burden estimates in countries with scarce or 
low-quality data on lung cancer mortality. At the all-cause 
level, using measures of continuous and cumulative 
exposure that take into account risk among former 
and occasional smokers has resulted in increases in 
attributable burden in 71·8% of countries compared with 
previously published estimates.
In 2017, low birthweight and short gestation was the 
third leading Level 3 risk factor globally for all-age 
DALYs. Age-standardised DALY rates attributable to 
this risk declined from 4558 (95% UI 4347–4739) DALYs 
per 100 000 in 1990 to 2680 (2543–2812) DALYs per 
100 000 in 2017. Although exposure to low birthweight 
and short gestation decreased globally between 1990 
and 2017, most of the declines in risk-attributable 
burden came from declines in mortality from causes 
attributable to this risk. For low birthweight, the biggest 
improvements in risk-attributable mortality were in 
Saudi Arabia, Maldives, and Singapore (appendix 2). 
Increasing SDI was associated with decreasing 
exposure and decreasing attributable burden. Exposure 
and attributable burden were highest in eastern, 
central, and western sub-Saharan Africa. For short 
gestation, the biggest improve ments were in Saudi 
Arabia, Maldives, and Turkey. Similar to low birthweight 
trends, increasing SDI was associated with a decrease 
in exposure, as well as a decrease in attributable burden. 
Exposure and attribut able burden were highest in south 
Asia and eastern, central, and western sub-Saharan 
Africa.
High BMI accounted for 4·72 million (95% UI 
2·99–6·70) deaths and 148 million (98·6–202) DALYs 
globally in 2017 (table 3). It ranked fourth among risk 
factors for mortality, primarily due to the effect of high 
BMI on cardiovascular disease. Globally, the SEV for high 
BMI for both sexes has increased 70·4% (57·1–84·5) 
since 1990 (table 2), and trends among children suggest 
that this will continue to rise. The resulting disease 
burden is large and increasing, with the absolute number 
of DALYs attributable to high BMI increasing by 36·7% 
(31·5–44·5) between 2007 and 2017 and by 127% 
(99·5–172) between 1990 and 2017, and age-standardised 
DALY rates attributable to high BMI increasing 6·84% 
(2·60–13·0) between 2007 and 2017 and 19·3% 
(4·83–43·2) between 1990 and 2017. In 2017, high BMI was 
the leading cause of premature mortality, as measured by 
YLLs, in seven countries and territories: Ecuador, Peru, 
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Figure 8: Ratios of observed to expected attributable DALY rates based on Socio-demographic Index for each Level 1 risk for both sexes by location, 2017
Ratios for environmental and occupational risk factors (A), behavioural risk factors (B), and metabolic risk factors (C). Observed to expected ratios are based on age-standardised DALY rates.
ATG=Antigua and Barbuda. DALYs=disability-adjusted life-years. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and 
the Grenadines. 
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Kuwait, Qatar, Saudi Arabia, United Arab Emirates, and 
American Samoa. Among risk factors assessed in GBD 
2017, BMI prevalence continues to have one of the highest 
rates of increase over time. Trends in BMI prevalence and 
burden exhibit marked geographical variation, with the 
highest levels among wealthier countries.
Globally, high FPG was the third leading risk factor for 
both mortality and DALYs in 2017, accounting for 
6·53 million (95% UI 5·23–8·23) deaths and 171 million 
(144–201) DALYs. Cardio vascular disease was the leading 
Level 2 cause of death due to high FPG, accounting for 
54·5% of deaths attributed to the risk. Diabetes and 
kidney diseases was the second ranking Level 2 cause of 
disability attributable to high FPG and accounted for 
51·9% of DALYs attributable to this risk.
In 2017, 5·25% (95% UI 4·49–6·01) of all deaths were 
attributable to ambient particulate matter pollution, 
making it the eighth leading risk for deaths, with a total 
of 2·94 million (2·50–3·36) deaths globally, and 
1·05 million (0·88–1·22) deaths in southeast Asia, east 
Asia, and Oceania. It has increased from 15th leading 
risk for deaths in 1990, with 1·75 million (1·48–2·03) 
deaths, with a percentage change of 67·7% (56·6–79·3). 
It is among the top ten ranked Level 4 risk factors for 
deaths in 95 of the 195 countries and territories for which 
we produce estimates. Mortality rates attributable to 
ambient particulate matter pollution are notably high in 
Bahrain (11·9% [10·2–13·3] of all deaths were attributable 
to ambient particulate matter; fourth leading risk factor 
for deaths), Egypt (11·8% [9·07–14·4]; sixth leading risk 
factor), and Kuwait (10·6% [8·94–12·3]; sixth leading risk 
factor). The Level 3 causes with the largest proportion of 
burden attributable to ambient particulate matter 
pollution are COPD and lower respiratory infection: 
ambient particulate matter is responsible for 19·3% 
(12·6–25·4) of all COPD DALYs, 17·4% (13·7–21·6) of all 
lower respiratory infection DALYs, and 17·5% (13·2–22·7) 
of lower respiratory infection DALYs in children younger 
than 5 years. In GBD 2017, we added type 2 diabetes as 
an outcome of ambient particulate matter pollution, 
which contributes 10·5 million (6·70–13·9) or 12·6% of 
the 83·0 million (71·4–94·3) DALYs attributable to 
ambient particulate matter pollution in 2017 (table 3).
In 2017, 4·32 million (95% UI 3·33–5·44) deaths and 
94·9 million (78·8–112) DALYs were attributable to high 
LDL cholesterol. Overall, 3·80% (3·14–4·56) of total 
DALYs were attributable to high LDL cholesterol. The age-
standardised DALY rate in males (1480 per 100 000 
[1230–1750]) was higher than in females (880 per 100 000 
[714–1070]). Globally, between 1990 and 2017, age-
standardised DALY rates declined markedly (29·9% 
[28·1–31·7] decline). Notable reductions in age-stan-
dardised DALY rates occurred in both the high-income 
(61·8% [60·4–63·2] decline) and Latin America and 
Caribbean super-regions (40·7% [38·9–42·5] decline).
Globally in 2017, dietary risks were the leading Level 2 
risk factor for deaths and the second leading Level 2 risk 
factor for DALYs, accounting for 10·9 million (95% UI 
10·1–11·7) deaths and 255 million (234–274) DALYs 
(table 3). Among dietary factors, high intake of sodium 
was the leading risk for mortality, accounting for 
3·20 million (1·42–5·45) deaths. Low intake of whole 
grains was the leading risk factor for DALYs, accounting 
for 82·5 million (59·0–109) DALYs. Diet with high sugar-
sweetened beverage consumption continues to show a 
marked increasing trend in overall attributable burden, 
with SEVs for this risk increasing 12·1% (7·02–18·2) 
between 2007 and 2017 and 17·1% (8·34–28·0) since 1990 
(table 2).
Discussion
General findings
We estimated the burden of disease attributable to 
84 metabolic, environmental and occupational, and 
behavioural risk factors or clusters of risks from 1990 to 
2017 in 195 countries and territories, based on 46 749 data 
sources. In 2017, all included risks combined contributed 
to 61·0% (95% UI 59·6–62·4) of deaths and 48·3% 
(46·3–50·2) of DALYs worldwide, compared with 61·4% 
(59·9–62·7) of deaths and 52·4% (50·4–54·5) of DALYs 
in 1990. With each iteration of GBD, including GBD 2017, 
an increasing proportion of burden of disease has been 
attributed to risk factors. The contributions of risk factors 
to total deaths in the year 2010 (the most recent year for 
which we have comparable estimates from the most GBD 
iterations) were estimated to be 55·7% in GBD 2013, 
57·3% in GBD 2015, 60·2% in GBD 2016, and 61·3% in 
GBD 2017. Similarly, in 2010, the contribution of risk 
factors to DALYs was 40·4% in GBD 2013, 41·5% in 2015, 
46·5% in 2016, and 49·5% in 2017. This increase stems 
from the growing collection of risk–outcome pairs 
included in each iteration. With the addition of new risk 
factors and new risk–outcome pairs, future iterations of 
the GBD study should explain an increasing portion of 
the remaining unattributed burden of disease.
The role of changes in risk factors in explaining 
changes in deaths and DALYs varies considerably across 
causes and ages. Since 1990, in the 64 individual or 
Level 4 risks, exposure levels increased significantly for 
20 risks, did not change significantly for 14 risks, and 
decreased significantly for 31 risks. The risks with the 
highest increases in SEVs globally include high BMI, 
ambient particulate matter pollution, and high FPG; the 
risks with the largest decreases in exposure are unsafe 
sanitation, diet high in trans fatty acids, and household 
air pollution. These trends are consistent with what are 
expected with socioeconomic development.
We found considerable heterogeneity across super-
regions in the leading risk factors. Some notable patterns 
are the role of unsafe sexual practices as a driver of the 
HIV/AIDS epidemic in eastern and southern sub-
Saharan Africa and the role of alcohol consumption in 
eastern Europe and central Asia. There are also marked 
spatial patterns for other risks such as high BMI in 
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central America, north Africa and the Middle East, and 
Oceania. Interpretation of spatial patterns needs to take 
into account the fact that some risks have a strong 
relation ship with socioeconomic development. The 
numbers of some environmental and behavioural risks, 
including unsafe water, sanitation, and handwashing, 
household air pollution, and childhood growth failure, 
decrease rapidly with increased development. Other risks 
tend to increase with development, including high BMI, 
high SBP, red meat consumption, high sugar-sweetened 
beverage consumption, and drug and alcohol use.
Risk exposure and socioeconomic development
Risks form clusters with regard to the nature of their 
association with development. In this regard, we 
observe four categories of risks as follows: (1) risks 
positively associated with SDI; (2) risks negatively 
associated with SDI; (3) risks with clear, but non-
monotonic associations with SDI; and (4) risks that 
show little association with SDI.
The category of risks that are positively associated with 
SDI includes smoking, high BMI, alcohol use, and high 
LDL cholesterol. This category includes predominately 
behavioural and meta bolic risks that are associated with 
NCDs. The category of risks that are negatively associated 
with SDI includes child wasting, unsafe water source, 
diet low in fruits, household air pollution, unsafe 
sanitation, and no access to handwashing facility. This 
category includes pre dominately environmental and 
behavioural risks that are associated with CMNNDs. The 
category of risks that have non-monotonic associations 
with SDI includes high FPG and ambient particulate 
matter pollution, which both follow an inverted U-shaped 
association with develop ment, and low birthweight, 
which has a U-shaped association with development. 
The category of risks showing little association with SDI 
includes high SBP and diet low in whole grains.
Notably, for some risks, the trends of O/E ratios and 
SEVs are in opposite directions. For example, O/E ratios 
for household air pollution and unsafe water increased 
between 1990 and 2017, indicating that, for a given level of 
SDI, exposure levels have increased during that period. 
Conversely, SEVs for those risks declined during the 
same period. Thus, although exposure to these risks is 
broadly improving with socioeconomic development and 
time, improvements in development are occurring more 
rapidly than are improvements in the underlying risk 
structure in a population. For other risks, SEVs show 
temporal trends that run counter to trends expected on 
the basis of SDI. For example, although SDI was strongly 
positively associated with smoking, both SEVs and 
O/E ratios for smoking have declined despite concurrent 
increases in SDI. The marked declines in O/E ratios for 
smoking across all super-regions again suggest that the 
expected increase in smoking has not been fully realised 
with increasing SDI. In the case of smoking, the declining 
O/E ratios probably reflect benefits of smoking-reduction 
policies.16 Similarly, alcohol use was strongly positively 
associated with SDI, and trends in alcohol use SEVs did 
not change greatly, resulting in reductions in O/E ratios 
for alcohol use in all super-regions except south Asia.
Risk exposure and sex
In addition to spatiotemporal variation in risk exposure, 
there were important differences between males and 
females within a given location. Females had notably 
higher SEVs for household air pollution, second-hand 
smoke, low bone mineral density, and diet low in fibre, 
legumes, calcium, and vegetables; whereas males had 
notably higher SEVs for lead exposure, smoking, alcohol 
use, ambient particulate matter pollution, red meat 
consumption, and most occupational risks.
For smoking, SEVs were higher for males than for 
females at all SDI levels, and, for both sexes, SEVs 
increased with increasing SDI. However, although 
smoking SEVs for males increase nearly linearly with 
SDI, smoking SEVs for females remain very low at lower 
SDI, and then increase rapidly between SDI values of 0·6 
and 0·9. This suggests that smoking interventions that 
target males might be most effective in lower SDI set-
tings, whereas interventions in higher SDI settings 
should target males and females more equally. Similarly, 
alcohol use remains low among females across lower 
and middle SDI levels but increases with SDI at higher 
SDI levels, suggesting that interventions should target 
males in low to middle SDI settings, but be targeted 
more broadly in higher SDI settings.
SEVs for high BMI increased for both sexes between 
1990 and 2007, 2007 and 2017, and 1990 and 2017. 
Although this increase continues for males across the 
entire range of SDI, the increase for females slows and 
the curve flattens at an SDI of 0·66. Consequently, 
although females have higher BMI SEVs than males at 
low and middle SDI, they have lower SEVs than males at 
high SDI. Similarly, there was a crossover in sex 
differences for high SBP. Although high SBP SEVs for 
females decline slightly with SDI, they increase slightly 
with SDI for males. Consequently, expected SBP SEVs 
are lower for males than for females where SDI is 0·36 
or below, and they are higher for males than for females 
where SDI is greater than 0·36.
Cross-cutting themes
The number of all-cause DALYs declined for both males 
and females between 2007 and 2017, because the effects of 
improvements in both risk exposures and risk-deleted 
DALY rates have outpaced the opposing effects of 
population growth and ageing. Decreases in risk-deleted 
DALY rates are probably a function of improvements in 
treatments and improvements in risk factors that are not 
captured in the GBD analysis, as well as uncaptured 
social, cultural, and economic factors. Although changes 
in environmental and occupational and behavioural risks 
have driven declines in all-cause DALYs, increasing 
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exposure to metabolic risks has had the opposite effect. 
This pattern is remarkably consistent across geographies. 
Consequently, increasing exposure to metabolic risks 
stands as one of the key drivers of increasing DALYs from 
NCDs. Although concerns about NCD burden have 
historically focused on high-income countries, previous 
iterations of the GBD study, as well as other studies, have 
clearly shown the large and growing problem of NCDs in 
low-income and middle-income settings.4,17 Similarly, 
although metabolic risk factors such as high LDL 
cholesterol, high SBP, and high BMI have historically 
been viewed mostly as challenges in high-income settings, 
these key metabolic risk factors are now commonly 
increased even in low-income settings. Between 1990 and 
2017, 47 countries and territories had greater than 100% 
increases in SEVs for high BMI and, of these, 37 (79%) 
had an SDI that was less than the median value in 1990. 
Although these increases have occurred in connection 
with increasing SDI, increasing O/E ratios show that 
trends in these metabolic risks are outpacing the 
expectations based on development.
High LDL cholesterol and high SBP are among the 
leading risk factors for all-cause risk-attributable burden in 
2017. Both are commonly increased even in low-resource 
settings, and both are increased by obesity. Although both 
are also easily reduced or treated with inexpensive and 
cost-effective medications, these treatments remain inac-
cessible to broad segments of the world’s population.18 
Growing evidence from studies such as the SimCard Trial19 
in rural India and China suggests that effective methods 
exist to deliver these kinds of important pharmacotherapy, 
even in the most resource-limited locations. A 2018 trial 
of a fixed low-dose triple-combi nation antihypertensive 
drug tested in urban Sri Lanka, consisting of amlodipine, 
telmisartan, and chlorthali done, showed substantial im-
prove ment in control of blood pressure compared with 
usual care at 6 months, and no difference in adverse 
events.20 Another trial from 2016 showed that lowering 
LDL cholesterol with a high-potency statin was effective 
even among individuals only at intermediate risk of 
cardiovascular events.21 Efforts to improve universal health 
coverage must directly address how these therapies can be 
delivered even more effectively. Studies have further 
identified public health interventions that are cost-effective 
outside of high-income settings. Legislative interventions 
targeting sodium and trans fat, improve ments in food 
labelling and advertising, and health-focused and diet-
focused media campaigns are cost-effective interventions 
in south Asia, for example.22 Fortunately, philanthropic 
donors are beginning to identify cardiovascular risk as an 
important target for improving global health.23
O/E ratios offer a useful benchmarking tool for national 
policy makers who are hoping to compare the risk 
exposure against an empirical standard for countries at 
a given level of development. Although the burden 
attributable to a given risk indicates the risks for which 
exposure reduction can offer the greatest health gains, 
O/E ratios offer insight into what might be achievable 
given the resource constraints that exist at a certain level 
of development. For example, in the southeast Asia, 
east Asia, and Oceania super-region, high SBP and high 
FPG are among the leading risks, but both have SEV 
O/E ratios below 1·0. This suggests that, despite the 
high risk-attributable burden, the countries in this 
super-region show better than expected performance in 
managing exposure to these risks. Conversely, ambient 
particulate matter pollution and household air pollution 
are the tenth and 15th leading risks in the super-region, 
but the corresponding SEV O/E ratios are 1·32 and 3·05, 
suggesting that the countries in the super-region have 
greater exposure to these risks than other countries at 
similar levels of development. The degree of under-
performance suggests that gains in managing these risks 
might be more easily achieved than would be gains from 
risks in which the super-region is already outperforming 
its peers.
Important changes in GBD 2017 compared with 
GBD 2016
GBD 2017 marks the first time that bullying victimisation 
by peers of children and adolescents attending school 
has been included as a risk factor. It is one of only 
three psychosocial risk factors to be included in GBD, 
one of only two risk factors for major depressive disorder, 
and the first-ever risk factor for anxiety disorders in 
GBD. The substantial proportion of major depressive 
disorder and anxiety disorder YLDs attributable to 
bullying victimisation highlights the importance of 
considering psychosocial risk factors when assessing 
health outcomes. The small number of risk factors for 
mental disorders has been an ongoing criticism of GBD, 
especially considering that mental disorders are a leading 
cause of disability worldwide.24 GBD estimates suggest 
that the prevalence of mental disorders has changed little 
in the past few decades despite growing recognition of 
the associated burden. Psychosocial risk factors can be 
challenging to assess and quantify, which in turn can 
make them easy to overlook. However, bullying 
victimisation has an operationalised definition, can be 
measured in population surveys, and is consistently 
associated with risk of mental disorders.25,26 Scientifically 
assessed school-based interventions that address bully-
ing show positive programme effects.27 A reduction in 
the prevalence of bullying victimisation could help 
reduce the prevalence, and therefore burden, of major 
depressive disorder and anxiety disorders later in life. 
Crucially, the inclusion of bullying victimisation as a risk 
factor in GBD might motivate investment in intervention 
pro gram mes to reduce bullying. The inclusion of 
bullying victimisation in GBD also shows the importance 
of integrating cross-disciplinary research in the identi-
fication of the complex aetiology of mental disorders.
Using continuous and cumulative measures of 
smoking, which capture both former and occasional 
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smokers, has shown that the burden of smoking is 
higher than previously thought. The implications of the 
new methods on attributable burden varies across out-
comes and locations. For 71·8% of countries, the burden 
attributable to smoking has increased as a result of 
the new methods. For the largest causes of burden 
(ischaemic heart disease, COPD, lung cancer, and stroke) 
there are differential trends across countries and by sex. 
By quantifying this dose-response relationship, we are 
able to highlight the potential health benefits of policies 
and programmes that reduce smoking. We have also 
produced a globally complete time series of estimates for 
age of initiation that shows that the average age of 
initiation has changed little across time, even in locations 
with strong and successful tobacco control. Targeting 
interventions to reduce the initiation rate in the critical 
age window of 13–23 years will yield substantial health 
benefits.28 Finally, the concept of capturing exposure over 
an individual’s life course can and should be extended to 
other risk factors, for which the health effects are 
probably the result of cumulative exposure.
Comparison of GBD 2017 to other estimates
The GBD study is the most comprehensive population-
level CRA across countries and risks. For several risks, 
including ambient particulate matter pollution, house-
hold air pollution,29 intimate partner violence,30 unsafe 
water source,31,32 breastfeeding,33 and lead exposure,34 GBD 
estimates are generally lower than published WHO 
estimates.30–32,34,35 These discrepancies can be attributed to 
different definitions, methods, granularity, and input 
data. For some findings, annual estimates might disagree, 
but regional patterns are consistent between WHO and 
GBD. UNICEF produces estimates for child stunting36 
that are lower than GBD estimates, with some dis-
agreement in which locations progress has been made. 
There is more consistency in estimates between UNICEF 
and GBD for child wasting and child underweight.36 GBD 
estimates for the prevalence of low birthweight and short 
gestation are slightly lower than the WHO estimates but 
show similar geographical patterns.37 Scientific literature 
reveals similar results to GBD for impaired kidney 
function38 and low birthweight and short gestation.39 
Research published on iron-deficiency anaemia40 differs 
from GBD in methods and definitions, resulting in 
generally higher GBD estimates. GBD estimates were 
much lower than published research on occupational 
estimates,41–43 largely because of different cause–outcome 
pairs and GBD’s application of the CRA approach.
Improvements in our smoking estimation methods 
have resulted in higher estimates of smoking-attributable 
burden. Although smoking estimates from previous 
iterations of the GBD study were slightly lower than 
those published by WHO,35 our GBD 2017 estimates 
show marked similarities. Among the 142 countries and 
territories included in the WHO report and estimated in 
GBD, the correlation coefficient for 2017 smoking 
prevalence estimates for females was 0·91 and for males 
was 0·85. Where estimates diverge, these differences 
can be attributed to differing modelling methods or data 
sources. For example, the WHO model was fit on 
1175 country-year data sources whereas the GBD model 
was fit on 2870 country-year data sources.
Future directions
As with previous iterations of GBD, we have continued 
to use the World Cancer Research Fund criteria of 
convincing or probable evidence as the threshold for 
including a risk–outcome pair in GBD 2017.44 The 
subjectivity of some aspects of these definitions might 
result in differing interpretations of the available evi-
dence and different conclusions about the strength of the 
evidence supporting the inclusion of a given risk–
outcome pair. Moving toward more objective and quanti-
fiable criteria could help reconcile these different 
interpretations. Quantifiable criteria would also permit 
simplified evidence scores that could help policy makers 
who, faced with scarce resources, might choose to 
prioritise interventions that address risks supported by 
the strongest evidence base. Objective and quantifiable 
criteria would facilitate such comparisons, allowing 
stakeholders to more easily understand the variable 
strength of evidence supporting the causal connection 
for each risk–outcome pair. In an effort to summarise the 
evidence base for each risk–outcome pair in GBD 2017, 
we present the number of studies that are available, 
by type of study design. However, we recognise that 
quantifying the strength of evidence requires moving 
beyond simple quantification of the number of studies. 
To that end, we have begun to extract detailed information 
from all 3638 studies used across risk–outcome pairs. 
This effort includes details about study design, the 
study population and sampling, exposure measurement, 
outcome assessment, potential sources of bias and 
confounding, and analytic efforts to address bias and 
confounding. With this information, we can system-
atically analyse the degree to which different study 
limitations affect the resulting strength of associations, 
allowing us to objectively assess study quality. Looking at 
the studies for a given risk–outcome pair, we can then 
calculate an objective evidence score based on the 
number and quality of the supporting studies, and the 
potential for publication bias. Such a score would 
facilitate evidence-based decision making in the face of 
scarce political and financial resources, allowing 
attention to be focused on risks with both the greatest 
attributable burden and strongest supporting evidence.
The inclusion of bullying as a new risk in GBD 2017 
suggests potential areas for future work. We hope that 
its inclusion will help in setting a higher standard of 
measure ment in future research on both the occurrence 
and health effects of bullying. It also provides a starting 
point for including additional risk factors related to 
violence against children, such as non-sexual forms of 
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child abuse in addition to childhood sexual abuse, which 
is the only GBD 2017 risk factor pertaining to child 
maltreatment.
A growing body of research has shown direct 
connections between ambient temperature and health 
outcomes. For example, the Multicountry Observational 
Study,45 the largest study of all-cause mortality risk 
and ambient temperature to date, estimated that 7·71% 
(95% CI 7·43–7·91) of deaths were attributable to 
suboptimal ambient temperature: 7·29% (7·02–7·49) of 
deaths were attributable to low ambient temperatures 
and 0·42% (0·39–0·44) were attributable to high 
temperatures. The growing evidence base, especially in 
the context of global concerns about the potential health 
effects of climate change, makes the inclusion of 
meteorological risk factors a priority for future iterations 
of GBD. We have already begun work to estimate the 
cause-specific burden directly attributable to effects of 
ambient temperature, with plans to include suboptimal 
ambient temperature as a risk in future estimations of 
GBD. The inclusion of exposure to suboptimal tem-
perature is intended also to lay the groundwork for 
exploring other components of weather and climate in 
future GBD analyses.
Limitations
A study of this scope has many limitations. The new 
proportional PAF strategy that we have implemented for 
particulate matter pollution reflects a broader challenge 
with disentangling inherently connected risks with non-
linear relationships between exposure and disease risk. 
In the case of particulate matter pollution, risk for a given 
outcome rises sharply with increased exposure at the low 
end of the exposure range, and the marginal increase in 
risk declines as the risk curve flattens at the upper end 
of the exposure range. Two risks compose particulate 
matter pollution: ambient particulate matter pollution 
and household air pollution. If exposure to each of these 
two sources were sequentially reduced to the TMREL, the 
reduction in burden per µg/m3 reduction in exposure for 
whichever source is removed first will be less than the 
reduction for the source that is removed second. This 
occurs because, for the first source, the exposure 
reduction occurs where the risk curve is flatter, whereas 
for the second source, exposure reduction occurs where 
the risk curve is steeper. No clear solution to this problem 
that does not raise a new problem exists within the CRA 
framework. Treating each exposure in isolation, as we 
did in previous GBD iterations, results in overestimates 
of attributable burden, because both risks will have their 
burden estimated from the steepest part of the risk curve. 
Considering both exposures together and treating each 
exposure as the first to be removed, in line with the CRA 
approach, results in underestimates of risk, because both 
risks will have their burden estimated from the flattest 
part of the risk curve. We have chosen instead to estimate 
burden for total particulate matter pollution and divide 
this total burden proportionately between the two 
sources. This accurately captures burden but deviates 
somewhat from the CRA approach. The challenge 
extends beyond ambient and household particulates. 
Smoking and second-hand smoke are additional sources 
of particulate matter exposure that we have not yet 
incorporated into our proportional burden strategy. This 
is a limitation of the CRA approach, and other areas 
probably have similar challenges with non-linear and 
inherently connected risks that have not yet been 
identified and corrected.
Bullying is characterised by intention to harm, a power 
imbalance, and repetition; however, studies vary greatly 
with regard to how they specifically define these criteria. 
For example, we were unable to include many studies 
where the threshold for repetition was either insuf-
ficiently specific or not reported. Second, the relative risk 
data used in the calculation of PAFs were only from high-
income countries. The magnitude of the association 
between bullying victimisation and outcomes might 
differ between high-income countries and low-income 
and middle-income countries.
Our updated continuous measures of smoking better 
capture true risk, but also introduce new challenges. 
First, because of data limitations, we assume the risk of 
all smoked tobacco products is equivalent to the risk 
of cigarettes. Second, smoking histories were recon-
structed on the basis of cross-sectional survey data, not 
longitudinal data. Third, we were not able to effectively 
adjust for illicit tobacco in our estimates of supply-side 
consumption. Fourth, we have not incorporated the 
effects of tobacco-control policies on various exposures. 
Consequently, if no survey data are collected after 
implementation of a tobacco-control policy, the impact of 
that policy will not be reflected in the modelled estimates. 
Fifth, insufficient evidence is available to estimate risk-
reduction curves for individuals with different smoking 
histories, so the rate of risk reduction has been assumed 
to be the same for all levels of exposure. Sixth, we 
recognise that our exposure definitions are summaries of 
an individual’s smoking history, and that more nuanced 
exposure definitions might perform better for individual-
level risk prediction.
Conclusion
This study provides a comprehensive and comparable 
assessment of 84 environmental and occupational, 
behavioural, and metabolic risks across locations and 
time. By quantifying levels and trends in exposures to 
risk factors and the resulting disease burden, this 
assessment offers insights into past programme and 
policy successes and highlights the current priorities for 
public health action. Our findings show that improve-
ments in behavioural, environmental, and occupational 
risks, and decreases in risk-deleted DALY rates have 
largely outpaced the effects of population growth and 
ageing, in terms of absolute burden. Sustained efforts in 
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reducing these risks are crucial to maintaining trends 
in declining burden from injuries and CMNNDs. 
Conversely, the combination of increasing metabolic 
risks and population ageing will probably continue to 
drive the increasing trends in NCDs at the global level, 
which presents both a public health challenge and 
opportunity. Working down from the global to national 
level reveals considerable heterogeneity in levels of 
risk exposure and risk-attributable burden. Although 
development underlies some of this hetero geneity, ratios 
of observed burden to the burden expected based on SDI 
reveal risks for which countries are overperforming or 
underperforming relative to their level of socioeconomic 
development. As such, these ratios provide a bench-
marking tool to help focus local decision making. Our 
findings reinforce the importance of both risk exposure 
monitoring and epidemiological research to assess 
causal connections between risks and health outcomes, 
and they highlight the essential role of GBD in 
synthesising data to draw the comprehensive and robust 
conclusions that are necessary to inform evidence-based 
policy.
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